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Malar ia,  the paras ite and disease
Malaria is a vector-born disease of global health importance [1] with 216 million cases in 
91 countries in 2016 resulting in around 445.000 deaths [2]. The greatest burden of malaria 
is in sub-Saharan Africa, where it takes the lives of more than 1,200 children each day [2]. 
Malaria is caused by a protozoan unicellular parasite, Plasmodium, which is transmitted by 
Anopheles mosquitoes. Five Plasmodium species are responsible for malaria in humans: 
Plasmodium falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi [3]. Most clinical 
cases are caused by P. falciparum and P. vivax, with P. falciparum being the deadliest [1, 
3]. P. falciparum infections can cause severe anaemia, fever and organ damage, including 
cerebral complications; in contrast, P. vivax infections are usually not fatal but can be severe 
with recurrent clinical episodes of malaria associated with morbidity [4]. P. malariae and P. 
ovale infections are less well studied but the severity of illness caused by these parasites 
is similar to P. vivax malaria [4]. P. knowlesi is primarily a zoonotic infection encountered in 
Southeast Asia that can cause severe malaria [5].
The P. falciparum life cycle
Figure 1 depicts the life cycle of P. falciparum. A malaria infection in humans begins with 
the inoculation of Plasmodium sporozoites into the host dermis by the bite of an infected 
female Anopheles mosquito [4, 6]. The sporozoites can take 1-3 hours to exit from this site. 
Here they rely on gliding motility to penetrate a blood vessel, entering the blood stream 
and migrating to the liver [7]. Sporozoites recognise hepatocytes and infect these cells 
after the sporozoite become activated through a mechanism that involves interactions 
of host and parasite membrane proteins. Entry is gained by proteins that are released 
from the apical organs of the sporozoite, specifically the micronemes and rhoptries. 
Once hepatocyte infection is established, the parasite grows and divides in the next 2-10 
days. These liver-stage (LS) or exo-erythrocytic forms (EEF) mature and release up to 
40.000 merozoites per infected hepatocyte into the blood stream [3]. Once released into 
the circulation, the merozoites invade erythrocytes, where they grow, divide and form new 
merozoites, which upon release invade new red blood cells, initiating the repeated asexual 
replication cycles. All symptoms of malaria are associated with the blood-stage infection [8]. 
Within a red blood cell P. falciparum parasites progress over the course of 48 hours through 
the ring and the trophozoite stage before replicating into 8-32 merozoites at the schizont 
stage (schizogony) [1]. During the schizogony cycles in red blood cells, a proportion of 
parasites stop asexual division and undergo a developmental switch, initiating sexual 
development by development into male or female gametocytes (gametocytogenesis). 
These gametocytes mature through five defined stages over the course of 8-11 days 
[1, 9]. Once ingested by a mosquito the mature male and female gametocytes emerge 
from the red blood cell and rapidly produce gametes (gametogenesis), with the male 
gametocyte dividing into eight flagellated microgametes (exflagellation) and the female 




the male in the mosquito midgut, resulting in a diploid zygote, which elongates into an 
ookinete that penetrates the mosquito gut wall. The ookinete develops into an oocyst that 
undergoes cycles of replication to form several thousand sporozoites (sporogony), over 
a period of 9-12 days. These oocysts then burst to release the sporozoites that migrate to 
the salivary glands, resulting in mosquitoes that are infectious to humans [9, 10].
Malar ia,  the health problem 
Malaria incidence and transmission depends on environmental suitability for local 
mosquito vectors, which includes altitude, climate, vegetation, and implementation of 
control measures. The intensity of the host-vector-host transmission depends on factors 
related to the parasite, the vector, the human host and the environment [11]. Currently, half 
of the world’s population is at risk of malaria, with some population groups at higher risk 
of developing severe disease than others. These include infants, children under 5 years of 
age, pregnant women and immunosuppressed patients [2]. Early diagnosis and treatment 
reduces disease, prevents death and directly contributes to a reduction in malaria parasite 
transmission [4, 11]. However after considerable global success in malaria control over 
the past 10-15 years, progress has now stalled according to the WHO World Malaria report 
2017 [2]. A major problem is insufficient funding at both domestic and international levels, 
resulting in gaps in coverage of the use of insecticide-treated nets, antimalarial drugs, 
indoor residual spraying (IRS) with insecticides and other lifesaving tools [2]. Moreover, 
there is a global increase in resistance to front-line antimalarial drugs, such as chloroquine, 
sulfadoxine/pyrimethamine [12] and recently to artemisinin [13]. This highlights the need 
for novel drug and vaccine intervention programs against both the parasite and vector. 
In addition to novel insecticides and approaches to reduce transmission by mosquitoes, 
the identification of new classes of drugs as well as vaccines that target different stages 
of the parasites are required to protect the groups most at risk [2, 12] and to develop 
the most cost-effective means to prevent, eliminate and eradicate malaria [11]. 
Malar ia,  vaccine and drug development
Malaria vaccines are generally classified in different types of vaccines, defined by 
the different life-cycle stages of the parasite that are targeted by the vaccine. Specifically, 
(1) pre-erythrocytic vaccines, which induce antibodies and/or cell-mediated immune 
responses that block sporozoite invasion of hepatocytes or remove infected hepatocytes 
[11]; (2) blood-stage vaccines that are designed to block merozoite invasion of red blood 
cells or to eliminate infected red blood cells [12]; and (3) transmission blocking vaccines (TB 
vaccines) that generate antibodies that can block transmission of parasites in the mosquito 
by either blocking parasite fertilisation or zygote development. Pre-erythrocytic vaccines 
have been shown to prevent infection and can induce sterile protection against malaria. 
Blood-stage vaccines are likely to reduce the overall parasite burden in the blood and 
therefore reduce malaria symptoms and TB vaccines may be an effective means to reduce 
the spread of malaria within a population [12]. 
Currently, the most extensively tested vaccine candidate for prevention of P. falciparum 
malaria is RTS,S/AS01 (RTS,S; also known as Mosquirix), a pre-erythrocytic vaccine candidate 
[14]. This subunit vaccine targets the sporozoite and the infected liver cell and is based on 
the immunodominant antigen that covers the surface of the sporozoite, circumsporozoite 
protein (CSP). In RTS,S the CSP fragment is fused to hepatitis B virus surface antigen 
and administered with the adjuvant AS01 [14]. This is the only vaccine that has shown 
protective efficacy against clinical malaria in a Phase III clinical trial, but protective efficacy 
is modest and wanes over time and may be age dependent [15]. In vaccine development 
against P. vivax the CSP protein is also seen as an important vaccine target since evidence 
from pre-clinical and clinical studies has indicated that immune responses against P. vivax 
CSP play a role in mediating protection against P. vivax infections [16]. 
In addition to CSP, several other antigens of sporozoites and liver-stages have been 
identified as target antigens for subunit vaccines, for example CelTOS (cell traversal 
protein for ookinetes and sporozoites) and TRAP (thrombospondin-related adhesion 
protein). Recombinantly produced CelTOS  of P. falciparum, a micronemal secreted-
Figure 1. Schematic representation of the P. falciparum life cycle. Upper panel, P. falciparum 
development in mosquitoes (grey box) and in humans. Lower panel, the five developmental stages 
of P. falciparum gametocytes and mature P. vivax gametocytes. This image was taken from Bousema, 




protein, is one of the few vaccines that has recently entered clinical testing (NCT01540474 
https://clinicaltrials.gov/). A viral-vectored sub-unit vaccine directed against TRAP fused to 
a multi-epitope string, demonstrated some protection against malaria infection in malaria-
naïve adults [17]. 
Most research on the development of asexual blood-stage vaccines has focused on 
only a few antigens, for example merozoite surface protein 1 (MSP1) and apical membrane 
antigen 1 (AMA1). Antibodies against both proteins correlate with naturally-acquired 
immunity in multiple epidemiological studies and vaccines targeting these antigens 
induced protective immune responses in preclinical studies in rodents [18]. However, 
although some studies performed in humans have shown some efficacy, no blood-stage 
vaccine has reached phase III testing [19]. It is important to consider the challenges that 
have faced the development of blood-stage vaccines, such as high levels of antigenic 
polymorphism and redundant pathways of invasion of red blood cells by merozoites. 
Different preclinical assays are used to predict the efficacy of blood-stages vaccines [19, 20]. 
The growth inhibition assay (GIA) is one of the most widely used functional assays to test 
interventions against asexual blood-stage development. In vaccine-based studies, blood-
stage parasites are co-cultured with either control or test antibodies and the percentage 
of reduction in parasitemia is measured after a defined culture period [19].
For TB-vaccines, the leading target antigens include the ookinete surface protein 
Pf25 and the gametocyte/gamete antigens Pf48/45 and Pf230. Antibodies against these 
antigens perform well in inhibition of transmission in comparative preclinical studies, with 
functionality assessed by the standard membrane feeding assay (SMFA) using mosquitoes 
that are fed with cultured gametocytes in the presence of antibodies, whole serum or 
purified IgG [21]. The most advanced TB vaccine candidates are based on the antigens 
P48/45 of gametes and P25 of zygotes and ookinetes and recombinant vaccines of P25 of 
both P. falciparum and P. vivax have progressed into Phase I trials [22-24].
Despite three decades of testing different (recombinant) sub‐unit vaccines, both 
in the clinic and the field, only modest protection against infection has been achieved 
[15, 25-27], which has renewed an interest in whole parasite-based vaccine approaches 
[28, 29]. It was first shown in rodent models of malaria that complete protection against 
infection could be obtained by vaccination using live attenuated sporozoites [30, 31]. 
Subsequently, sterile protection against malaria was also demonstrated in humans after 
immunization with Plasmodium falciparum sporozoites, either attenuated by radiation 
[32, 33] or administered under chemoprophylaxis [34]. A prerequisite for induction 
of protective immunity using sporozoite-based vaccines is that sporozoites retain their 
capacity to invade liver cells after administration. While the precise mechanisms of 
protection mediated by immunization with attenuated sporozoites remain unknown, T 
cells appear to be critical for protection and in particular CD8+ T cells are thought to play 
a major role in eliminating infected hepatocytes [35]. The most advanced live-attenuated 
vaccine is based on irradiation-attenuated sporozoites (Irr-Spz), which is currently being 
evaluated both in the clinic and in field trials [36, 37]. In rodent models, immunization 
with sporozoites of genetically-attenuated parasites (GAP) can induce similar or even 
better levels of protective immunity compared to  Irr-Spz [35, 38]. Genetic attenuation 
of sporozoites has been achieved through the deletion of one or more genes that play 
a critical role during liver-stage development, resulting in complete arrest of parasite 
growth in the liver, thereby preventing a blood-stage infection after immunization with 
GAP sporozoites. Currently two P. falciparum GAP-based vaccines are undergoing clinical 
evaluation [38-42]. 
While the search for an effective vaccine against malaria remains a very active area 
of research, the most effective means to treat and prevent malaria remains the use of 
drugs [43]. However, resistance to available antimalarials continues to spread, including 
resistance to the widely used artemisinin-based combination therapies [44]. As multi-drug 
resistance spreads, there is an urgent need for new antimalarial agents to control malaria 
infections [43]. At the forefront of antimalarial development is the Medicines for Malaria 
Venture (MMV), a not-for-profit, public–private partnership (www.mmv.org). The current 
MMV portfolio contains many promising compounds at various stages of development [43]. 
New classes of antimalarial compounds have been identified in high-throughput screens 
of large compound libraries [45]. Most of such screens involve the exposure of different 
life cycle stages of P. falciparum parasites to the compounds and the measurement of 
inhibition of development. For example in short-term cultures of the blood-stages and 
determination of inhibition of blood-stage growth and multiplication. Such screening of 
large compound libraries requires highly reproducible and cost-effective assays that are 
amenable to automation and can be performed in a small culture volumes [43, 45]. 
Malaria elimination is likely to require a combination of interventions, including 
the generation, testing and implementation of new drugs and vaccines as well as new 
vector control strategies.
Genetical ly  modif ied malar ia paras ites and 
their  use in malar ia research:  the a im of the 
studies descr ibed in this  thesis
In the mid-nineties, genetic modification to create permanent modifications in malaria 
parasite genomes was first described in the rodent malaria parasite Plasmodium berghei 
[46]. This technology was extended to other Plasmodium species, including the human 
malaria parasite P. falciparum, and was initially used for loss-of-function analyses to 
uncover the function of Plasmodium genes, including genes encoding potential vaccine 
candidate antigens (reviewed in [47, 48]). In addition to gene disruption and gene mutation, 
methodologies have been developed for creating malaria parasites that express ‘foreign’ 
genes from other organisms, so-called transgenic parasites. Among the first transgenic 
mutants were rodent malaria parasites (RMP) that were modified to express fluorescent and 
luminescent reporter proteins. These parasites have been used to visualize and analyse 




analyse cellular and molecular aspects of malaria parasite biology (reviewed in [49-52]), 
and to study host-parasite interactions and pathology [53-58]. In addition, transgenic 
rodent parasites have been used to develop and evaluate vaccines (reviewed in [59]). For 
example, chimeric RMP expressing P. falciparum or P. vivax antigens have been used to 
directly evaluate human malaria vaccines before their advancement to clinical testing.
Transgenic parasites expressing fluorescent or luminescent reporter proteins have also 
been created in the human parasite P. falciparum and the primate parasite P. cynomolgi. 
These transgenic parasites have been exploited in screening assays to measure (inhibition 
of) parasite growth at different points of the parasite life cycle. GFP- and luciferase-
expressing P. falciparum parasites have been used in vitro to examine the effect of 
drugs and other inhibitors on blood-stage growth and on gametocytes [51, 60-63] and 
fluorescent P. cynomolgi parasites have been generated to screen for compounds that 
target the hypnozoite stage in the liver [64]. 
For RMP, the availability of transgenic parasite lines expressing different reporter 
proteins under the control of stage-specific or constitutive promoters has been of great 
benefit to research of parasite gene function and on research focused on evaluation of 
novel drugs and vaccines. The availability of similar P. falciparum transgenic reporter lines 
would open up possibilities to perform these studies directly with the human malaria 
parasite. For example, strongly fluorescent liver-stage P. falciparum parasites could create 
possibilities for enriching infected hepatocytes by flow-sorting methods, which would 
aid identification of novel vaccine targets, or mCherry-expressing P. falciparum parasites 
could be used to analyse parasite interactions with host cells (e.g. sporozoites with cells 
of the immune system or hepatocytes). Increasingly, cell-cell interactions in culture are 
examined using transgenic host cells expressing, for example, green fluorescent protein; 
therefore, the availability of transgenic P. falciparum parasites expressing different 
fluorophores can boost such studies. The creation of transgenic RMP expressing more than 
one transgene has permitted more elaborate and intricate studies on parasite biology 
and immunity. For example, fluorescent parasites that also express the immunological 
reporter antigen ovalbumin have been used to better understand how parasite antigens 
induce protection by examining interactions of infected hepatocytes with anti-OVA OT-1/2 
T-cells [55]. The creation of transgenic parasites stably expressing multiple transgenes 
is dependent on the presence of multiple suitable target loci in the parasite genome, 
which can be modified without altering parasite growth and development. In P. falciparum 
the p47 gene locus has most frequently been used to introduce transgenes [65, 66]. 
Therefore, the identification of other suitable ‘neutral’ genomic loci would greatly aid in 
the generation of mutants expressing multiple transgenes.
The main aim of the studies described in this thesis was to develop novel CRISPR/
Cas9 methodologies to improve P. falciparum transgenesis. This was done in order to 
create novel transgenic reporter parasites that can be used to analyse host-pathogen 
interactions and for anti-malarial drug and vaccine research. We first focused on improving 
CRISPR/Cas9 gene editing technology and on introducing transgenes into the P. 
falciparum genome using a new potential ‘neutral’ locus. Using this improved CRISPR/
Cas9 methodology, transgenic P. falciparum parasites were created that either express 
fluorescent-luminescent reporters or express a major vaccine candidate from the other 
major human malaria parasite, P. vivax. The outline of the different studies is explained in 
more detail below, as well as the rationale for the different approaches taken to generate 
these transgenic parasites.
Outl ine of  this  study
In Chapter 2 we provide a review on the use of transgenic malaria parasites in 
the development of malaria vaccines targeting different stages of the parasite life-cycle. 
While transgenic P. falciparum parasites have been used in studies to evaluate both 
antimalarial drugs and vaccines, the majority of the studies use transgenic RMP, for which 
a greater number of techniques is available to genetically modify and examine the parasite 
throughout the complete life cycle.  
Improved CRISPR/Cas9 genetic modification of P. falciparum (Chapter 3)
For rodent malaria parasites (RMP) efficient technologies have been developed for stably 
introducing transgenes into the parasite genome and efficient and rapid methods are 
available for the generation of transgenic reporter parasites that do not contain drug-
selectable markers [67, 68]. Such ‘marker-free’ parasites make it considerably easier to 
further genetically modify transgenic parasites; moreover, they can be used for drug-
sensitivity testing, as possible interference from an introduced drug-selection marker 
is absent. For RMP, a variety of transgenic reporter parasite lines have been generated 
in multiple strains of three different Plasmodium species [69]. In comparison to RMP, 
the technologies to genetically modify the human malaria parasite P. falciparum are much 
less efficient [48]. Traditional approaches to engineer the P. falciparum genome have been 
hampered by the limited methods available and transfection inefficiencies for introducing 
exogenous DNA into the parasite genome. Also, the limited number of drug-selectable 
markers restricts genetic engineering of P. falciparum; for example, performing sequential 
genetic manipulations in the same parasite line. Several technologies have been developed 
for the removal (re-cycling) of drug-selectable markers from the modified parasite 
genome, specifically using FLP and Cre recombinases [70, 71]. However, the application 
of these techniques is time consuming, as it can take 4-5 months to generate cloned 
‘marker-free’ genetically modified parasites. The RNA-guided CRISPR/Cas9 (clustered 
regularly interspaced short palindromic repeats/CRISPR-associated protein 9) system has 
transformed genome editing in a wide variety of organisms [72]. This powerful genome 
editing technique has also been applied to P. falciparum and provides efficient methods to 
manipulate the parasite’s genome, such as site-directed mutagenesis, gene disruption and 
the introduction of transgenes [73, 74]. Generation of P. falciparum transgenic reporter 




permit the rapid introduction of different transgenes into the parasite genome without 
permanently integrating a drug-selectable marker cassette. Currently, no cloned reporter 
lines have been published that are drug-selectable marker free.
In Chapter 3 we describe studies aimed at improving CRISPR/Cas9 genetic modification 
for introduction of transgenes into the genome of P. falciparum without the inclusion of 
a drug-selectable marker cassette. We describe the generation of transgenic parasites 
expressing GFP under control of different P. falciparum promoter regions that were 
selected based on their high (and constitutive) expression in different life cycle stages. 
The GFP-expression cassettes were introduced into the genome in the p230p gene 
locus, which we predicted to be a ‘neutral’ locus. We examined and compared the GFP-
reporter expression of the three novel transgenic lines at different points during blood-
stage development. However, disruption of the P230p locus unexpectedly resulted  in 
parasites that could not infect and develop in mosquitoes. The phenotype of the ‘gene-
deletion’ mutants in mosquitoes and the potential role of the P230p protein in mosquito 
development is described in more detail in Chapter 4. 
Characterization of P. falciparum mutant (reporter) lines lacking P230p 
expression (Chapter 4)
In P. falciparum the p47 gene locus has been most frequently used to introduce transgenes 
into the P. falciparum genome [65, 66]. We initially had selected the p230p gene locus to 
introduce transgenes as an alternative to the p47 gene, since the P47 protein has been 
shown to be important for limiting the host-defence responses against the parasite in 
mosquitoes [75, 76] . Consequently, P. falciparum parasites lacking P47 expression are less 
efficiently transmitted by some strains of Anopheles mosquitoes, as they have a decreased 
capacity to escape the mosquito immune response. In two rodent Plasmodium species 
the male-specific P230p protein appears to be dispensable throughout the parasite’s 
complete life cycle [77-79]. P. berghei and P. yoelii mutants lacking expression of P230p can 
develop in the vertebrate host and in the mosquito vector without a discernible phenotype 
and p230p knock-out parasites manifest a wild type parasite phenotype. Consequently, 
as P230p is non-essential, the p230p gene is the locus most frequently used to introduce 
additional transgenes into rodent malaria parasite genomes [78]. 
P230p and P47 belong to the s48/45 domain 6-cysteine (6-cys) family of Plasmodium 
proteins, a small family with 14 members that show stage-specific expression throughout 
the parasite life cycle and most members localize at the parasite surface [80]. Most members 
have critical roles in parasite development, either in the vertebrate host or in the mosquito 
vector, and several members are leading targets for malaria vaccines. These include 
vaccine antigens that target parasites in the mosquito, the so called transmission blocking 
vaccines, i.e. P48/45 and P230 which are paralogs of P47 and P230p, respectively [81-83]. 
In both P. berghei and P. falciparum P47 is specifically expressed in female gametocytes/
gametes and is located on the surface of female gametes, zygotes and ookinetes [84]. 
P47 is important in protecting ookinetes from the mosquito’s complement-like immune 
response in both rodent and human malaria species [76, 85, 86]. In addition, P. berghei 
P47 plays an essential role in the attachment and recognition of the female gamete by 
the male gamete [77, 85]. In contrast, P. falciparum P47 does not play such a crucial role 
in gamete fertilization [84].
In Chapter 4 we characterise in more detail some of the transgenic reporter lines 
we have described in Chapter 3, where the reporter cassette had been introduced into 
the P230p locus. Specifically, we examine the phenotype of these parasites during sexual 
blood-stage development and early mosquito stages. 
Generation of a transgenic P. falciparum parasite line expressing fluorescent 
and luminescent protein in different life cycle stages (Chapter 5)
For RMP the availability of transgenic reporter parasites expressing different fluorescent 
and luminescent proteins under the control of stage-specific or constitutive has been of 
great benefit to research of parasite gene function and research focused on evaluation of 
novel drugs and vaccines. Such transgenic reporter lines for P. falciparum would benefit 
research where P. falciparum parasites are used (see the sections above). 
In Chapter 3 we described studies to test different P. falciparum promoter-GFP 
expression cassettes. These studies were performed in order to generate parasite lines 
that express fluorescent proteins at high levels throughout the complete life cycle. 
However, given that the insertion of transgenes into the P. falciparum p230p locus resulted 
in parasites that could no longer infect mosquitoes (Chapter 3 and 4), we reverted to 
using the standard ‘neutral’ p47 gene locus for introduction of a novel reporter expression 
cassette. In Chapter 5, we describe the creation and evaluation of a reporter line that 
expresses a fusion of mCherry and luciferase driven by the promoter of the etramp10.3 
gene and examine these transgenic parasites in blood- and liver-stage cultures, as well 
as in mosquitoes. We selected this promoter because etramp10.3 has structural similarity 
to the uis4 gene of RMP and both genes have the same syntenic genomic location. In 
transgenic RMP lines the promoter of the uis4 gene has been used to drive expression of 
multiple transgenes specifically in sporozoites and liver-stages, such as genes encoding 
mCherry, ovalbumin or human malaria proteins [87-93]. The uis4 gene is highly transcribed 
in sporozoites and liver-stages and encodes a parasitophorous vacuole membrane (PVM) 
protein that surrounds the parasite in the infected hepatocyte [87]. Evidence has been 
presented for expression of etramp10.3 in P. falciparum sporozoites and in blood- and 
liver-stages where the protein is located at the PVM, similar to the PVM location of UIS4 in 
liver-stages of RMP [94]. We chose to generate an mCherry-expressing P. falciparum line, 
as it could be used to visualise interactions of Plasmodium sporozoites with host-cells (e.g. 
immune cells or hepatocytes) which are often labelled with green fluorescent proteins. 
Moreover, we fused the mCherry gene to the gene encoding firefly luciferase as luciferase 
expression can be used to quantify parasite numbers (e.g. sporozoites and liver-stages) 




Generation of chimeric P. falciparum parasites that express vaccine candidate 
antigens from the human malaria parasite, P. vivax (Chapter 6) 
Testing the next generation of P. falciparum vaccines and vaccine formulations is greatly 
aided by being able to perform immunization studies in people followed by malaria-
parasite challenge in controlled human malaria infections (CHMI) [97-100]. CHMI studies 
have increased the speed of vaccine evaluation by using well-controlled early-phase 
proof-of-concept clinical studies. Such studies facilitate the down-selection of vaccine 
candidates and the identification of those candidates most suitable for further evaluation 
in more expensive and complex phase II/III trials in areas where malaria is endemic.
 Although recently CHMI has also been developed for P. vivax [101] and has been 
applied to assess pre-erythrocytic vaccine candidates [102, 103], the use of P. vivax CHMI 
to rapidly screen different P. vivax vaccines is limited because of the lack of methods to 
continuously propagate P. vivax blood-stages in culture and to produce gametocytes in 
vitro that can be used to infect mosquitoes to produce sporozoites for challenge infections 
[101]. Therefore, P. vivax CHMI is dependent on sporozoites that have been obtained 
from mosquitoes fed on infected patients [101]. Moreover, P. vivax sporozoites can 
produce hypnozoites, dormant forms that can persist in the liver for prolonged periods, 
which requires safe and effective means to clear these forms from the liver in CHMI 
studies [101, 104]. 
In preclinical evaluation of vaccines, chimeric rodent malaria parasites (chimeric RMP) 
expressing P. falciparum and P. vivax pre-erythrocytic antigens have been used to analyse 
protective immune responses induced by P. vivax or P. falciparum vaccines in vivo in mice. 
These chimeric RMP have been used to assess the protective immune responses induced 
by vaccination that influence sporozoite invasion of hepatocytes both in vitro and in vivo, 
and the removal of infected hepatocytes in vivo [59]. For example, chimeric RMP have been 
generated where the endogenous csp gene has been replaced either with P. falciparum 
csp or different P. vivax csp alleles. These chimeric parasites produce sporozoites that are 
infectious to rodent hepatocytes in vivo and human hepatocytes in culture [59]. 
Based on studies with chimeric rodent parasites, we reasoned that the availability of 
chimeric P. falciparum parasites that express P. vivax antigens would open up possibilities 
to analyse protective immune responses induced by vaccination using P. vivax antigen-
based vaccines in CHMI, bypassing the need for P. vivax parasite production and measures 
to ensure that P. vivax  hypnozoites are removed. As a proof of concept we explored in 
Chapter 6 the possibility to create, using CRISPR/Cas9 gene editing methodologies, two 
chimeric P. falciparum parasites where the gene encoding circumsporozoite protein (CSP), 
was replaced by csp genes of P. vivax. CSP is the major protein of the sporozoite surface 
[14, 109] and plays a critical role both in sporozoite formation and in sporozoite invasion of 
mosquito salivary glands and liver cells of the host [105-108]. CSP is the target antigen of 
the most advanced P. falciparum malaria vaccine (RTS,S) and is also an important vaccine 
target for P. vivax [110, 111].  
In Chapter 7 the results of the studies described in Chapters 3-6 are summarized 
and discussed, including a discussion on the use of transgenic P. falciparum parasites in 
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Chapter 2 The use of transgenic parasites in malaria vaccine research
Abstract
Introduction
Transgenic malaria parasites expressing foreign genes, for example fluorescent and 
luminescent proteins, are used extensively to interrogate parasite biology and host-
parasite interactions associated with malaria pathology. Increasingly transgenic parasites 
are also exploited to advance malaria vaccine development. 
Areas Covered
We review how transgenic malaria parasites are used, in vitro and in vivo, to determine 
protective efficacy of different antigens and vaccination strategies and to determine 
immunological correlates of protection. We describe how chimeric rodent parasites 
expressing P. falciparum or P. vivax antigens are being used to directly evaluate and rank 
order human malaria vaccines before their advancement to clinical testing. In addition, we 
describe how transgenic human and rodent parasites are used to develop and evaluate 
live (genetically) attenuated vaccines. 
Expert Commentary
Transgenic rodent and human malaria parasites are being used to both identify vaccine 
candidate antigens and to evaluate both sub-unit and whole organism vaccines before they 
are advanced into clinical testing. Transgenic parasites combined with in vivo pre-clinical 
testing models (e.g. mice) are used to evaluate vaccine safety, potency and the durability 
of protection as well as to uncover critical protective immune responses and to refine 
vaccination strategies.
Keywords
Plasmodium, Malaria, Transgenic, Vaccine, Reporter, GAP, Chimeric. 
Introduct ion
In the mid-nineties genetic modification to create permanent modifications in malaria 
parasite genomes was first described in the rodent malaria parasite Plasmodium berghei[1]. 
This technology was extended to other Plasmodium species, including the human 
malaria parasite P. falciparum, and was initially used for loss-of-function analyses to 
uncover the function of Plasmodium genes, including genes encoding potential vaccine 
candidate antigens (reviewed in[2, 3]). In addition to gene-disruption and gene-mutation, 
methodologies have been developed to create malaria parasites that express ‘foreign’ 
genes from other organisms, so called transgenic parasites. Amongst the first transgene 
mutants were rodent malaria parasites that expressed fluorescent and luminescent 
reporter proteins. These parasites have been used to visualize and analyze parasite 
growth and development in vitro and in vivo and have been valuable tools to analyze 
cellular and molecular features of malaria parasite biology (reviewed in [4-7]). Transgenic 
rodent parasites have also been used to provide mechanistic insights into host-parasite 
interactions that regulate host (immune) responses to infection or those that mediate 
malarial pathology [8-13]. 
Transgenic parasites expressing fluorescent or luminescent reporter proteins have 
been created in rodent malaria species, the human parasite P. falciparum and the primate 
parasite P. cynomolgi. These parasites have been exploited in screening assays to measure 
(inhibition of) parasite growth at different points of the parasite life-cycle. Fluorescent 
and luminescent P. falciparum parasites have been used in vitro to examine the effect 
of drugs and other inhibitors on blood stage growth and on gametocytes[6, 14-17]and 
fluorescent P. cynomolgi parasites have been generated to screen for compounds that 
target the hypnozoite stage in the liver[18]. Transgenic fluorescent and luminescent rodent 
parasites have been used in in vitro screening assays to test inhibitors that target parasite 
development in the blood and liver [6, 19-22].  
In addition to measuring growth inhibition in vitro, transgenic rodent parasites have 
been used to examine the impact of drug or vaccine interventions in vivo, where inhibition 
of parasite development is measured as the reduction of reporter signal(mostly luminescent) 
in organs of the treated (compared to unimmunized/untreated) rodent host[6, 17, 19, 22, 
23]. As the life-cycle and basic biology of rodent and human Plasmodium parasites are 
very similar and since the vast majority of genes within their genomes are conserved [24], 
transgenic rodent parasites are frequently used to evaluate protective immunity against 
candidate Plasmodium antigens in vivo and are used to assess different vaccine delivery 
platforms and vaccination regiments. Several of these studies have been conducted 
in different inbred mice strains that exhibit different, often polarized, immunological 
responses to infection. Transgenic rodent parasites have been used in preclinical studies 
to examine protective immune responses to pre-erythrocytic (sporozoite and liver stage) 
vaccines (see Section 2).
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More recently transgenic rodent parasites have been generated that express proteins 
of the human Plasmodium species P. falciparum and P. vivax. These so-called ‘chimeric’ 
parasites have been used to evaluate the (in vivo) action of drugs against human Plasmodium 
protein targets [25, 26], to study malaria pathology during pregnancy, in vivo [27] and 
to evaluate the protective efficacy of vaccines that target human Plasmodium antigens 
(reviewed in [28-30] and see Table 1). In these vaccine studies, mice are immunized with 
P. falciparum or P. vivax antigens and subsequently challenged with chimeric rodent 
parasites expressing the cognate P. falciparum or P. vivax antigens. Such chimeric parasites 
permit an in vivo immunological evaluation of novel target Plasmodium antigens and 
vaccination strategies and can indicate the magnitude and type of protective immune 
response induced. This knowledge can be used to down-select from candidate antigens 
under consideration before proceeding to clinical studies [31].
Lastly, genetic modification of rodent and human malaria parasites has also been used 
to generate parasites that arrest in the liver. These parasites can provoke strong protective 
immune responses in the host and are therefore being evaluated as live, attenuated vaccines 
[32-34].Many gene-deletion rodent parasites have been tested in rodents for growth-arrest 
in the liver and for their capacity to induce potent protective immune responses. These 
so called GAPs have been created in transgenic reporter lines, which simplifies the in vivo 
evaluation of both their safety and protective efficacy. In order to generate completely safe 
GAP vaccines, GAPs must be generated that completely arrests in the liver. Consequently, 
multiple gene-deletions in the same GAP are considered necessary, each governing 
independent but essential processes during liver stage development. Therefore, in order 
to generate and test a P. falciparum GAP in human test subjects, large scale screening 
of single and multiple gene-deletion mutants in rodents is necessary to identify suitable 
genes for deletion in P. falciparum. 
In this review we describe the use of transgenic malaria parasites and their use as 
preclinical evaluation tools to measure vaccine efficacy and immune responses after 
vaccination. We describe: (i) transgenic rodent and human parasites that express reporter 
proteins that have been used to evaluate immunogenicity of vaccine antigens and vaccine 
efficacy; (ii) the use of transgenic chimeric rodent parasites, expressing antigens of P. 
falciparum or P. vivax, to compare immunogenicity of vaccines and vaccine strategies; 
and (iii) the use of transgenic parasites to identify and evaluate genetically attenuated 
parasite(GAP) vaccines and to examine immunological correlates of protection after 
vaccination in vivo.
Transgenic paras ites expresing reporter 
proteins
transgenic rodent and human malaria parasites that express fluorescent and luminescent 
reporter proteins have been used in screening assays to efficiently and rapidly measure 
inhibition of parasite growth at different points of the parasite life-cycle [6, 17, 22, 35]. 
Table 1. Transgenic rodent and human malaria parasites used in malaria vaccine research





A number of RMP expressing different fluorescent reporter proteins have 
been used to quantify parasite growth of different life cycle stages and to 





A number of different luminescent reporter RMP have been generated that have 
been used to quantify parasite growth of different life cycle stages, both in vitro 
and in vivo (see Sections2and 4 for references)a
Ovalbumin 
(OVA)
Several  OVA-expressing RMP have been used to analyze interactions of 
the parasite with the host immune system (see Sections2and 4 for references)a
Transgenic P. falciparum parasites expressing reporter proteins
Reporter Remarks
GFP GFP-expressing P. falciparum parasites have been used in GAI assays [16]
Luciferase Luminescent P. falciparum parasites have been used to quantify inhibition of oocyst 
production in SMFA assays [14]




P. vivax gene Remarks
RMgm 
ID Ref
PfLSA-1 PF3D7_1036400 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; in Pb (ANKA)
#1314 [31]
PfLSA-3 PF3D7_0220000 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; in Pb (ANKA)
#1315 [31]
PfCelTOS PF3D7_1216600 Additional copy; Pf (NF54) gene under 




PF3D7_1302200 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; inPb (ANKA)
#1311 [31]
PfLSAP1 PF3D7_1201300 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; inPb (ANKA)
#1308 [31]
PfLSAP2 PF3D7_0202100 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; inPb (ANKA)
#1312 [31]
PfETRAMP5 PF3D7_0532100 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; inPb (ANKA)
#1309 [31]
PfFalstatin PF3D7_0911900 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; inPb (ANKA)
#1313 [31]
PfCSP PF3D7_0304600 Additional copy; Pf (NF54) gene under 
the control of Pbuis4 promoter; inPb (ANKA)
#1316 [31]
PfTRAP PF3D7_1335900 Additional copy; Pf (NF54) gene under 






(2) Additional copies; Pf (NF54) genes under 






(2) Additional copies; Pf (NF54) genes under 
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These assays have been used to identify and characterize anti-Plasmodium drugs and 
small molecule inhibitors, as well as vaccines targeting parasite development at different 
points of the life-cycle. Transgenic parasites expressing fluorescent or luminescent proteins 
have been generated in three RMP, P. berghei, P. yoelii and P. chabaudi. For P. berghei and 
P. yoelii a number of transgenic lines exist that express different reporter proteins such as 
GFP, mCherry or luciferase (or fusions thereof). Most of these lines express these proteins 
under control of Plasmodium promoters of constitutively expressed Plasmodium genes 
(often housekeeping genes), which creates parasites that can be visualized and quantified 
throughout the complete life cycle (Figure 1A,B). Frequently used promoter regions of 
RMP genes include elongation factor 1-apha (eef1α), dihydrofolatereductase-thymidylate 
synthase (dhfr-ts) or heat shock protein 70 (hsp70). Information on all published RMP 
transgenic lines can be found in the RMgm database of genetically modified rodent 
parasites (www.pberghei.eu).
Different assays have been developed to quantify parasite growth using reporter 
parasites. To test the effect of inhibitors on blood and liver stage growth, simple and rapid 
assays exist that can quantify parasite numbers in blood samples, infected hepatocytes 





P. vivax gene Remarks
RMgm 
ID Ref
PfCSP PF3D7_0304600 Replacement copy; Pb (ANKA)csp replaced 
by Pf(Wellcome strain) csp, full-length Pbcsp 
promoter & 302bp Pbcsp3’UTR.
Reduced sporozoite production
#69 [73]
PfCSP PF3D7_0304600 Replacement copy; Pb (ANKA) csp replaced by 
Pf(NF54) csp under control of endogenous Pbcsp 
promoter and 3’UTR; No drug selectable marker.
Normal sporozoite production and infectivity
#4110
PfCSP PF3D7_0304600 Replacement copy;Py (17XNL) csp replaced with 
Pf (3D7) csp. Human DHFR selectable marker. 
Pbhsp70 3’UTR
Normal sporozoite production and infectivity
#1442 [96]
PfTRAP PF3D7_1335900 Replacement copy;Pb (ANKA)trap replaced by 
Pf(NF54)  trap  under control of endogenous 
Pbtrap  promoter and 3’UTR; No drug  
selectable marker
Normal sporozoite production and infectivity
#4112
PvTRAP PVP01_1218700 Replacement copy;Pb (ANKA) trap replaced with 
Pv (Sal-1) trap. No selectable marker. 
Normal sporozoite production and infectivity
#1103 [97]
Pv25 PVX_111175 Replacement copy; Pb25 and Pb28 replaced with 
Pv  25; in Pb (ANKA)
#222 [49]
Pf25 PF3D7_1031000 Replacement copy; Pb25 and Pb28 replaced with 
Pf25; in Pb (ANKA)
#273 [50]
PfCelTOS PF3D7_1216600 Replacement copy; Pb (ANKA) celtos replaced 
by Pf (NF54) celtos under control of endogenous 
Pbceltos promoter and 3’UTR; No drug  
selectable marker
Normal sporozoite production and infectivity
#4066 [74]
PvCSP (VK210) PVX_119355 Replacement copy; Pb (ANKA) csp replaced by 
PvVK210 csp under control of endogenous Pbcsp 
promoter and 3’UTR; No drug selectable marker
Normal sporozoite production and infectivity
[77]
PvCSP (VK247) PVX_119355 Replacement copy; Pb (ANKA) csp replaced by 
Pv VK247 csp under control of endogenous Pbcsp 
promoter and 3’UTR; No drug selectable marker
Normal sporozoite production and infectivity
[77]
PvCelTOS PVX_123510 Replacement copy; Pb (ANKA) celtos replaced by 
Pvceltos under control of endogenous Pbceltos 
promoter and 3’UTR; No drug selectable marker 
Normal sporozoite production and infectivity
#4111 [75]
Rodent malaria parasites expressing HMP-RMP fusion proteinsb
CSP PF3D7_0304600 The repeat region of Pb(NK65) csp is replaced 






P. vivax gene Remarks
RMgm 
ID Ref
MSP1 PF3D7_0930300 The Pb (ANKA) msp-1_19 C-terminal replaced 
with the Pf (D10)  msp-1_19 C-terminal
#201 [78]
MSP1 PF3D7_0930300 ThePb(ANKA)  msp-119 C-terminal replaced with 
the Pf (FCC1/HN)  msp-1_19 C-terminal
#330 [99]
CSP (VK210) PVX_119355 The repeat region of Pb (ANKA) csp is replaced 
with the  Pv (210) csp repeat region. 
#906 [100]
CSP (VK210) PVX_119355 The repeat region ofPb (ANKA) csp is replaced 
with (part of) Pv (210) csp gene
#1104 [47]
CSP (VK247) PVX_119355 The majority of Pb (ANKA) csp gene is replaced 
with Pv (247) csp; the fusion gene retains Pb signal 
sequence (1-20aa) and Pb GPI anchor  
sequence (372-395aa) 
#1443 [101]
P25 PVX_111175 The Pb (ANKA)25 and 28 genes replaced with 
a fusion of Pv25 and Pb 25
#223 [49]
VAR2CSA PF3D7_1200600 A synthetic Pf 3D7 DBL1X-6ε gene (var2csa) fused 
to Pb (ANKA) fam-a
#1436 [27]
Genetically Attenuated Parasites (GAPs)
See Section 4for details (and references) of transgenic parasites used to generate and test  
GAP vaccines
aFor full list of transgenic reporter parasites generated in RMP see the RMgm Database www.pberghei.eu
bPlasmodium species abbreviations: Pf - P. falciparum; Pv- P. vivax; Pb- P. berghei; Py- P. yoelii
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positive parasite-infected red blood cells [20, 36, 37](Figure 1A) or quantification of 
luminescence signals to determine parasite numbers or parasite loads in blood, liver 
or other organs [19, 21](Figure 1B). Infecting mice with defined numbers of luciferase 
expressing parasites and subsequent quantifying parasite loads (luminescence signal) in 
the liver by real time imaging of live mice is frequently used to establish the in vivo effect of 
either inhibitors and vaccines on liver stage development [6, 17, 22, 23]. Bioluminescence 
imaging is simple to execute and can be used to monitor the course of an infection without 
sacrificing the animal [19] (Figure 1B). This reduces the number of animals required for 
experimentation because multiple measurements can be made in the same animal over 
time that also minimizes the effects of biological variation. In addition, since imaged 
mice do not have to be sacrificed, additional features of parasite development can be 
established, for example characteristics of the ensuing blood stage infection such as 
the prepatent period, i.e. the duration between sporozoite infection and a microscopically 
detectable blood infection. Bio-luminescence imaging is a proven and sensitive method 
to measure parasite liver loads in mice, even after infection with low sporozoite doses. It 
has been shown that parasite liver loads can still be determined even after inoculation of 
1-10 sporozoites and that in vivo imaging quantification of parasite loads correlates very 
well with qPCR quantification methods [38]. The sporozoite doses used in different studies 
vary according to the vaccines being tested. Specifically, when examining potential GAP 
vaccines (see below) high doses of the GAP sporozoites are used to infect mice in order 
to establish if these parasites completely arrest in the liver, an essential and critical safety 
requirement of a live-attenuated vaccine. In addition, mice immunized with GAP parasites 




Figure 1. The use of transgenic reporter parasites in malaria vaccine research. A. Representative 
fluorescent images of different life cycle stages of P. falciparum and P. berghei (mCherry and GFP) 
reporter parasites. Blood stage trophozoites (Tr); schizonts (Sc); dissected infected mosquito midguts 
(Mid) with mature oocysts (Oo); salivary gland sporozoites (Spz); P. berghei liver stage schizont (LS). 
Host and parasite DNA are stained with Hoechst or DAPI (blue). B. Representative rainbow images of 
luminescence intensity in blood (upper panels) or liver (bottom panels) of live mice either uninfected 
(U) or infected (I) with luminescent reporter parasites. Parasite density (luminescence intensity) can 
also be determined in extracted tissue (ex vivo); lungs (lg), kidney (K), adipose/fat tissue (F), liver 
(Lv), spleen (S), brain (B) and heart (H). Bottom panel shows luminescence in extracted livers of 
infected and uninfected mice, 48 h after infection with sporozoites. C. Schematic representations 
showing the use of transgenic reporter parasites in assays to determine efficacy of erythrocytic, 
transmission blocking (TB) and pre-erythrocytic (sporozoite and liver stage) vaccines. Erythrocytic 
Vaccines: The inhibitory activity of sera from (semi) immune individuals or purified immunoglobulins 
from vaccinated animals/people on parasite invasion and growth in red blood cells are frequently 
determined in Growth Inhibition Assays (GIA). GFP expressing P. falciparum parasites have been 
used in GIA where inhibition of parasite growth was determined by measuring parasitemia by flow 
cytometry. Transmission Blocking Vaccines: The standard membrane-feeding assay (SMFA) is a well-
established method to evaluate the activity of antibodies/serum against human malaria parasites 
in the mosquito, mainly quantified by determination of oocyst production. A transgenic reporter 
P. falciparum line expressing luciferase have been used in SMFA to quantify oocyst production in 
mosquitoes, thus eliminating the need for mosquito dissections. Pre-erythrocytic (sporozoite and liver 
stage) Vaccines: Assays employing luciferase-expressing RMP have been developed to visualize and 
quantify liver stage development. Quantification of parasite liver loads by real time imaging has 
been performed in vaccinated and unvaccinated mice that have been challenged with luminescent 
parasites that either only express luciferase (e.g. in GAP studies; Section 4) or also express human 
malaria proteins (e.g. in studies on human malaria vaccines; Section 3).  
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order to test the protective efficacy of different GAP vaccines and vaccination regiments. 
In sub-unit vaccine studies mice are usually challenged with lower doses of sporozoites 
(1-3 x 103), a dose reflective of 1-5 mosquito bites, after which parasite liver loads 
are established.
As well as transgenic RMP lines, reporter parasites have been generated for the human 
parasite P. falciparum. Transgenic P. falciparum parasites expressing fluorescent or 
luminescent proteins have been used to quantify blood stage growth in vitro in standard 
growth inhibition assays(see below),to quantify parasite development in the mosquito 
in standard membrane feeding assays to measure transmission-blocking (TB) activity 
and in high-throughput screening of TB compounds against P. falciparum gametocytes 
(see below). For the TB assays against mosquito stages and gametocytes, transgenic P. 
falciparum (NF54 strain)parasite lines have been generated that express a GFP-luciferase 
fusion protein under control of the strong constitutive hsp70 [39] or the gametocyte 
specific pfs16 promoter [40]. 
In addition to RMP expressing fluorescent and luminescent proteins for vaccine studies, 
multiple transgenic RMP lines expressing the model antigen OVA as an immunological 
reporter have been created to study immune responses after vaccination. Transgenic 
Plasmodium parasites expressing OVA have been exploited to examine parasite-specific 
CD8+ T cell responses during both blood and liver infections [9, 10, 41-43]. For example, 
intravital two-photon microscopy of livers of mice infected with P. berghei parasites that 
express OVA and GFP in their cytoplasm showed that transferred OVA-specific CD8+ T 
cells recognize and forms clusters around infected hepatocytes, leading to the elimination 
of the intra-hepatic parasites [41]. In addition, analysis of liver stage parasites expressing 
OVA, either in their cytoplasm or exported to the parasitophorous vacuole membrane, in 
conjunction with OVA-specific CD8+ and CD4+ OVA T cells demonstrated that export of 
parasite proteins into the infected hepatocytes enhanced immunogenicity and CD8+ T cell 
based protection[10]. 
Below we describe the use of transgenic Plasmodium reporter parasites in preclinical 
assays to evaluate different Plasmodium vaccines and vaccination approaches, that target 
the 3 major points of the parasite life-cycle: erythrocytic vaccines, transmission blocking 
vaccines and pre-erythrocytic vaccines.
Erythrocytic vaccines
Although a number of RMP transgenic reporter parasites have been used in screening 
assays to evaluate drugs or other inhibitors, not many studies have reported the use of 
these parasites in assays to assess blood stage vaccines.  The inhibitory activity of sera 
from (semi) immune individuals or purified immunoglobulins from vaccinated animals or 
people is mostly evaluated in P. falciparum using in vitro erythrocyte reinvasion and GIA 
assays. These assays are used to quantitatively measure antibody-mediated effects on 
parasite invasion and growth, often in small scale synchronized cultures of blood stage 
parasites that are maintained in microtiter plates for 1-2 cycles in the presence or absence 
of antibodies. Determination of inhibition of invasion and growth in these assays is mainly 
performed by (automatic and high-throughput) microscopic, enzymatic or flow cytometric 
assays using wild type P. falciparum parasites [30, 44-46].In one study, a flow cytometric 
assay was developed that used transgenic P. falciparum parasites expressing GFP [16]. In 
this study P. falciparum parasites of the D10 strain were genetically modified to express 
GFP under control of the constitutive Pfhsp86 promoter and inhibition of parasite growth 
by inhibitory antibodies and human serum was determined by measuring parasitemia by 
flow cytometry. This assay was superior to microscopy based approaches and comparable 
to DNA-staining based techniques to quantify growth inhibition (Figure 1C).
Transmission blocking vaccines
Mutant RMP are frequently used in (loss-of-function) studies that aim to identify and 
characterize Plasmodium proteins essential for parasite development in mosquitoes, 
which may be suitable targets for TB vaccine strategies. Often these deletion mutants 
have been created in transgenic RMP that express fluorescent or luminescent reporters, 
under control of constitutive stage specific promoters permitting a detailed examination 
of parasite development in the mosquito, for example enabling easier quantification 
of gametocyte development, fertilization and oocyst or sporozoite production. While 
the use of transgenic RMP in TB vaccine studies is limited, chimeric RMP lines expressing 
the ookinete surface protein P25 of P. vivax and P. falciparum have been used in direct 
mosquito feeding (DMF) assays for evaluation of the efficacy of vaccines targeting P25 of P. 
vivax and P. falciparum. In these assays immunized mice were challenged with the chimeric 
RMP parasites expressing the human antigen, followed by determination of oocyst 
reduction in mosquitoes that were fed on the immunized and challenged mice [44, 47-50]. 
The SMFA is a well-established and recognized method to evaluate TB activity of 
antibodies/serum against human malaria parasites [51]. This assay has been utilized 
widely to assess the TB activity of purified antibodies and serum, both in preclinical and 
clinical vaccine studies. TB activity in the SMFA is defined by the reduction in oocyst 
numbers in mosquitoes that have been fed with infected blood containing gametocytes 
in the presence of antibodies/serum compared to no(or control) antibodies(Figure 1B).
Often oocyst production is measured by a microscopic analysis of dissected mosquito 
midguts. Recently, a transgenic reporter P. falciparum line expressing luciferase has been 
used in SMFA to quantify oocyst production in mosquitoes, thus eliminating the need for 
mosquito dissections[39]. This transgenic line was made in parasites of the P. falciparum 
NF54 strain and expresses a fusion protein of GFP and luciferase which is under control 
of the constitutive Pfhsp70 promoter and parasites of this line do not express a drug-
selectable marker. This novel dissection-free luminescence-based SMFA method, using 
a transgenic P. falciparum reporter parasite which is not resistance to known antimalarials, 




Chapter 2 The use of transgenic parasites in malaria vaccine research
Pre-erythrocytic vaccines
Transgenic RMP are frequently used in preclinical sporozoite and liver stage vaccine 
studies. Simple and sensitive in vitro and in vivo assays employing luciferase-expressing 
P. berghei and P. yoelii parasites have been developed to visualize and quantify liver 
stage development [19, 22]. In these assays, parasite hepatic development is determined 
by bioluminescence measurement of cultured liver stages or by real-time imaging of 
luminescence emanating from the liver of live mice. These measurements correlate well 
with established (but more laborious) quantitative RT-PCR methods [38, 52]. Both in 
vitro and in vivo luminescence imaging assays have been used to screen inhibitors and 
vaccines against liver stages (Figure 1C; [23, 29, 31, 53, 54]).The simplicity and speed 
of quantitative analysis of parasite liver loads by real-time imaging and the possibility to 
analyze parasite development in live mice without surgery, greatly enhances the analysis 
of the effect of individual vaccines or vaccine strategies that target pre-erythrocytic stages. 
Quantification of parasite liver loads by real time imaging has been performed in mice that 
have been first vaccinated with human Plasmodium sub-unit vaccines and then challenged 
with luminescent chimeric RMP that express human parasite antigens (see Section 3) or in 
mice that have been immunized with genetically attenuated parasites and subsequently 
challenged with luminescent RMP(see Section 4). In addition, imaging of luminescent 
parasites in mice has been successfully used to examining host factors regulating liver 
infections[55]and to analyze the impact of immune responses on inhibition of liver stage 
development[23, 56-58]. Such studies have revealed the importance of adaptive and innate 
immune responses in protective immunity after vaccination. In these studies passively or 
actively immunized mice (including immunological compromised mice) were challenged 
with luciferase-expressing parasites to monitor reduction in parasite liver loads. In addition 
to the use of luminescent RMP, transgenic RMP expressing fluorescent proteins have been 
used to provide insight into interactions of sporozoites with cells in lymph nodes and with 
dermal tissue and blood vessels, and their interactions specifically with cells of the innate 
and adaptive immune system [59-64]. Using fluorescent P. berghei sporozoites it was 
demonstrated that fewer sporozoites enter the blood and reach the liver in sporozoite-
immunized mice than naïve mice. Specifically, high circumsporozoite protein (CSP) 
antibody titers were shown affect sporozoite motility in the skin, preventing immobilized 
sporozoites of entering dermal blood vessels [65].
No assays have yet been reported to analyze P. Falciparum liver stage development in 
vitro with fluorescent or luminescent parasites. Most studies on P. falciparum liver stages, 
either cultured in hepatocytes (primary human or HC-O4 hepatocytes) or in chimeric mice 
with human liver tissue, have used wild type parasites that were analyzed by RT-PCR or 
by microscopy of fixed and stained cells. One study reported the use of transgenic P. 
falciparum parasites that express luciferase to study liver infection in immune compromised 
mice engrafted with human liver tissue [57]. This FRG huHep mouse is susceptible to 
a P. falciparum sporozoite infection and supports complete liver stage development. 
The reporter P. falciparum (NF54) parasites express a gfp-luciferase fusion gene under 
the constitutive Pfeef1a promoter and the reporter expression cassette is introduced into 
the pf47 locus [66]. In this study [57]a clear effect could be detected on infection of livers 
of FRG huHep mice by passively transferred antibodies against CSP and parasite liver 
loads in these mice were analyzed using bioluminescence imaging 6 days after infection 
with sporozoites (i.e.at the peak of liver-stage luciferase activity).
Chimeric  rodent paras ites express ing human 
plasmodium proteins
In addition to transgenic reporter parasites, rodent parasites expressing human malaria 
parasite proteins (HMP; P. falciparum and P. vivax) have been used in vaccine studies. 
These ‘chimeric’ RMP are used both to analyze immune responses against HMP antigens 
and to evaluate in vivo protective efficacy of vaccines that target HMP antigens (reviewed 
in [28, 29] and see Table 1). The preclinical evaluation of protective immunity involves 
mice being immunized with vaccines targeting different P. falciparum or P. vivax antigens 
followed by challenge with chimeric rodent parasites that express the corresponding 
HMP antigen. Mainly chimeric RMP expressing pre-erythrocytic HMP antigens have been 
generated (Table 1). Chimeric parasites have also been used to study immunogenicity and 
protective efficacy of transmission blocking HMP vaccine antigens, i.e. P. falciparum and P. 
vivax P25 [47, 49, 50]and blood stage vaccine antigens, i.e. P. falciparum MSP1 (Table 1).
Generation of chimeric parasites have been performed using standard methods of RMP 
transfection [67]by introducing HMP genes into the RMP genome, either as additional gene 
copies or by replacing the complete RMP with its HMP ortholog [29]. In addition, chimeric 
parasites have been generated that express fusions of the RMP and HMP orthologous 
genes (Table 1). The recently described GIMO (Gene Insertion-Marker Out) transfection 
method [68] greatly simplifies and speeds up the generation of transgenic parasites 
expressing heterologous proteins, which are free of drug-selection marker genes. Using 
this method two principle types of chimeric RMP expressing HMP proteins have been 
created ([29]; Figure 2A). The first type are ‘additional copy mutants’; here the HMP gene 
is introduced as an additional gene copy into a silent/neutral locus of the GIMO mother-
line and the HMP gene is under the control of a constitutive or stage-specific RMP gene 
promoter. This strategy is often used when an ortholog of the HMP gene is absent from 
the RMP genome. The second type of chimeric parasites are ‘replacement mutants’; here 
the coding sequence (CDS) of the RMP gene is replaced with the CDS of the orthologous 
HMP gene. This method creates chimeric parasites expressing the HMP gene under control 
of the endogenous RMP gene promoter and transcriptional terminator. The absence of 
a drug-selectable marker in both the additional copy and replacement mutants makes it 
possible to rapidly introduce additional genetic modifications in these chimeric parasites, 
e.g. introduction of additional HMP genes or fluorescent/ luminescent reporter genes.
Chimeric parasites have been used in vaccine studies for a number of reasons. While 
a high level of genetic orthology exists between genes of RMP and HMP, critical differences 
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often exist in the sequence and structure of the encoded proteins [24]. In addition, HMP 
express a number of genes encoding vaccine candidates that are absent from RMP 
[24, 31].These differences complicate the analysis of immunogenicity and protective efficacy 
of HMP antigens in rodent models and compromise the effective translation of findings 
into a human malaria vaccine. Therefore ‘humanizing’ RMP by introducing HMP genes into 
rodent parasite genomes can help to circumvent some of these problems. HMP cannot 
readily infect small animals and testing of P. falciparum parasites in rodents is expensive 
as it is largely restricted to immune-deficient mice (i.e. DRAG or FRG) transplanted with 
human hematopoietic stem cells and/or liver tissue [69, 70]. While it is possible to test 
both pre-erythrocytic and blood stage P. falciparum vaccine candidates directly in human 
subjects, these studies are expensive and laborious to perform and therefore less suitable 
for larger screening studies[71]. Preclinical screening studies using chimeric RMP make it 
possible to rapidly evaluate and compare the protective efficacy of novel target antigens 
and vaccination strategies in order to down select candidate antigens and strategies that 
can proceed into clinical studies.
Recently 10 pre-erythrocytic P. falciparum vaccine candidate antigens were tested for 
their protective efficacy using chimeric parasites [31]. The antigens were selected based 
on published literature, immuno-profiling and expression studies. Mice, immunized with 
viral-vectored vaccines expressing the HMP antigens, were challenged with chimeric 
parasites for evaluation of protective immune responses and characterization of 
the immune responses (see Figure 2B for the immunization/challenge protocol). In this 
study two antigens, PfLSA1 and PfLSAP2, generated better protective efficacy than two 
leading pre-erythrocytic P. falciparum vaccine antigens, PfCSP or PfTRAP, in both inbred 
BALB/c and outbred CD-1 mice. The chimeric parasites used in this study had the HMP 
gene introduced as an additional gene copy as a number of the selected genes did not 
have an ortholog in the P. berghei genome, thereby excluding the possibility to make 
replacement mutants. A number of other chimeric RMP have been used, which express 
a HMP ortholog in place of their own RMP gene (Table 1), for example chimeric parasites 
expressing pre-erythrocytic vaccine candidates such as P. vivax and P. falciparum CSP and 
CelTOS ([72-75]; Table 1). 
Chimeric parasites have also been used to evaluate immunogenicity of antigens against 
other lifecycle stages (i.e. TB vaccines see Figure 2C) as well as being used to evaluate 
different vaccine delivery platforms and to optimize the vaccination strategy and schedule. 
For example, the use of a single chimeric parasite expressing two HMP genes, TRAP and 
UIS3, showed that combination of two vaccines expressing these antigens could protect 
100% of immunized mice, despite these antigens demonstrating only modest protective 
immunity when administered as a single antigen formulation [76]. This synergistic effect 
was only evident when the two vaccines were mixed and administered into two legs. 
Another study, testing different vaccine delivery platforms targeting P. vivax CSP using 




Figure 2. The use of chimeric RMP expressing human malaria parasite (HMP) proteins in malaria 
vaccine research. A. Additional Copy Mutants have the HMP gene (e.g. the P. falciparum gene coding 
sequence; Pf CDS) introduced as an additional gene copy into a silent/neutral locus of the RMP; 
the HMP gene is under the control of a constitutive or stage-specific RMP gene promoter. Replacement 
Mutants have the RMP coding sequence (Pb CDS) replaced by the orthologous HMP CDS. This often 
2 step replacement method, employing the methods of GIMO transfection, creates chimeric parasites 
expressing the HMP gene under control of the endogenous RMP gene promoter and transcriptional 
terminator.  B. Vaccine immunogenicity and protective efficacy measured in mice immunized with 
HMP liver stage sub-unit vaccines or rodent GAPs. Immunized (and naïve) mice are challenged either 
with luminescent chimeric RMP expressing the cognate HMP antigen or with luminescent ‘wild-type’ 
RMP. Protective efficacy, relative to unvaccinated mice, is quantified by measuring the parasite load 
by real time imaging of the liver of live mice at 44-48 h after challenge with sporozoites (in vivo 
imaging of luminescence) and/or measuring the time to establish a detectable blood stage infection 
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was generated by virus like particles (VLP) expressing P. vivax CSP compared to other 
formulations, including viral-vectored vaccines or protein plus adjuvant [77].
Chimeric parasites expressing either full length HMP proteins or fusions of HMP-RMP 
proteins can be instructive in determining critical immunological determinants of 
the protective immune responses after vaccination, for example in GIA using material 
obtained from immunized humans or animals [78-80]. However, the mechanisms of 
protection after vaccination can be lost in in vitro assays if only individual components 
of the adaptive immune response are examined in isolation. For example, responses that 
require both antibody and cell-mediated responses, either acting independently or when 
they work in concert such as in antibody-dependent cell-mediated cytotoxicity responses 
[81]. Ultimately, however, even positive results generated using chimeric parasites in 
rodents or in vitro assays will need to be validated in human vaccine trials.
Attenuated paras ite vaccines
Transgenic parasites have not only been used for development and evaluation of 
immunogenicity of antigens and protective immunity of subunit vaccines, they have also 
been used to develop and evaluate whole organism vaccines consisting of (genetically) 
attenuated parasites. Vaccination with live, attenuated, sporozoites has been shown to 
induce strong protective immune responses both in rodents and in humans (reviewed in 
[32]). Sporozoite attenuation has been performed by radiation or by genetic modification of 
parasites (reviewed in [32-34, 82, 83]). A prerequisite for induction of protective immunity 
is that the attenuated sporozoites enter the liver, since heat-killed or over-irradiated 
sporozoites that do not invade hepatocytes do not efficiently confer protection [33, 84]. 
These so-called genetically attenuated parasites (GAPs) have genes encoding proteins 
essential for parasite development in the liver removed, thereby producing parasites 
that arrest in the liver. For both GAPs and radiation-attenuated parasites immunogenicity 
(protective efficacy) and safety are critical factors for further clinical development as whole 
organism vaccines. Transgenic rodent parasites have been used extensively in preclinical 
evaluation studies to establish the safety profile of GAPs, i.e. absence of a blood stage 
infection in mice after inoculation with high numbers of GAPs[34]. A number of different 
GAP vaccine candidates have been generated in rodent parasites, by deletion of either 
single or multiple genes. These have been analyzed in mice to ensure they completely 
arrest in the liver and therefore meet the necessary safety profile for translation into human 
GAP. Introducing genes encoding fluorescent and luminescent genes into the genomes of 
GAPs has permitted a detailed analysis on the timing and magnitude of arrest in the liver 
[85, 86] (Figure 1B). Based on studies on growth arrest and safety of rodent GAPs, three 
multiple gene-deletion P. falciparum GAPs have been developed that have advanced into 
clinical evaluation [87-89]. 
In addition to examining the safety profile of a GAP, transgenic RMP have also been used 
to evaluate the protective immunity induced by attenuated sporozoites, both radiation-
attenuated sporozoites and GAPs. In multiple studies, mice immunized with attenuated 
parasites have been challenged with fully infectious sporozoites that express luciferase 
to determine liver loads by real time imaging, similar to what has been described above 
for evaluation of protective immunity of sub-unit vaccines (Section 2and 3; Figure 2B). 
Quantification of parasite liver loads and the pre-patent period provide a direct 
measurement of protective immunity induced by different immunization regimens. 
Rodent GAPs expressing luciferase have also been used to investigate different 
attenuated sporozoite administration strategies [90, 91]. These studies demonstrated 
that the route and dose of administration of attenuated sporozoites are critical factors in 
inducing protective immunity.  Intradermal, subcutaneous and intramuscular administration 
of attenuated sporozoites resulted in reduced parasite liver loads when compared to 
the same number of sporozoites introduced intravenously. Lower parasite liver loads 
after intradermal delivery was associated with reduced protective efficacy compared to 
intravenous immunization. Transgenic fluorescent rodent GAPs have been used to analyze 
direct interactions of lymphocytes with infected hepatocytes using intravital imaging of 
mice that had previously been immunized with attenuated sporozoites [13, 41, 92, 93]. 
These studies have revealed the importance of CD8+ T cell mediated killing and elimination 
of infected hepatocytes in mice immunized with attenuated sporozoites. Further, using 
transgenic RMP expressing the immunological reporter protein ovalbumin, it has been 
possible to analyze direct interactions and effects of antigen specific CD8+ T cell mediated 
immune responses in the liver of mice immunized with attenuated sporozoites ([10, 41]; 
see also Section 2).
Expert commentary
The ability to genetically manipulate the malaria parasite by deleting, mutating genes 
or introducing transgenes in the parasite genome has advanced our understanding of 
the molecular and cellular biology of malaria parasites for the last 20 years. Genetic 
modification has been central to the functional characterization of genes including genes 
encoding putative vaccine candidate antigens. The generation of reporter parasites with 
additional genes in their genome has resulted in the increased use of transgenic parasites in 
translation-oriented research, for example in preclinical studies evaluating immunogenicity 
and protective efficacy of novel antigens and vaccines. These studies involve transgenic 
parasites of both rodent and human malaria species. Two examples of transgenic human 
parasites are luminescent P. falciparum parasites that have been used in high-throughput 
(pre-patent period; % survival). C. Vaccine efficacy of HMP transmission blocking vaccines determined 
in a direct mosquito feeding assay (DMFA) in mosquitoes. In these assays mice are immunized with 
the HMP transmission blocking vaccine. Immunized  and naïve mice are then infected with chimeric 
RMP parasites expressing the cognate HMP antigen. The infected mice are used to feed mosquitoes 
and (reduction in) oocyst production in mosquitoes is quantified 8-10 days after feeding in order to 
measure of the transmission blocking potential of the HMP vaccine.
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assays to quantify transmission blocking activity and the use of luminescent P. falciparum 
parasites to analyze the effects of (passively transferred) immune sera on liver infection 
in mice engrafted with human liver tissue (Section 2). These assays are used to generate 
insights into the immunogenicity of putative vaccine candidate antigens, knowledge which 
in turn can be used to improve vaccine strategies that target transmission blocking stages 
and pre-erythrocytic stages, respectively.  
Compared to transgenic P. falciparum parasites, transgenic rodent malaria parasites 
have been more widely applied in experimental vaccine studies, especially in the evaluation 
of pre-erythrocytic antigens and to assess different pre-erythrocytic vaccination strategies. 
For example, luminescent parasites are frequently used to challenge immunized mice in 
standard assays that measure the reduction in parasite liver load as a consequence of 
the protective immune responses induced by different antigens or vaccine strategies. 
Another example is the application of intravital imaging using fluorescent parasites in 
immunized mice, which has revealed critical insights into the immune response targeting 
sporozoites and infected liver cells (Section 2). Such in vivo assays to analyze crucial 
protective immune responses after vaccination and to evaluate protective immunity are 
valuable tools to improve pre-erythrocytic vaccines. 
In addition to reporter rodent parasites, chimeric rodent parasites expressing proteins 
of the human malaria parasites P. falciparum and P. vivax are now being increasingly used in 
vaccine studies. Chimeric RMP expressing HMP proteins are used to determine protective 
efficacy in mice immunized with different sub-unit vaccines expressing P. falciparum 
and P. vivax antigens (Section 3). These studies have been used to select novel vaccine 
candidate antigens for advancement into clinical trials. Chimeric RMP can not only support 
identification of novel antigens, but also contribute to the in vivo evaluation of novel 
delivery platforms and vaccine strategies, both for vaccines targeting pre-erythrocytic 
parasites and transmission blocking vaccines (Section 3). The use of chimeric rodent 
parasites to evaluate protective immunity or transmission blocking immunity is not without 
its limitations. First, the use of chimeric RMP still relies on a murine model, often inbred 
mice strains, and encounter issues related to restriction of MHC epitopes and marked 
immune-dominance of certain epitopes [94]. Outbred mice can possibly be used to more 
accurately reflect what may be seen in humans but it is possible that some antigens 
identified as poorly immunogenic in these studies may in fact be immunogenic in humans. 
Second, when using ‘Additional copy’ chimeric parasites, the HMP gene expression is 
dependent on the RMP promoter used, which is unlikely to exactly mimic the timing and 
magnitude of the expression of the HMP protein in the HMP. In studies where multiple 
vaccine antigens are examined the chimeric parasites will express the different HMP 
antigens at the same level, which is unlikely to be the case in wild-type HMP. Therefore, 
where possible, it would be useful to also compare protective vaccine efficacy in mice 
using a chimeric RMP parasite where the HMP antigen expression matches its expression 
in the HMP, both in timing and magnitude. Despite these limitations, chimeric RMP allow 
for rapid vaccine (rank-order) screening in vivo and can provide critical insights into both 
the importance of the vaccine target and the mechanism of protection. Indeed data from 
chimeric RMP is being used to justify the selection of novel HMP antigen vaccines (and 
delivery platforms) to advance into clinical testing.
In addition to the role of transgenic parasites in the development of subunit vaccines, 
transgenic parasites have played a central role in the development and evaluation of whole 
organism vaccines consisting of attenuated sporozoites. Studies in rodent malaria models 
on the safety and immunogenicity of GAPs has formed the basis of the development 
of different (multiple gene deletion) P. falciparum GAPs that have now advanced into 
clinical trials (see Section 4). Given the data from rodents studies with both GAPs and 
irradiated sporozoites and from data emerging from irradiated sporozoite vaccine research 
in humans it is anticipated that further improvements can be made to increase GAP 
potency. Here again transgenic RMP can play an important role, for example to optimize 
the routes of attenuated parasite vaccine administration (e.g. studies with devices to 
improve intradermal or intramuscular delivery, use of adjuvants etc) and in development 
of the so-called ‘next generation’ GAP vaccines with increased potency requiring fewer 
sporozoites per dose and fewer vaccination doses to achieve sustained sterile protection 
(e.g. GAPs which arrest late into liver stage development). 
Transgenic parasites used in conjunction with ‘humanized’ animal models or in 
sophisticated in vitro assays are designed to aid and speed up malaria vaccine design, 
specifically to suggest potential priorities for expensive and time-consuming clinical 
trials. As mentioned above, however, the predictive power of these assays can only be 
determined after human trials have been performed and lessons learnt from the success 
and discrepancies that will arise. In addition, over-reliance on a single experimental model 
may result in putative valid vaccine targets not being advanced further, as they did not 
generate sufficient immunity in the testing platform (e.g. in mice).   
Five-year v iew
Despite considerable effort, over decades, a highly effective vaccine against malaria still 
does not exist. This is in part due to the limited number of antigens and methods of 
immunization that have advanced into clinical testing. Most vaccine studies have focused 
on a limited number of antigens but for a broad acting, highly durable and potent malaria 
vaccine this is likely to be too restrictive and insufficient to provide the protection required. 
Therefore, in order to create multi-antigen and multi-stage vaccines many more antigens 
and improved vaccine delivery platforms will need to be investigated and evaluated as 
a priority in the next 5 years. In addition, the critical host and parasite factors mediating 
protective immunity and those that are necessary for maintaining durable protection 
need also further investigation in the upcoming years. The use of transgenic parasites in 
conjunction with other enabling technologies (e.g. genetic modification of mice or human 
cell lines, advances in imaging etc) has opened up new possibilities and will be used to 
contribute to a more rapid preclinical evaluation of vaccines, vaccination strategies and 
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identification of critical factors of protective immune responses. Transgenic P. falciparum 
parasites expressing luminescent reporter proteins are currently valuable tools to assess 
drugs and inhibitors against the parasite in high-throughput assays and are now also 
being used to test the immunogenicity of (novel) transmission blocking antigens and will 
continue to be used to evaluate novel transmission blocking vaccine strategies. In addition, 
the recent availability of luminescent P. falciparum parasites that express luciferase under 
strong promoters (i.e. constitutive, sporozoite or liver-stage specific) will act as a bridge 
between rodent and clinical studies. They will be increasingly used in assays to evaluate 
the effects of (human) immune serum, cells and factors on P. falciparum blood and liver 
cell infection, both in cultured cells and in humanized mice with human hematopoietic 
and human liver cells. Such assays will contribute to generate essential insights into 
the immunogenicity of (in particular pre-erythrocytic) antigens and vaccination strategies. 
Both reporter RMP expressing fluorescent and luminescent proteins as well as chimeric 
RMP expressing HMP antigens will contribute to these studies examining protective 
immune responses in particular of vaccine strategies targeting pre-erythrocytic  vaccines. 
The use of transgenic parasites may not only help to rank order existing candidates but 
also help to reveal novel vaccine candidate antigens and vaccination strategies. Loss of 
function and protein-tagging mutants often reveal parasite proteins that have critical roles 
in parasite development or, for example, are located on the surface of extracellular forms 
of the parasite and may therefore be vulnerable to antibody-based vaccines. Uncovering 
critical protective immune responses and efforts to establish correlates of protection after 
vaccination may be greatly aided by the use of both transgenic parasites and humanized 
mice, which could be used to examine both the induction and recall of immune responses 
in different organs. Transgenic RMP will continue to play an important role in preclinical 
evaluation of novel attenuated sporozoite vaccines both in studies to develop GAPs that 
are more immunogenic and in studies to improve vaccination strategies (e.g. optimizing 
the route of administration). In particular, next generation P. falciparum GAPs that have 
been further modified to express multi-stage and antigens from multiple strains.
Key issues
 · Most vaccine studies have focused on a limited number of antigens but for a broad 
acting, highly durable and potent malaria vaccine this is likely to be too restrictive 
and insufficient to provide the protection required. Multi-stage, multiple-antigen 
sub-unit or genetically attenuated parasite vaccines may provide a solution.
 · Transgenic (human and rodent) malaria parasites expressing ‘foreign’ proteins, 
for example fluorescent and luminescent proteins, have been used to determine 
the protective efficacy of different antigens and to evaluate vaccination 
platforms/strategies. 
 · Transgenic parasites (e.g. expressing OVA) are being used to understand the critical 
determinants of protection after vaccination; specifically to examine the  induction 
and recall of protective immune responses in the blood and the liver 
 · Luminescent rodent parasites are now increasingly used to challenge vaccinated 
mice, and non-invasive measurements of parasite liver load permits examination 
of both the protective responses generated by different antigens and to evaluate 
novel vaccine strategies.
 · Luminescent P. falciparum parasites are being used both in high-throughput 
assays to quantify transmission blocking activity and to analyze the effects of 
human immune sera/immunoglobulins on parasite development in the liver of 
 humanized mice. 
 · Chimeric rodent parasites, expressing P. falciparum or P. vivax antigens, are being 
used to directly evaluate and rank-order human malaria vaccine candidates and 
determination of the most suitable for clinical testing. 
 · Chimeric rodent parasites permit an in vivo comparison of different P. falciparum/
vivax vaccine delivery platforms and vaccination strategies; they are being used 
to determine the best combination of antigens, delivery system and immunization 
protocol to move forward into clinical testing.
 · Transgenic parasites play a central role in the development and evaluation of whole 
organism vaccines consisting of attenuated sporozoites. Both in evaluation of safety 
and in assessing protective efficacy. Improvements in genetically attenuated parasite 
vaccines and strategies for vaccination (i.e. optimizing the route of administration) 
will continue to require the use of transgenic parasites.
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The CRISPR/Cas9 system is a powerful genome editing technique employed in a wide 
variety of organisms including recently the human malaria parasite, P. falciparum. Here we 
report on further improvements to the CRISPR/Cas9 transfection constructs and selection 
protocol to more rapidly modify the P. falciparum genome and to introduce transgenes into 
the parasite genome without the inclusion of drug-selectable marker genes. This method 
was used to stably integrate the gene encoding GFP into the P. falciparum genome under 
the control of promoters of three different Plasmodium genes (calmodulin, gapdh and 
hsp70). These genes were selected as they are highly transcribed in blood stages. We 
show that the three reporter parasite lines generated in this study (GFP@cam, GFP@gapdh 
and GFP@hsp70) have in vitro blood stage growth kinetics and drug-sensitivity profiles 
comparable to the parental P. falciparum (NF54) wild-type line. Both asexual and sexual 
blood stages of the three reporter lines expressed GFP-fluorescence with GFP@hsp70 
having the highest fluorescent intensity in schizont stages as shown by flow cytometry 
analysis of GFP-fluorescence intensity. The improved CRISPR/Cas9 constructs/protocol will 
aid in the rapid generation of transgenic and modified P. falciparum parasites, including 
those expressing different reporters proteins under different (stage specific) promoters.
Introduct ion
A wide variety of transgenic parasite lines have been generated in rodent malaria 
parasites, including those that express fluorescent and/or luminescent reporter proteins 
under the control of constitutive or stage-specific promoters. Such transgenic ‘reporter’ 
parasites have proven to be useful tools to interrogate Plasmodium gene function, examine 
the effect of inhibitors on parasite development, to evaluate sub-unit vaccine efficacy in 
vivo and to rank order and evaluate live-attenuated parasite vaccines [1-12]. For rodent 
malaria parasites technologies have been developed to stably introduce transgenes into 
the parasite genome and efficient and rapid methods exist for the generation of reporter 
parasite lines that do not contain drug-selectable markers [13, 14]. Such ‘marker-free’ 
parasites make it considerably easier to further genetically modify transgenic parasites 
and, moreover, they can be used for drug-sensitivity testing, as possible interference from 
an introduced drug-selection marker is absent. In rodent malaria parasites such reporter 
parasite lines have been generated in multiple strains of three different Plasmodium 
species [15].
In comparison to rodent malaria parasites the technologies to genetically modify 
the human malaria parasite, P. falciparum, are much less efficient [16] and the number of 
stable reporter parasite lines in different P. falciparum strains is limited [17, 18]. In addition, 
currently no cloned reporter lines have been published that are drug-selectable marker free. 
The traditional approaches to engineer the P. falciparum genome have been hampered 
by the limited methods available and transfection inefficiencies in introducing exogenous 
DNA into the parasite genome. Also the limited number of drug-selectable markers 
restricts genetic engineering of P. falciparum, for example, performing sequential genetic 
manipulations in the same parasite line. Several technologies have been developed for 
the removal (re-cycling) of drug-selectable markers from the modified parasite genome, 
specifically using either FLP or Cre recombinases [19, 20]. However,  the application 
of these techniques are time consuming as it can take 4-5 months to generate cloned 
‘marker-free’ genetically modified parasites. 
The RNA-guided CRISPR/Cas9 (clustered regularly interspaced short palindromic 
repeats/CRISPR-associated protein 9) system has transformed genome editing in a wide 
variety of organisms [21]. This powerful genome editing technique has also been applied 
to P. falciparum and provides an efficient method to manipulate the parasite’s genome, 
such as site directed mutagenesis, gene disruption and the introduction of transgenes 
[22, 23]. The CRISPR/Cas9 method is based on the initial generation of site-specific 
double strand DNA break induced by a Cas9 endonuclease and subsequent repair and 
modification of the DNA locus. The Cas9 enzyme is guided to a specific site in the genome 
by a single guide RNA (sgRNA) that can be modified to specify the exact DNA sequence 
within the genome. The presence of a template or ‘donor DNA’ that contains sequences 
surrounding the double stranded DNA break can result in guided (or homology directed) 
repair, resulting of introduction of donor DNA at the site of the break [24]. Frequently 
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a two plasmid approach is used to introduce Cas9, the single guide RNA (sgRNA) 
composed of a fusion between CRISPR RNA (crRNA) and trans-activating CRISPR RNA 
(tracrRNA), and donor DNA into the nucleus of the organism. P. falciparum transfections 
have been performed with Cas9 and sgRNA either expressed on two separate plasmids 
or combined on one plasmid and different selectable markers have been used to maintain 
the plasmids in transformed parasites after transfection [22, 23, 25-27]. The selectable 
markers used are human dihydrofolate reductase (hdhfr), blasticidin S deaminase (bsd), 
neomycin phosphotransferase (neo) and yeast cytosine deaminase/uridyl phosphoribosyl 
transferase (yfcu). Generation of P. falciparum transgenic reporter parasites would benefit 
from the availability of standard CRISPR/Cas9 plasmids that permit the rapid introduction 
of different transgenes into the parasite genome without permanently  integrating 
a drug-selectable marker cassette. Recently improved CRISPR/Cas9 constructs have been 
reported for marker-free editing of the P. falciparum genome [26]. One plasmid contains 
Cas9, the sgRNA and a bsd selectable marker cassette, whereas the other construct, 
containing the donor DNA, does not encode a drug selectable marker. The use of this 
‘marker-free’ construct thus can permit an introduction of larger donor DNA sequences. 
Using these constructs marker-free GFP-expressing parasites have been reported. 
In this paper we describe the generation of marker-free reporter parasites by using 
modified CRISPR/Cas9 constructs compared to the constructs described in previous 
studies. We generated a standard plasmid that encodes Cas9 and contains the bsd 
selection marker cassette. The sgRNA and donor DNA are both present on a second 
plasmid, which contains the positive selectable marker, hdhfr, fused to the negative 
selectable marker, yfcu. This dual positive-negative selectable marker cassette is not 
integrated into the genome but is used to rapidly select ‘marker-free’ transgenic parasites 
by the successive application of positive drug selection followed by negative selection. 
By generating three reporter lines which stably express GFP under the control of different 
promoters we show that cloned marker-free reporter parasite lines can be obtained within 
a period of 10-12 weeks. In addition, we show that these reporter parasites have the same 
in vitro blood-stage growth kinetics and drug-sensitivity profiles as the parental wild-type 
parasites and we compared the relative strengths of the different promoters to drive GFP 
expression. The constructs and selection protocol described in this study provide a simple 
set of tools to rapidly generate modified P. falciparum lines, in particular transgenic 
parasites that can be used to examine different Plasmodium regulatory elements to 
control transgene expression. The same constructs can be used to perform other genetic 
modifications, for example gene disruption or gene mutation, to interrogate gene function 
and can be used to perform rapid and multiple successive genetic manipulations.
Results
Improved CRISPR/Cas9 plasmids to introduce transgenes into the Plasmodium 
genome without the addition of drug selectable markers
Homologous recombination using the CRISPR/Cas9 protocol requires introduction of 
the Cas9 endonuclease complexes with a sgRNA and DNA sequences (donor DNA) that 
will induce a double stranded break in the genome and then repair the target region. 
Often these different elements are present on two different plasmids encoding different 
drug-selectable markers. To introduce Cas9 we used the plasmid described by Ghorbal 
et al. [22]. However, in this construct (pLf0019) we replaced the ydhodh drug-selectable 
marker (SM) by the more standardly used bsd SM (Figure 1), as the drug Blasticidin (BSD) 
is easier to obtain than DSM1 that is used in conjunction with the ydhodh SM.
 A second plasmid (pLf0022) was generated that both contains the donor DNA, 
the sgRNA expression cassette and drug-selectable marker. For sgRNA we used 
the expression cassette of the published plasmid pL6-eGFP [22], which contains the BtgZ1 
adaptor sequence and the tracrRNA sequence under control of the Plasmodium u6 
RNA promoter. The drug-selectable marker cassette we used is a fusion of the positive 
selectable marker hdhfr (human dihydrofolate reductase), and the negative selectable 
marker yfcu (yeast cytosine deaminase/uridyl phosphoribosyl transferase) [28]. This fusion 
gene, hdhfr::yfcu, was placed under control of the P. falciparum hsp86 promoter and 
the P. berghei dhfr/ts transcriptional terminator (3’UTR)  and the positive-negative drug 
selection marker was tested in a transient transfection drug-sensitivity assay. In this assay, 
parasites of the P. falciparum NF54 line were transiently transfected with a circular plasmid 
(pLf0033; Figure S1A) encoding the hdhfr::yfc fusion protein and were treated with 
either WR99210 (positive) or 5-FC (negative) for 12-16 days. The transiently transfected 
parasites treated with WR99210 exhibit a growth rate comparable to untreated NF54 
wild type parasites (Figure S1B), whereas treatment with negative drug selection (using 
5-FC) killed transfected parasites (Figure S1C). The hdhfr::yfcu fusion cassette therefore 
confers both resistance to WR99210 and sensitivity to 5-FC and can be used efficiently 
for positive and negative selection in P. falciparum transfections. We reasoned that by 
applying first positive selection (with BSD and WR92210) followed by negative selection 
(with 5-Fluorocytosine, 5-FC), would improve the selection of parasites where the donor 
DNA had been integrated into the genome. Specifically, applying first positive selection 
will select for parasites that contained both plasmids, resulting in a DNA break followed by 
donor DNA mediated repair of the target locus. Once parasites were visible in blood stage 
cultures we applied negative selection to select only parasites free of episomal plasmid 
DNA. Moreover, we placed the selectable marker fusion cassette outside the donor DNA 
cassette in the plasmid (Figure 1). This location permits the introduction of donor DNA 
sequences into the target locus without the introduction of a drug-selectable marker into 
the parasite genome (Figure 1). The fusion of the positive and negative selectable marker 
cassette also reduces the size of the overall plasmid compared to a construct where both 
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selectable markers were controlled by separate regulatory elements.  This  increases the 
size of heterologous DNA that can be introduced as donor DNA; in Figure S2 the plasmid 
maps of both the Cas9 (pLf0019) and the crRNA/Donor (pLf0022) are shown in more detail. 
Generation of (donor DNA) constructs to introduce different GFP-expression 
cassettes into the P. falciparum genome
To introduce transgenes into the P. falciparum genome we further modified pLf0022, and 
introduced homology sequences to target the P. falciparum p230p (Pf230p) gene locus. 
The Pf230p gene is not transcribed in asexual blood stages [29] and is therefore unlikely 
to be essential for asexual blood stage development/multiplication. Homology region 1 
(HR1) and homology region 2 (HR2) were both PCR amplified from P. falciparum (NF54) 
genomic DNA and cloned into plasmid pLf0022.
A 20 nucleotide crRNA sequence specific for Pf230p was identified  using Protospacer 
software and this crRNA was introduced into the pLf0022 by replacing the BtgZI adaptor 
sequence, resulting in a Pf230p sgRNA (sgRNA2) in the construct. This modified pLf0022 
vector containing two HR of Pf230p and  sgRNA2 created the plasmid pLf0024. We identified 
promoters to drive strong GFP transgene expression in blood stages. Specifically, promoters 
of three strong constitutively expressed genes based on published transcriptional profiles 
(RNAseq) data available from the PlasmoDB database (www.plasmodb.org). Genes were 
selected that had transcript levels (RNAseq values) that were similar or higher than that 
of the constitutively expressed elongation factor 1α (PF3D7_1357100), the promoter of 
this gene has been previously used in both P. falciparum and rodent models of malaria to 
drive the expression of reporter proteins [30]. These promoters were from the following 
genes: calmodulin (PF3D7_1434200; cam), glyceraldehyde-3-phosphate dehydrogenase 
(PF3D7_1462800; gapdh) and heat shock protein 70 (PF3D7_0818900; hsp70); see 
Table S2 for data on the transcript levels of these genes. In the cam and gapdh promoter 
GFP-expression cassettes the gfp gene was placed under control of the P. berghei 
calmodulin transcriptional terminator (3’ UTR), whereas for hsp70 the 3’UTR of P. falciparum 
histidine-rich protein II was used. In the final constructs the GFP expression cassette 
of gfp@cam and gfp@gapdh are consequently in a different orientation to gfp@hsp70; 
see the Material and Methods section for further details. Cloning of the different GFP 
expression cassettes in pLf0024 resulted in the following constructs; gfp@cam (pLf0026), 







Figure  1.  Schematic  representation  of  improved  CRISPR/Cas9  plasmids  and  selection 
protocol 
Parasites are  transfected with  two plasmids  (Cas9  construct and  sgRNA/donor  construct). 
The Cas9 construct contains the bsd selectable marker. The sgRNA/donor construct contains 
a  fusion of  the positive  selectable marker hdhfr  and  the negative  selectable marker  yfcu 
genes and  two homology  regions  (HR1 and HR2)  that  target a gene of  interest  (GOI) and 
introduce  the  donor DNA  by  homologous  recombination. Double  positive  selection  using 
Figure 1. Schematic representation of improved CRISPR/Cas9 plasmids and selection protocol. 
Parasites are transfected with two plasmids (Cas9 construct and sgRNA/donor construct). The Cas9 
construct contains the bsd lectable marker. The sgRNA/donor con truct contains  fusion of 
the positive selectable marker hdhfr and the negative selectable marker yfcu genes and two 
homology regions (HR1 and HR2) that target a gene of interest (GOI) and introduce the donor DNA 
by homologous recombination. Double positive selection using both BSD and WR99210 is applied 
from day (d) 1 resulting in the selection of parasites that contain both plasmids within a period of 3 
weeks (w). After positive selection, cultures are maintained 2-4 days without drug before negative 
selection is applied using 5-FC to select parasites free of episomal plasmid DNA. Parasites are 
genotyped by diagnostic PCR for integration of the donor DNA followed by cloning of the parasites 
by limiting dilution (w6). Clones are genotyped for the correct genotype by diagnostic PCR and 
Southern analysis. This transfection and selection protocol can result in the generation of cloned 
mutant parasites within a period of 11 weeks.
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Figure 2. Generation of three P. falciparum reporter lines (GFP@cam, GFP@hsp70, GFP@gapdh) 
expressing GFP under control of different promoters. A. Schematic of the different sgRNA/donor 
constructs generated to introduce the GFP expression cassettes into the P. falciparum (Pf) 230p gene 
locus. Pf230p homology regions (HR1, HR2) used to introduce the donor DNA (i.e. gfp expression 
cassettes), location of primers (p) and sizes of restriction fragments (S: SpeI, X: XhoI; in red) and 
PCR amplicons (in black) are indicated. Primer sequences (shown in black and bold) are shown in 
Table S1. Note that the GFP expression cassette from GFP@cam and GFP@gapdh was cloned in 
the same orientation whereas that the GFP expression cassette form GFP@hsp70 was cloned in 
Generation of three transgenic reporter P. falciparum lines expressing GFP 
under different promoters
All construct were used to transfect P. falciparum ring stage parasites that were obtained 
from cultures after sorbitol synchronization. In each transfection 300 µl of pelleted infected 
RBC from cultures with a 6-15% parasitemia were mixed with 50 µg of the Cas9 and 50 µg 
of the donor plasmid. After transfection parasites were cultured in 10 ml flasks of an semi-
automated culture system [31]. Twenty-four hours after transfection we applied ‘double’ 
positive selection by adding the drugs WR99210 and BSD to the cultures to select only for 
parasites that contain both plasmids. Drug pressure was maintained until infected RBC were 
detected by thin blood-smears analysis (usually 3 weeks after transfection). Subsequently, 
both drugs were removed from the cultures for 2-4 days, followed by the application of 
negative drug selection by the addition of 5-FC. This was performed in order to remove 
parasites that still retain episomal donor construct plasmid DNA, thereby enriching for 
transfected parasites that have the donor DNA integrated into their genome. To avoid any 
potential bystander killing effect of 5-FC at higher parasitemias we treated the cultures 
with 5-FC only after reducing the culture parasitemia to 0.5%. Negative drug pressure was 
maintained until thin blood-smears were parasite-positive (usually 7 days after application 
of 5-FC; Figure 1). 
During both the positive and negative drug selection, parasites were analysed for GFP 
expression by fluorescence microscopy to determine the ratio of wild type and transgenic 
parasites present in the population. In multiple transfection experiments (exp.) with 
the three constructs with the different GFP-expression cassettes we obtained GFP-positive 
parasites after positive and negative selection (exp. 22 and 33 for pLf0026; exp. 44 for 
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the reverse orientation. See Figure 1 and S1 for details of the drug selectable marker and sgRNA 
sequences. This Figure is not shown to scale. B. Diagnostic (first 3 lanes) and long-range (LR-) PCR 
confirming correct integration of the GFP-expression cassettes into the Pf230p locus. Integration 
PCR of cloned parasites of GFP@cam (clone 1; primers p23/p24; expected size: 2538bp), GFP@
hsp70 (clone 5; primers p25/p26; expected size: 1622bp) and GFP@gapdh (clone 7; primers p23/p24; 
expected size: 2538bp). LR-PCR: GFP@cam (primers p23/p28; expected size: 4522bp), GFP@hsp70 
(primers p23/28; expected size: 4861bp) and GFP@gapdh (primers p30/p26; expected size: 5095bp); 
size of expected products shown in black and in bold in Figure 2A. Control PCR: P. falciparum lisp2 
gene (primers p21/p22; expected size: 5383bp); GFP: gfp gene (primers p24/p27; expected size: 
606bp ). C. Diagnostic Southern analysis confirms correct integration of the GFP-expression cassettes 
in the cloned lines of GFP@cam, GFP@hsp70 and GFP@gapdh. P. falciparum NF54 (wild type WT) 
DNA, transfected parasite DNA after positive and negative selection (Uncloned; see Figure 1) and 
DNA from the different cloned lines was digested with SpeI and/or XhoI. The digested DNA fragments 
hybridized to probes recognizing either HR1 (GFP@hsp70; expected size: 2604bp) or HR2 (GFP@
cam; expected size: 3764bp and GFP@gapdh; expected size: 4821bp) of the Pf230p target locus. In 
red are indicated the clones that have the correct genotype; absence of both plasmid and WT DNA 
(clone 1 and 5 for GFP@cam; clone 4 and 5 for GFP@hsp70; and clone 4 and 7 for GFP@gapdh). As 
controls sgRNA/donor plasmid (Plasmid) DNA was digested and hybridised with a probe recognizing 
ampicillin (amp) of the donor DNA plasmid; *indicates probe used. 
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was determined and in the positive experiments the percentage of GFP-positive parasites 
ranged between 70 and 90%. Diagnostic PCR analysis for double cross-over integration 
after negative selection confirmed the presence of parasites with correct integration of 
the donor DNA. Based on the high GFP+/GFP- ratios and positive diagnostic PCR we 
proceeded to clone parasites from the following transfections exp. 22 (GFP@cam), exp. 
35 (GFP@hsp70) and exp. 44 (GFP@gapdh). Cloning was performed by limiting dilution 
and GFP-positive clones were cultured in the semi-automated culture system for further 
genotyping by diagnostic PCR and Southern analysis. Both analyses confirmed correct 
integration of the donor DNA into the genome of the three cloned transgenic lines GFP@
cam (exp. 22 clone 1 and 6), GFP@hsp70 (exp. 35 clone 4 and 5) and GFP@gapdh (exp. 44 
clone 4 and 7) and absence of the wild type DNA (Figure 2B,C). The cloning experiments 
indicated that >50% of the cloned lines we generated had the desired integration (i.e. 
GFP@cam 66%, 3 clones analysed; GFP@gapdh 57%, 7 clones analysed; and GFP@hsp70 
66%, 3 clones analysed) (Figure 2C). In these 3 independent transfections the time from 
transfection to obtaining the marker-free GFP-expressing clones ranged between 10 and 
12 weeks.
P. falciparum reporter lines retain WT-like growth kinetics and drug sensitivity 
during blood stage development
The three reporter lines are free of a drug-selectable marker and consequently are easier 
to further genetically modify. In these reporter lines, using the same constructs described 
above, it is possible to delete, mutate or tag P. falciparum proteins in order to investigate 
their function and importance during parasite development. A prerequisite for additional 
genetic modifications using DNA constructs described above is that the parasite retains 
the same sensitivity to the drugs used to select parasite after transfection. It has been 
reported that parasites can spontaneously acquire blasticidin resistance when exposed 
to sustained BSD treatment independent of the bsd selectable marker [32]. We therefore 
compared the sensitivity of the three parasite lines to BSD and WR99210.
The drug-sensitivity of the asexual blood stages of clones of the three transgenic lines 
was determined in standard 72 h short-term culture assays in 96-wells culture plates. Serial 
dilutions of BSD and WR99210 were made with concentrations ranging from 0.1 to 1 µg/
ml or 0.01 to 100 nM, respectively. Parasitemias in the culture wells were determined by 
flow cytometry and the parasite survival rate calculated (Figure 3A). The drug-sensitivity 
curves of the three reporter lines are comparable to that of wildtype NF54 parasites, with 
IC50 values between 0.34 and 0.54 µg/ml for BSD and  0.16 and 0.27 nM for WR99210 
(Figure 3A). 
In addition, in order to use these reporter lines to analyse the effect of additional 
modifications and/or inhibitors on the growth characteristics of P. falciparum blood stages, 
it is important that these parasites retain growth and development kinetics of the parental 
NF54 strain. We therefore compared the growth rate of the three different reporter lines. 









72 h cultures  in 96 well plates. Cultures of  infected  red blood cells  (RBC) were  incubated 
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Figure 3. Drug-sensitivity and growth rate of asexual blood stages of three P. falciparum reporter lines 
(GFP@cam, GFP@gapdh, GFP@hsp70). A. Sensitivity to the drugs BSD and WR99210 as determined 
by flow cytometry in standard 72 h cultures in 96 well plates. Cultures of infected red blood cells 
(RBC) were incubated with different drug concentrations (in triplicate) and after 72 h samples were 
stained with the DNA-specific dye, Hoechst 33 58, to termine parasitemia (% f infected RBC) 
by flow cytometry. Dot plots are shown of uninfected RBC (control, upper panel) selected using 
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33 collected daily from cultures maintained in the semi-automated culture system during a period of 5 days. Growth rates of the transgenic lines were highly comparable to that of 
NF54 wild type parasites and parasitemias increased from 0.5 to 4-8% during the culture 
period (Figure 3B) also the number of merozoites per schizont in the reporter lines was 
also comparable to that of the parental P. falciparum (NF54) WT line. 
GFP expression of GFP@cam, GFP@gapdh and GFP@hsp70  during blood 
stage development in vitro
We examined GFP expression in the different reporter lines during blood stage 
development by fluorescence microscopy. Expression of GFP was detectable in merozoites 
and ring forms of the GFP@hsp70 and GFP@gapdh lines whereas  all lines exhibited GFP 
expression in schizonts and gametocytes (Figure 4A and S3-5). This is in agreement 
with data on transcription of the three genes from which the promoters were used 
(Table S2). Next we more precisely compared the GFP-fluorescence intensity of 
the different lines by examining the following synchronized stages by flow cytometry: 
rings (16 hours post invasion; hpi), trophozoites (30 hpi) and schizonts  (42 hpi) 
(Figure 4B). Rings (G1), trophozoites (G2) and schizonts (G3) were distinguished based 
on their DNA content after staining with the DNA-specific dye Hoechst33258. While 
fluorescence increased during growth of trophozoites of all three lines, the fluorescence 
intensity did not further increase during schizogony. The GFP@cam parasites exhibited 
the lowest GFP expression with a mean fluorescence intensity (MFI) in trophozoites 
(MFI 149) only slightly higher that of uninfected cells whereas trophozoites of GFP@
hsp70 parasites and GFP@gapdh exhibiting much stronger GFP expression (MFI of 1339 
and 1671, respectively). GFP@hsp70 schizonts showed highest levels of GFP expression 
(MFI of 3174; Figure 4B). 
Discuss ion
Here we report the generation of P. falciparum reporter parasites expressing GFP under 
control of three different P. falciparum gene promoters using optimized CRISPR/Cas9 
constructs and selection protocol. The introduction of CRISPR/Cas9 based genome 
editing to P. falciparum research has provided a powerful tool, which can be used to 
better and faster interrogate parasite gene regulation and function [33]. Before CRISPR/
Cas9, modifications of the P. falciparum genome, such as gene disruption or mutation 
Forward Scatter parameter (FSC-A) and from cultures with the lowest and highest drug concentration 
(G1: infected RBC). Parasite survival is defined as the percentage of infected RBC in drug-treated 
wells divided by the percentage of infected RBC in non-treated wells multiplied by 100. IC50 values 
WR99210 (nM): (NF54 PfWT) 0.16; (GFP@cam) 0.25; (GFP@gapdh) 0.27; (GFP@hsp70) 0.19. IC50 
values BSD (µg/ml): (NF54 PfWT) 0.48; (GFP@cam) 0.34; (GFP@gapdh) 0.54; (GFP@hsp70) 0.48. B. 
The growth rate of asexual blood stages in cultures maintained in the semi-automated culture system 






Figure  4. GFP‐expression  in  blood  stages  of  three  reporter  P.  falciparum  parasite  lines 
(GFP@cam, GFP@gapdh, GFP@hsp70)  
A.  Fluorescence microscopy  of  different  blood  stages.  R:  rings;  T:  trophozoites;  ES:  early 
schizonts; LS: late schizonts; G: gametocytes. Nuclei were stained with the DNA‐specific dye 
Hoechst  33342.  All  pictures  were  recorded  with  standardized  exposure/gain  times  to 
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Figure 4. GFP-expression in blood stages of three reporter P. falciparu  parasite lines (GFP@
cam, GFP@gapdh, GFP@hsp70). A. Fluorescence microscopy of different blood stages. R: rings; 
T: trophozoites; ES: early schizonts; LS: late schizonts; G: gametocytes. Nuclei were stained with 
the DNA-specific dye Hoechst 33342. All pictures were recorded with standardized exposure/gain 
times to visualize differences in fluorescence intensity (GFP 0.7 s; Hoechst 0.136 s; bright field 0.62 s 
(1x gain)). In Figure S3, S4 and S5 the complete set of microscope images are shown. B. Fluorescence 
intensity of rings (16 h), (late) trophozoites (30 h) and schizonts (42 h) as determined by flow cytometry. 
Infected red blood cells (RBC) were stained with the DNA-specific dye Hoechst 33258 to distinguish 
infected RBC from uninfected RBC and rings (Gate G1), trophozoites (Gate G2) from schizonts (Gate 
G3). Left side panels show dot plots of both Hoechst fluorescence intensity (DNA content) and GFP 
fluorescence intensity. Right side panels show GFP fluorescence intensity from parasites with either 
G1 and G2 (black) gate or G3 (red). MFI: mean fluorescence intensity and the black- (rings and 
trophozoites) and red- (schizonts) bar show the region selected to calculate the MFI.
Chapter 3 Rapid generation of marker-free P. falciparum fluorescent reporter lines
70 71
33
or the introduction of transgenes into the genome, required 1-3 months of continuous 
culture to select for parasites in which episomally maintained plasmids became integrated 
into the parasite’s genome, either by single or by double cross-over recombination [33]. 
Further, the process of generating cloned genetically modified and drug-selectable 
marker-free parasites would typically take 5 months or more to complete [20]. With 
the methods described here we are able to generate cloned marker-free parasite lines 
that stably express reporter proteins within a period of 10-12 weeks. 
The constructs we have generated can be modified and used in future studies as 
template constructs to remove or introduce transgenes into the P. falciparum genome, for 
example they could be used to generate reporter lines that express additional (fluorescent/
bioluminescent) reporter proteins or used to analyse the regulatory elements that control 
Plasmodium gene expression. 
In addition the sgRNA/donor DNA construct can be adapted to permit the introduction 
of transgenes into other P. falciparum genetic loci by adapting the homology regions in 
the donor plasmid, or the construct can be modified to introduce other transgene (e.g. 
reporter) expression cassettes under the control of a variety of regulatory promoter and 
transcription terminator (5’- and 3’- UTR) regions. All the plasmids and P. falciparum mutant 
lines described in this study are available on request.
In the sgRNA/donor plasmid we have placed the selectable marker cassette outside 
the donor DNA cassette which then does not result in the introduction of the selectable 
marker into the parasite genome upon repair of the target locus. Hence the locus can 
be modified without the inclusion of a selectable marker cassette. The same type of 
constructs can also be used to perform other genetic manipulations, notably gene-
disruption and gene-mutations, which can be used to interrogate gene function and 
importance. As a consequence of the absence of a drug-selectable marker in the genome of 
the mutants, these constructs can be adapted and used to create rapid successive genetic 
modifications in the same parasite line. For example, ‘doubly’ modified parasites that 
contain both a reporter gene as well as a disrupted (or mutated) gene. Such rodent malaria 
mutants have been used extensively to analyse the phenotypic consequences of a gene 
disruption/mutation using a variety of imaging technologies. Moreover, our transfection 
protocol permits for a more rapid generation of multiply modified parasites since it is 
possible to further transfect the uncloned population of a modified parasite (after parasite 
emerge from negative selection). With the high transfection efficiencies we observe in 
our transfection protocol, combined with the rounds of positive and negative selection, 
it is possible to create cloned and SM free, doubly transgenic parasites in the same time 
(~5 months) it would have taken to create a single SM-free genetic modification in P. 
falciparum using conventional approaches. Indeed a cloned P. falciparum double gene 
deletion mutant (PfΔmrp1Δmrp2), which still contained a drug-selectable marker, has 
been recently reported and it required 3 independent transfections, 2 rounds of cloning, 
1 round of SM recycling and took nearly a year to generate [34]. 
To select for parasites with the donor DNA integrated into the genome we made use of 
a selectable marker cassette containing a fusion gene of the human dihydrofolate reductase 
(hdhfr) positive selectable marker and a negative selectable marker, the bifunctional 
protein that combines yeast cytosine deaminase and uridyl phosphoribosyl transferase 
(yfcu). Negative selection based on yFCU expression has been used for both for genetic 
modification of P. falciparum [35] and for rodent malaria parasites [36]. The drug 5-FC 
efficiently kills parasites that express yFCU both in in vitro cultures and in vivo in laboratory 
animals. We established that the positive/negative selectable marker (hdhfr::yfcu) cassette 
was functional in P. falciparum by transiently transfecting parasites with a plasmid (pLf0033) 
containing the hdhfr::yfcu fusion cassette and obtaining parasites using positive drug 
(WR99210) selection, followed by the application of negative drug (5-FC) selection that 
killed the parasites demonstrating that they were sensitive to this drug. In the CRISPR/
Cas9 method described here, we apply negative selection to kill parasites that still retain 
the sgRNA/donor plasmid DNA, enriching for the population of parasites where the donor 
DNA has integrated into the parasite’s genome. Negative selection will also not kill 
‘wild type’ parasites that are still present in the population, i.e. parasites that had lost 
the donor DNA construct without an integration event. From the ratio of GFP-positive 
and GFP-negative parasites present in the cultures after negative selection, as well as 
the results of cloning, we found that percentage of stable transgenic parasites was in 
excess of 50% and therefore the presence of wild type parasites appeared not to be an 
obstacle for obtaining the desired mutants. It has also been reported that homologous 
repair mediated by a donor DNA in P. falciparum after CRISPR/Cas9 transfection appears 
to more efficient than parasite mediated non-homologous end joining repair of DNA, 
which therefore favours the selection of transgenic parasites over either wild type parasites 
or parasites that have repaired the double strand break through the introduction of a site 
specific frame shift [26]. Though it was not necessary in this study, fluorescent reporter 
parasites can be further enriched or indeed cloned after negative selection by flow/FACS 
sorting of fluorescent cells. 
We generated in this study three different reporter parasite lines principally to select 
for constitutive and strong promoters that can be used to drive reporter gene expression. 
In previous studies only a limited number of promoters have been used for genetic 
modification of P. falciparum. For driving transgene expression eef1α [17, 18] and hsp86 
[37, 38] have been reported, while cam and hsp86  have been used to drive expression 
of selectable markers [39]. By comparing RNAseq data of blood stages we selected three 
genes with expression levels higher than eef1α, a promoter that has been previously used 
to generate GFP-expressing reporter P. falciparum lines [17, 18]. We found that the cam 
promoter resulted in relatively weak GFP-expression compared to gapdh and hsp70 
which is in agreement with the RNAseq data. GAPDH is an enzyme involved in glycolysis, 
the main pathway for ATP production in Plasmodium [40] and therefore this protein is 
likely to be expressed throughout the complete life cycle. Indeed proteome analyses of 
oocysts and sporozoites provide evidence for high abundance of GAPDH in these stages 
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(PlasmoDB; www.plasmodb.org). Therefore, we believe, that this promoter can be a useful 
tool to drive transgene expression throughout the complete life cycle. 
Currently several CRISPR/Cas9 methods using two plasmid based strategies have been 
described for  P. falciparum genetic modification. The constructs described in Ghorbal 
et al. [22] like our study, have both the sgRNA and donor sequences on one plasmid. In 
contrast to our method, the use of these constructs result in generation of mutants, both 
deletion mutants and transgenics, that carry a drug selectable marker into their genome. 
This method has the advantage that there is no need for negative selection to remove 
parasites that retain the plasmid. While in the Ghorbal et al. study marker free point 
mutation mutants have been generated, it is unclear if their constructs could be used for 
complete gene deletion or a large genetic insertion without inclusion of a drug selectable 
marker. As both our and the Ghorbal et al. method have the cas9 gene introduced on 
a separate plasmid, only one plasmid has to be modified for each subsequent modification 
(i.e. changing the sgRNA and/or donor sequences) and therefore multiple P. falciparum 
genes can be targeted using a pool of constructs in a single transfection experiment. 
Consequently, multiple mutants can be obtained from a single transfection experiment. In 
contrast the method described by Lu et al. [26], where the sgRNA and donor sequences 
are on separate plasmids, requires both plasmids to be modified to create an additional 
gene modification/disruption. However the strategy described by Lu et al, where 
the donor DNA is on a separate plasmid, allows for the introduction of larger DNA inserts 
into the parasite’s genome.
When we examined clones from the 3 different transgene mutants 57-66% had 
the expected genotype. The other clones were WT clones or, more commonly, clones 
where the donor construct appears to integrate into the parasite genome by single 
cross-over recombination. While ‘single cross-over’ parasites retain the hdhfr::yfcu SM 
a reduction in sensitivity to 5-FC is expected, due to reduction of hdhfr::yfcu copies in 
the genome compared to parasites containing multiple episomal plasmids. A reduction 
in the selection of the clones with the undesired genotype can be accomplished by 
increasing the 5-FC concentration during selection and/or by increasing the expression of 
the hdhfr::yfcu SM, for example by replacing the promoter of the SM (Pfhsp86) with that 
of a more highly expressed gene (e.g. Pfhsp70). This is particularly important when a gene 
deletion may result in a growth defect (unlike Pf230p) and WT parasites may ‘over grow’ 
the deletion mutant. 
In summary, we have created improved constructs and describe an efficient transfection 
protocol to create modified P. falciparum parasites and these reporter parasites are 
suitable for further genetic modifications since they are SM-free. Improving the ability to 
perform genetic manipulations, including making it easier to perform successive gene-
deletions and gene-mutations, will not only be of value to interrogate parasite gene 
function but also for the development of multiple attenuated malaria parasites suitable for 
vaccination [41].
Materia ls  and methods
Parasites and in vitro cultivation of blood stages
P. falciparum parasites from the NF54 strain [42] were obtained from the Radboud University 
Medical Center (Nijmegen, The Netherlands). These parasites were used to generate 
the different transgenic parasite lines. Parasites were cultured following the standard 
conditions in RPMI-1640 culture medium supplemented with L-Glutamine and 25mM HEPES 
(Gibco Life Technologies) to which was added 50 mg/L hypoxanthine (Sigma). Culture 
medium was supplemented with 10% human serum and 0.225% NaHCO3. Parasites were 
cultured at a 5% hematocrit under 4% O2, 3% CO2 and 93% N2 gas-conditions at 75 rpm 
at 37°C in a semi-automated culture system in 10ml flasks (Infers HT Multitron and Watson 
Marlow 520U)[22]. Fresh human serum and human red blood cells (RBC) were obtained 
from the Dutch National Blood Bank (Sanquin Amsterdam, the Netherlands; permission 
granted from donors for the use of blood products for malaria research and microbiology 
test for safety). RBC of different donors were pooled every two weeks, washed twice in 
serum free RPMI-1640 and resuspended in complete culture medium to 50% haematocrit. 
Human serum of different donors were pooled every 4-6 months and stored at -20°C 
until required.
Generation of new standard CRISPR/Cas9 constructs 
The first Cas9-expressing construct (Cas9; pLf0019),  was generated by replacing the drug-
selectable marker ydhodh of the standard construct pUF1-Cas9 [22] by the bsd selectable 
marker obtained from the pMV-FLPe construct [20] using the restriction enzymes EcoRI/SpeI. 
The second construct, containing both the sgRNA as well as the donor DNA sequences 
(sgRNA/Donor construct; pLf0022), was generated in multiple cloning steps. This 
construct contains both the sgRNA expression cassette and the selectable marker cassette 
containing the fusion gene of the positive selectable marker hdhfr and the negative 
selectable marker yfcu (yeast cytosine deaminase/uridyl phosphoribosyl transferase [28]. 
Briefly, the sgRNA-expression cassette under control of the Plasmodium u6 RNA promoter 
(PF3D7_1341100) containing  the BtgZI adaptor sequence was digested from pL6-eGFP[22] 
using the restriction enzymes NcoI/AatII and cloned in the intermediate plasmid pLf0051. 
The P. falciparum hsp86 promoter (PF3D7_0708400) was obtained from JCK-3 plasmid 
(obtained from Prof. R.W. Sauerwein, Nijmegen, the Netherlands) using the restriction 
enzymes PvuII/SexAI and was cloned into the P. berghei transfection construct pL0034 
(RMgm-687; www.pberghei.eu) resulting in plasmid pLf0033. The P. falciparum hsp86 
promoter, replaced the existing P. berghei eef1α promoter and was placed upstream of 
the hdhfr:: yfcu fusion gene (positive/negative selectable marker) and the P. berghei dhfr/
ts (PBANKA_0719300) transcriptional termination (3’UTR) sequence, which were already 
present in pL0034 [28]. Subsequently the complete cassette was digested from pLf0033 
with the StuI/KpnI restriction sites and cloned into pLf0051 with EcoRV/KpnI, resulting 
in the final construct pLf0022. This construct contains additional restriction sites for 
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introducing homology/targeting sequences to target any gene of interest such as StuI/
SacII and ApaI/HindIII (see below). 
P. falciparum 230p (Pf230p) targeting constructs 
Constructs were designed to target the Pf230p locus (PF3D7_0208900) in the P. falciparum 
genome. To generate the Pf230p targeting vectors, plasmid pLf0022 (see above) was 
modified introducing two homology regions targeting Pf230p. Homology region 1 (HR1) was 
amplified using primers P1/P2 and  homology region 2 (HR2) with P3/P4 from P. falciparum 
NF54 genomic DNA (see Table S1 for primer details). HR1 was cloned in pLf0022 using 
restriction sites StuI/SacII and HR2 using ApaI/HindIII, resulting in intermediate plasmids 
CM162 and CM163. A guide sgRNA (sgRNA2) sequence for Pf230p was identified using 
the Protospacer software (alpha version; https://sourceforge.net/projects/protospacerwb/
files/Release/) and was amplified using the primers P7/P8. This sgRNA was selected based 
on the best off targets hits score throughout the genome given by Protospacer and the total 
number of mismatches of the sgRNA with respect to the PAM site. A 20 bp guide sgRNA, 
surrounded by 15 bp vector specific DNA necessary for InFusion cloning (HD Cloning Kit; 
Clontech), was annealed and used to replace the BtgZI adaptor as previously described 
[22], resulting in construct pLf0024. The construct was digested with BlnI and NruI to 
evaluate the successful cloning of the sgRNA and later confirmed by Sanger sequencing 
using primers P9/P10.
The generation of the three Pf230p targeting constructs that contain the gfp gene 
under different promoters were constructed in multiple cloning steps. The promoters were 
selected based on published transcript levels of their genes in asexual blood stages (RNA 
seq data available in PlasmoDB, www.plasmodb.org). The promoters of the following genes 
were selected cam (calmodulin; PF3D7_1434200); gapdh (glyceraldehyde-3-phosphate 
dehydrogenase; PF3D7_1462800) and hsp70 (heat shock protein 70; PF3D7_0818900). 
The cam promoter was amplified from NF54 genomic DNA using primers P11/P12 and 
cloned in the intermediate plasmid pLf0052 using the enzymes AatII/BamHI. This plasmid 
contains the gfp expression cassette with the P. falciparum cam promoter region and 
the 3’ UTR region from the calmodulin gene from P. berghei ANKA (PBANKA_1010600), 
which was previously amplified from intermediate plasmid Plf0012 using primers P17/P18. 
The gfp@cam expression cassette was obtained by digestion with ApaI/PvuII and cloned 
into plasmid pLf0024 (see above) using restriction sites ApaI/EcoRV, resulting in the final 
gfp@cam construct pLf0026. 
The gapdh promoter was amplified from NF54 genomic DNA using primers P13/
P14 and used to replace the cam promoter by the gapdh promoter in intermediate 
plasmid pLf0052 using the restriction sites AatII/BamHI. The complete gfp@gapdh 
expression cassette from this plasmid was digested with ApaI/PvuII and cloned into 
pLf0024 (see above) using restriction sites ApaI/EcoRV, resulting in the final gfp@gapdh 
construct pLf0032. 
The complete gfp@hsp70 expression cassette was obtained by digestion from 
the intermediate plasmid pLf0053 using restriction enzymes ApaI/PvuII and cloned 
into pLf0024 (see above) using restriction sites ApaI/EcoRV resulting in the final gfp@
hsp70 construct pLf0035. The hsp70 promoter was amplified from NF54 genomic DNA 
using primers P15/P16. For the 3’UTR of the gfp@hsp70 expression cassette the 3’UTR 
of the gene encoding the histidine-rich protein II (PF3D7_0831800) was amplified with 
primers P19/P20 from the plasmid pHHT-FRT-(GFP)-Pf52 [20]. 
The gfp@cam and gfp@gapdh plasmids were created using the intermediate plasmid 
pLf0052, resulting in the same orientation of the GFP expression cassette and the same 3’ 
UTR (calmodulin gene) whereas the gfp@hsp70 plasmid was created using an intermediate 
plasmid pLf0053 which resulted in the reporter cassette in a reverse orientation and 
the histidine-rich protein II 3’UTR. 
All PCR amplifications were performed with high-fidelity Phusion DNA polymerase 
(New England Biolab) following the recommended protocols, except for the promoters 
(cam, gapdh and hsp70) that were amplified with KOD Hot Start polymerase (Novagen) 
under standard conditions. All cloning and plasmid amplifications were done in Escherichia 
coli, XL10-Gold Ultracompetent Cells (Stratagene). Details of the primer sequences are 
shown in Table S1.
Transfection and selection of transgenic parasites
Plasmids for transfection were isolated from 250 ml cultures of Escherichia coli, 
XL10-Gold Ultracompetent Cells (Stratagene) by maxi-pep (using HiSpeed® Plasmid 
Maxi Kit (Qiagen®)) to generate the 50 µg of DNA used per transfection. Transfections 
were performed using ring stage parasites obtained from cultures with a parasitemia of 
6 – 15% that were synchronized by 5% D-sorbitol treatment 2 days before transfection [43]. 
Infected RBC were pelleted by centrifugation (1150g, 5 min.) and 300 µl of the pelleted 
cells were transferred to a 0.2 cm cuvette and mixed with ~50 µg of each circular plasmid 
(Cas9 construct and sgRNA/Donor construct) in 100 µl cytomix  [44].  Electroporation 
was performed with a single pulse (310 V and 950µF) in the Biorad Gene Pulser Xcell 
electroporator (including CE- and PC module). After transfection cells were immediately 
transferred in a 10 ml culture flask and cultures were maintained under standard conditions 
in the semi-automated culture system (see above). 
Selection of transfected parasites was performed by applying ‘double’ positive selection 
24 h after transfection using the drugs WR99210 (2.6 nM) and BSD (5 µg/ml). For WR99210 
100 µl of a stock solution (2.6 µM) was added to 100 ml complete culture medium resulting 
in a final concentration of 2.6 nM. To prepare the WR99210 stock-solution WR99210 was 
dissolved in DMSO (100mM). For BSD 50 µl of a stock solution (10mg/ml) was added 
to 100 ml complete culture medium resulting in a 5 µg/ml final concentration. The drug 
pressure was maintained until thin blood-smears were parasite-positive (usually after 14 to 
26 days). Positive selection will select for the parasites that were transfected successfully 
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with both plasmids (Cas9 and sgRNA/Donor constructs). Subsequently, both drugs 
were removed from the cultures for 2-4 days, followed by applying negative selection 
by addition of 5-Fluorocytosine (5-FC; 130 µl of a stock solution (0.77 mM) in 100 ml 
complete medium with a final concentration of 1 µM; [45]) in order to eliminate parasites 
that retained the sgRNA/Donor construct as episomal plasmid and enriching for those 
transfected parasites where the donor DNA had integrated into the genome. Negative 
drug pressure was maintained until thin blood-smears were parasite-positive (usually after 
7 days). During both positive and negative selection period, parasites were analysed for 
GFP expression by fluorescence microscopy (see below) to determine the ratio of wild 
type and mutant parasites present in the population. After negative selection parasites 
were harvested from cultures with 4 to 10% of parasitemia for genotyping by diagnostic 
PCR and Southern analysis (see below). 
Cloning of transgenic parasites
Based on the percentage of GFP-positive parasites in cultures after negative selection and 
PCR confirmation of double cross-over integration the transgenic parasites were cloned by 
the method of limiting dilution as previously described [46] with minor modifications. Briefly, 
infected RBC from cultures with a 4% to 10% parasitemia were diluted with uninfected RBC 
to 105 infected RBC/100 µl in 2 ml culture medium (1% hematocrit and 20% serum). Serial 
dilutions were then performed with uninfected RBC in complete medium (1% hematocrit 
and 20% serum) and cultured in a total volume of 100 µl incubated in 96 well plates, 
resulting in 8 rows with the following numbers of parasites per well in the different rows: 
100, 10, 5, 2.5, 1.25, 0.6, 0.3, 0.15. Plates were incubated in a Candle Jar at 37°C and 
culture medium was changed every other day. Every 5 days RBC were added resulting in 
an increase of the hematocrit from 1% to 5%. Between days 10-14 samples were collected 
for thick smear analysis from the rows with the highest numbers of infected RBC/well; 
50 µl medium was removed and from the remaining culture 5 µl was used directly for 
preparing thick smears. At day 21 thick smears were made from all rows. Clones were 
selected from dilutions/row with less than 30% of the wells parasite positive. These clones 
were transferred in 10 ml culture flasks at 5% hematocrit under standard culture conditions 
(see above) in the semi-automated culture system for collection of parasites for further 
genotype and phenotype analyses (see below).
Genotype analysis of cloned transgenic parasite lines
For genotyping by diagnostic PCR and Southern analysis were performed from material 
isolated from infected RBC obtained from 10ml cultures (parasitemia 3 - 10%), pelleted by 
centrifugation (1150 g; 5 min.). RBC were then lysed with 5-10 ml of cold (4°C) erythrocyte 
lysis buffer (10x stock solution 1.5 M NH4Cl, 0.1 M KHCO3, 0.01 M Na2EDTA; pH 7.4; [43]) 
and parasites were treated with RNAse and proteinase-K before DNA isolation by standard 
phenol-chloroform methods. Correct integration of the donor construct was analysed 
by standard and long-range PCR (LR-PCR). In brief, for the GFP@cam and GFP@hsp70 
expression cassette integration was confirmed by LR-PCR using the primers P23/P28 and 
for GFP@gapdh the integration was confirmed using the P30/P26 primers (see Table S1 
for details of the primers). The LR-PCR fragments were amplified using KOD Hot start 
polymerase following standard conditions with an annealing temperature of 53.5°C for 
15 s and an elongation step of 68°C for 9 min. All other PCR settings were according to 
manufacturer’s instructions. 
Southern blot analysis was performed with genomic DNA digested with  XhoI and/
or SpeI restriction enzymes (4 h at 37°C) in order to confirm integration of the expression 
cassette into the  Pf230p locus. Digested DNA was hybridized with probes targeting 
the Pf230p homology regions, amplified from NF54 genomic DNA by PCR using the primers 
P1/P2 for HR1 and P3/P4 for HR2 respectively.
Phenotype analysis of parasites
The growth rate of asexual blood stages of clones of the three transgenic lines was 
monitored in 10 ml cultures maintained in the semi-automated culture system under 
standard culture conditions (see above). Briefly, a 0.5% parasitemia culture was established 
in complete culture medium at a haematocrit of 5%. Medium was changed twice daily and 
the culture maintained for a period of 5 days without refreshing RBC. For determination of 
the course of parasitemia, triplicate samples of 100 µl were collected daily from all cultures 
and cells pelleted by centrifugation (9485 g ; 30s). The culture medium was then removed 
and cells were washed twice in 1X PBS before and after fixation with 0.25% glutaraldehyde 
(30 min. at 4°C). Fixed RBCs were stained with the DNA-specific dye Hoechst33258 in 1 
ml of PBS by adding 4 µl of a 500 µM stock-solution (final concentration 2 µM). Samples 
were stained for 1hr at 37°C in the dark and analysed by FACS [47].Hoechst-fluorescence 
intensity of stained cells was measured using an LSRII flow cytometer (Becton Dickinson, 
Mountain View, CA, USA) and the data was analysed using FlowJo software (Treestar, 
Ashland, OR, USA). At least 50 000 cells were analysed per sample and the parasitemia 
was determined by FACS using an UV laser (355 nm) and band pass filter 450/50 nm [47] 
and examining the number of Hoechst-positive and Hoechst-negative cells. RBCs were 
selected by gating on Forward and Side Scatter parameters (FSC and SSC, respectively). 
Doublets are excluded by using FSC-Area and FSC-height parameters.
Drug-sensitivity of asexual blood stage parasites from cloned lines of the three 
transgenic lines was analysed as described previously [20], with the following modifications. 
Infected RBCs (0.1%-0.5% parasitemia) at 1% of haematocrit were cultured in 96-wells 
culture plates in a Candle Jar (in complete medium and 20% human serum). To each well 
containing 100 µl of the infected RBC culture was added another 100 µl of culture medium 
containing different concentrations of BSD or WR99210 with concentrations ranging 
from 0.1 to 1µg/ml BSD or from 0.01 to 100 nM WR99210; each drug concentration was 
performed in triplicate wells). Serial dilutions were made from stock-solutions of 1 mg/ml 
and 1 mM of BSD and WR99210, respectively. Medium of the cultures was changed daily. 
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Determination of the parasitemia in the culture wells was determined at 72 h after start 
of the cultures by flow cytometry.  Briefly, cells were pelleted by centrifugation (9485 g, 30 s) 
and cells were washed twice in 1XPBS before and after fixation with 0.25% glutaraldehyde 
(30 min. at 4°C). Fixed RBC cells were stained with the DNA-specific dye Hoechst 33258 in 
1 ml of PBS by adding 4 µl of a 500 µM stock-solution (final concentration 2 µM). Samples 
were stained for 1 h at 37°C in the dark and analysed by flow cytometry [47]. Determination 
of parasitemia (= percentage of infected RBC) by flow cytometry was determined as 
described above and was analysed using GraphPad Prism software (GraphPad software, 
Inc., US). Parasite survival is defined as the percentage of infected RBC in drug-treated 
wells divided by the percentage of infected RBC in non-treated wells multiplied by 100. 
For calculation of the survival curves, the mean fluorescence intensity value of samples with 
the highest drug concentration (i.e. with maximum inhibition of growth) is subtracted from 
the mean fluorescence intensity value of the samples with the other drug concentrations 
and the control samples without drug. The mean parasitemia of the control samples without 
drug is set at 100% and the mean parasitemia of the highest drug concentration is set at 
0% for calculation of the parasite survival. Growth inhibitory curves and statistical analysis 
of the data is performed using the GraphPad Prism software. The non-linear regression 
function for sigmoidal dose-response (variable slope) of the GraphPad Prism software is 
used to calculate the (best-fit) EC50 values.
GFP expression in different blood stages was analysed by standard fluorescence 
microscopy. In brief samples of approximately 200 µl were collected from 10 ml infected 
cultures with parasitemias between 4 and 10%. The RBC samples were stained with 
the DNA-specific dye Hoechst 33342 by adding 4 µl of a 500 µM stock-solution to a final 
concentration of 10 µM for 20 min. at 37°C. Five µl of the preparation was mounted 
on a microscopic slide under a cover slip to visualize the parasites by Hoechst and GFP 
fluorescence using a Leica fluorescence MDR microscope (100x magnification). Pictures 
were recorded with a DC500 digital camera microscope using Leica LAS X software and 
with the following exposure times: GFP 0.7 s; Hoechst 0.136 s; bright field 0.62 s (1x gain). 
The relative GFP-fluorescence intensity of different asexual blood stages was analysed 
by flow cytometry. Triplicate samples of 100 µl of infected RBC were collected from cultures 
that had been synchronized with sorbitol and cultured in the semi-automated in vitro 
system. Samples were collected at 30 and 42 h after synchronization and resuspended in 
1 ml of culture medium containing 5% serum. Cells were stained with the DNA-specific 
dye Hoechst33258 by adding 20 µl of a 500 µM stock-solution to a final concentration of 
10 µM [47]. Staining was performed for 30 min. at 37°C. GFP and Hoechst fluorescence 
intensity was determined using a LSRII flowcytometer (Becton Dickinson, Mountain View, 
CA, USA) and the data was analysed using FlowJo software (Treestar, Ashland, OR, USA). 
100.000 cells were analysed per sample and RBC were selected by gating on FSC and 
SSC. Doublets are excluded by using FSC-Area and FSC-height parameters. Excitation 
of cells for Hoechst33258 was performed with a UV laser (355 nm) and band pass filter 
450/50 nm and for GFP with a blue laser (488 nm) and a band pass filter of 530/30 
nm. The GFP fluorescence intensity was determined of the haploid blood stages (rings 
and trophozoites; Gate 1) and polyploid blood stages (schizonts; Gate 2). Haploid and 
polyploid blood stages were distinguished based on Hoechst-fluorescence intensity [47]. 
Data generation was performed using the FACS DIVA software (Becton Dickinson) and 
analysed with FlowJo software.
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A.  Vector  map  of  pLf0033,  expressing  the  hdhfr::yfcu  SM  cassette,  used  for  transient 
transfection.  
Supplementary figure 1. Drug sensitivity of P. falciparum parasites expressing the hdhfr::yfcu fusion 
cassette. A. Vector map of pLf0033, expressing the hdhfr::yfcu SM cassette, used for transient 
transfection. B. Growth of NF54 blood stage parasites in the absence or presence of the positive drug, 
WR99210 (WR; 2.6nM final concentration). WT P. falciparum NF54 parasites (NF54) were episomally 
transfected with the plasmid pLf0033, encoding a positive/negative drug selection hdhfr::yfcu fusion 
cassette (NF54 +/-plasmid) and selected under positive (WR) selection. Cultures were diluted to ~0.5% 
parasitemia with fresh erythrocytes when parasitemia reached 5-10%. C. Episomally transfected P. 
falciparum parasites (NF54 +/-plasmid), which were initially selected under positive (WR) selection, and 
WT P. falciparum NF54 parasites were subjected to negative (5-FC 1µM final concentration). Cultures 










B. Constructs used  for  introduction of  the GFP‐expression cassettes  into  the P.  falciparum 
genome: pLf0026  for gfp@cam, pLf0032  for gfp@gapdh and pLf0035  for gfp@hsp70  into 
Pf230p.   
Supplementary figure 2. A. Basic constructs: pLf0019 for Cas9-expression construct with the bsd 
selectable marker; pLf0022 sgRNA/donor construct and pLf0024 for targeting the Pf230p locus. B. 
Constructs used for introduction of the GFP-expression cassettes into the P. falciparum genome: 

















Fluorescence microscopy of GFP@gapdh blood  stages parasites. R:  rings; T:  trophozoites; 
ES: early schizonts; LS:  late schizonts; G: gametocytes. Nuclei were stained with  the DNA‐
specific  dye Hoechst  33342.  All  pictures were  recorded with  standardized  exposure/gain 
times  to visualize differences  in  fluorescence  intensity  (GFP 0.7  s; Hoechst 0.136  s; bright 
field 0.62 s (1x gain)).  
Supplementary figure 3. Fluorescence microscopy of GFP@gapdh blood stages parasites. R: 
rings; T: trophozoites; ES: early schizonts; LS: late schizonts; G: gametocytes. Nuclei were stained 
with the DNA-specific dye Hoechst 33342. All pictures were recorded with standardized exposure/
gain times to visualize differences in fluorescence intensity (GFP 0.7 s; Hoechst 0.136 s; bright field 









early  schizonts;  LS:  late  schizonts;  G:  gametocytes.  Nuclei  were  stained  with  the  DNA‐
specific  dye Hoechst  33342.  All  pictures were  recorded with  standardized  exposure/gain 
times  to visualize differences  in  fluorescence  intensity  (GFP 0.7  s; Hoechst 0.136  s; bright 
field 0.62 s (1x gain)).  
 
Supplementary figure 4. Fluorescence microscopy of GFP@hsp70 blood stages parasites. R: rings; 
T: trophozoites; ES: early schizonts; LS: late schizonts; G: gametocytes. Nuclei were stained with 
the DNA-specific dye Hoechst 33342. All pictures were recorded with standardized exposure/gain 
times to visualize differences in fluorescence intensity (GFP 0.7 s; Hoechst 0.136 s; bright field 
0.62 s (1x gain)). 












early  schizonts;  LS:  late  schizonts;  G:  gametocytes.  Nuclei  were  stained  with  the  DNA‐
specific  dye  Hoechst33342.  All  pictures  were  recorded  with  standardized  exposure/gain 
times  to visualize differences  in  fluorescence  intensity  (GFP 0.7  s; Hoechst 0.136  s; bright 
field 0.62 s (1x gain)). 
Supplementary figure 5. Fluorescence microscopy of GFP@cam blood stages parasites. R: rings; 
T: trophozoites; ES: early schizonts; LS: late schizonts; G: gametocytes. Nuclei were stained with 
the DNA-specific dye Hoechst33342. All pictures were recorded with standardized exposure/gain 
times to visualize differences in fluorescence intensity (GFP 0.7 s; Hoechst 0.136 s; bright field 
0.62 s (1x gain)).
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code Gene ID Sequence Enzymes Product (bp) Description
Pf230p deletion Homology Regions
P1 7865 PF3D7_0208900 TAATTAGGCCTGCCGGCCATATTTATGTGACTTCTTAAAC StuI/NaeI 848 Forward HR 1 pf230p
P2 7867 PF3D7_0208900 TTCCTCCGCGGGATATCCAACCTTCTATTGGATTC SacII/EcoRV Reverse HR 1 pf230p
P3 7869 PF3D7_0208900 TTATTGGGCCCGTCGACGTTGATAAGGATAGTGTTTCAG ApaI/SalI 867 Forward HR 2 pf230p
P4 7871 PF3D7_0208900 TCCTTAAGCTTTACGTAGGATTAATATTCCCATTAGG HindIII/SnaBI Reverse HR 2 pf230p
sgRNA 
P7 7882 PF3D7_0208900 TAAGTATATAATATTGAATATTATTCTAATGATAAGTTTTAGAGCTAGAA 50 Forward sgRNA 2 
P8 7883 PF3D7_0208900 TTCTAGCTCTAAAACTTATCATTAGAATAATATTCAATATTATATACTTA Reverse sgRNA 2 
Promoters
P11 7896 PF3D7_1434200 GTAATAGACGTCGGCCAAATAAGAAATATAAT AatII 704 Forward calmodulin promoter
P12 7897 PF3D7_1434200 ATCTGGATCCGATATATTTCTATTAGGTATTTATTATT BamHI Reverse calmodulin promoter
P13 7894 PF3D7_1462800 AACTATGACGTCGCTATGAAAAACATGGGTGTG AatII 1657 Forward gapdh promoter
P14 7895 PF3D7_1462800 AAATAGGATCCGAAAAGAATTAAAAAGCCGAAG BamHI Reverse gapdh promoter
P15 7733 PF3D7_0818900 AATAAGACGTCCGCATAAATATCTGGTGAAATACAAAC AatII 968 Forward hsp70 promoter
P16 7734 PF3D7_0818900 AAATTCTCGAGGAACCTTTTGCACTAGCCAATTTTTC XhoI Reverse hsp70 promoter
3’ UTRs
P17 7589 PBANKA_1010600 TTATTCAATTGACCGGTGGCCGCGACTCTAGAATTAT MunI/AgeI 448 Forward 3’ calmodulin UTR P. berghei
P18 7706 PBANKA_1010600 AATTACCCGGGTCGCGACGGTACCGACCATATAAGAATTAAC SmaI/NruI Reverse 3’ calmodulin UTR P. berghei
P19 7735 PF3D7_0831800 TTGTTTCTAGAGTTAACCTAGGGAAGTATATGAG XbaI 638 Forward 3’ histidin rich protein UTR
P20 7736 PF3D7_0831800 TAAATGGGCCCCTTCGAATTCTGGATTTAATAAATATG ApaI Reverse 3’ histidin rich protein UTR
Genotyping 
P21 7471 PF3D7_0405300 AGCCGCGGCATGGAGAAGGGTTCTATTTTATCG SacII 5383 Forward primer DNA control PCR lisp2
P22 7470 PF3D7_0405300 AACGCTAGCTTCCGGATCGCTGTCTTTAC NheI Reverse primer DNA control PCR lisp2
P23 7965 GAACCCAAAGATTGTTTTTCAC Forward Integration 1 GFP@cam
Forward integration 1 GFP@gapdh
Forward LRPCR GFP@cam
Forward LRPCR GFP@hsp70
P24 2547 CGAGCTGGACGGCGACGTAAAC Reverse Integration  1 GFP@cam
Reverse integration 1 GFP@gapdh
Forward gfp
P25 5515 GCATGGACGAGCTGTACAAG Forward Integration 1 GFP@hsp70
P26 7966 GTAGATGAACTATTTAATAATACATGTGATTTAG Reverse Integration 1 GFP@hsp70 Reverse LRPCR GFP@gapdh
P27 2548 CAGCAGGACCATGTGATCGCG Reverse gfp
P28 7967 GTATCTTTTAAATAATACGGTGTAACATC Reverse LR-PCR GFP@hsp70 
Reverse LR-PCR GFP@cam
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Abstract
Two members of 6-cysteine (6-cys) protein family, P48/45 and P230, are important for 
gamete fertility in rodent and human malaria parasites and are leading transmission 
blocking vaccine  antigens. Rodent and human parasites encode a paralog of P230, called 
P230p. While P230 is expressed in male and female parasites, P230p is expressed only 
in male gametocytes and gametes. In rodent malaria parasites this protein is dispensable 
throughout the complete life-cycle; however, its function in P. falciparum is unknown. 
Using CRISPR/Cas9 methodology we disrupted the gene encoding Pfp230p resulting 
in P. falciparum mutants (PfΔp230p) lacking P230p expression. The PfΔp230p mutants 
produced normal numbers of male and female gametocytes, which retained expression 
of P48/45 and P230. Upon activation male PfΔp230p gametocytes undergo exflagellation 
and form male gametes. However, male gametes are unable to attach to red blood cells 
resulting in the absence of characteristic exflagellation centres in vitro. In the absence of 
P230p, zygote formation as well as oocyst and sporozoite development were strongly 
reduced (>98%) in mosquitoes. These observations demonstrate that P230p, like P230 and 
P48/45, has a vital role in P. falciparum male fertility and zygote formation and warrants 
further investigation as a potential transmission blocking vaccine candidate.
Introduct ion
The s48/45 domain 6-cysteine (6-cys) family of Plasmodium falciparum proteins is a small 
family with 14 members that show stage-specific expression throughout the parasite life 
cycle and most members localize at the parasite surface [1]. Most members have critical 
roles in parasite development, either in the vertebrate host or in the mosquito vector, and 
several members are leading targets for malaria vaccines. Four members, P48/45, P47, P230 
and P230p are specifically expressed in the sexual stages of the parasite and are encoded 
by 2 paralogous pairs of genes. Immune responses directed against the proteins P48/45 
and P230 can prevent parasite transmission through the mosquito and these antigens are 
being actively pursued as so called transmission blocking vaccines [2-4]. Using specific 
antibodies and rodent and human parasite mutants lacking P48/45 and P230 it has been 
shown that both proteins are crucial for efficient transmission through mosquitoes [5-7]. In 
the rodent parasite P. berghei these proteins are expressed at the surface of male gametes 
and are critical for attachment of male gametes to female gametes [5]. In P. falciparum these 
proteins are expressed in both male and female gametocytes/gamete [8-10]. P. falciparum 
P230 has been shown to play a critical role in interactions of male gametes with red blood 
cells (RBC).  In mutants lacking P230 expression the characteristic clusters of uninfected 
red blood cells that form around male gametes, so-called exflagellation centres, are 
absent [7]. This ‘loss of exflagellation centres’ phenotype was not observed for equivalent 
P. berghei mutants lacking P230 expression [5]. In P. berghei and P. falciparum the paralog 
of P48/45, the female specific P47 protein is located on the surface of female gametes, 
zygotes and ookinetes [11]. P47 is important in protecting ookinetes from the mosquito’s 
complement-like immune response in both rodent and human malaria species [12-14]. 
In addition, P. berghei P47 plays an essential role in the attachment and recognition of 
the female gamete by the male gamete [5, 12]. In contrast, P. falciparum P47 does not play 
such a crucial role in gamete fertilization [11]. These observations indicate that differences 
exist in the precise function of the sex-specific 6-Cys members between human and rodent 
malaria species. 
In two rodent Plasmodium species the paralog of P230, the male-specific P230p 
protein, appears to be dispensable throughout the parasite’s complete life cycle [5, 15, 16]. 
P. berghei and P. yoelii mutants lacking expression of P230p can develop in the vertebrate 
host and in the mosquito vector without a discernible phenotype and p230p knock-out 
parasites manifest a wild type parasite phenotype. Consequently, as P230p is non-essential, 
the p230p gene is the most frequently locus used to introduce additional transgenes into 
rodent malaria parasite genomes [15]. 
The function of P230p of human malaria parasites is unknown but, like in rodent 
parasites, P. falciparum P230p is male specific [5, 8-10, 17-19]. Recently we generated 
transgenic P. falciparum parasites where we disrupted the p230p gene by introducing 
transgenes into this locus using adapted CRISPR/Cas9 methodology [20]. These PfΔp230p 
parasites show normal blood stage growth and are able produce gametocytes. In this 
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study, we analysed the phenotype of the sexual stages and subsequent developmental 
mosquito-stages of these PfΔp230p parasites. We show that P. falciparum P230p has a vital 
role during mosquito transmission, which is in strong contrast to P230p of rodent malaria 
parasites. PfΔp230p male and female gametes retain P48/45 and P230 expression on male 
gametocytes. However, like P. falciparum mutants lacking P230, the capacity of PfΔp230p 
male gametes to bind to RBC is strongly reduced. In the absence of P230p expression, 
ookinete and oocyst development in Anopheles stephensi mosquitoes is almost absent. 
These observations identify P230p as one of a limited number of gamete-specific proteins 
critical for P. falciparum transmission.
Results 
P. falciparum mutants lacking expression of P230p (PfΔp230p-1 and PfΔp230p-2)
We recently generated two transgenic P. falciparum mutants, where different GFP-
expression cassettes had been introduced into the p230p gene locus using CRISPR/Cas9 
technology [20]. In these mutants, GFP@cam and GFP@hsp70, GFP expression is driven 
by promoters of two different genes, calmodulin and hsp70. The introduction of GFP-
expression cassette resulted in the disruption of the p230p gene including removal of 
259 bp of the p230p coding sequence (Figure 1A). We name here these two mutants 
PfΔp230p-1 (GFP@cam) and PfΔp230p-2 (GFP@hsp70). Correct integration of the GFP-
expression cassettes in the p230p locus has been demonstrated by diagnostic PCR and 
Southern analysis [20]. The p230p gene is a paralogue of the p230 gene, which is located 
directly down-stream of p230p. To show that the integration of the GFP-expression 
cassette disrupted only the p230p gene and did not alter the p230 locus, we performed 
additional Southern analysis of SphI/SpeI restricted DNA of WT and PfΔp230p-1, using 
a probe targeting the p230p gene-homology region (867 bp) and a probe specific for 
745 bp of the p230 open reading frame. The first probe hybridized to expected DNA 
fragments which differ in size in WT and PfΔp230p-1 (4141 bp and 3755 bp, respectively), 
and the second probe hybridized to a fragment of the same size (5747 bp) in WT and 
PfΔp230p-1 (Figure 1A, B; see Table S1 for primer sequences). These hybridisation results 
indicate the specific targeting of the p230p locus by the CRISPR/Cas9 constructs.
P230p is expressed exclusively in male gametocytes as has been demonstrated by 
immunofluorescence and PCR analyses as well as RNAseq and proteome analyses 
of separated P. falciparum male and female gametocytes [8-10, 17-19]. In contrast, 
the paralog P230 and P48/45 have comparable expression levels in both males and 
females parasites ([8-10]; Table S2). To demonstrate that gametocytes of PfΔp230p-1 and 
PfΔp230p-2 were deficient in p230p expression, we performed RT-PCR and Northern blot 
analysis using mRNA isolated from gametocyte cultures (Figure 1C). No p230p transcripts 
were detected by RT-PCR in gametocytes from either PfΔp230p-1 or PfΔp230p-2, whereas 
a p230p transcript (259 bp) was amplified from WT gametocytes. We were able to amplify 




Figure 1. Generation and genotyping of PfΔ230p parasite lines and absence of p230p transcription in 
PfΔp230p parasites. A. Two PfΔp230p parasite lines were generated using CRISPR/Cas9 methodology 
as described previously [20]. The p230p gene was disrupted by insertion of a GFP-expression 
cassettes using plasmids pLf0026 (cam promoter driving GFP) or pLf0035 (hsp70 promoter driving 
GFP). A schematic representation of the locus containing the paralogous genes p230p and p230, 
before and after insertion of the construct showing the location of the restriction sites (SpeI, SphI), 
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and the PfΔp230p mutant lines. The lack of p230p transcripts and presence of p230 
transcripts in gametocytes of the mutant lines was confirmed by Northern blot analysis 
using the probes specific for the p230p and p230 gene loci (Figure 1C). 
In addition, we analysed P230p expression by immunofluorescence microscopy using 
polyclonal antiserum against P230p [17]. This antiserum reacted only to WT gametocytes 
and no signal was detected in PfΔp230p gametocytes (Figure 1D). Combined our analyses 
show correct disruption of p230p in PfΔp230p parasites resulting in absence of expression 
of p230p in gametocytes whereas the paralogous gene p230 is transcribed. The staining 
pattern in WT gametocytes suggests P230p is located at the surface in the mature stage 
V gametocyte, and is in agreement with the localisation in P. falciparum gametocytes 
expressing a GFP-tagged version of P230p (P230p-GFP;[9]). We also analysed P230p 
expression in activated male gametocytes, both using the polyclonal antiserum against 
P230p and in gametocytes of the transgenic P230p-GFP line. We were unable to 
clearly detect P230p in male gametes using the polyclonal serum or in live gametes of 
the P230P-GFP line but, staining with anti-GFP antibodies demonstrated that the tagged-
protein was present either in or on male gametes (Figure S1A, B and C). While P230p 
is expressed in/on male gametes it is likely to be weakly expressed given the low GFP 
fluorescence and that there was no detectable signal with polyclonal serum.  
Mosquito transmission of PfΔp230p-1 and PfΔp230p-2 parasites is strongly 
reduced
Since multiple members of the 6-cys family play a role in mosquito transmission (i.e. P48/45, 
P47, P230; [5-7, 11-14]) we analysed the ability of mosquitoes to transmit the PfΔp230p 
lines. A. stephensi mosquitoes were fed with WT and PfΔp230p gametocytes using 
the standard membrane feeding assay and the number of oocysts and salivary gland 
sporozoites were determined at day 6 and day 14 respectively. We fed WT and PfΔp230p 
gametocytes in independent experiments and used different clones of the mutant parasites 
(WT, 7 experiments (exp.); PfΔp230p-1 clone 0022cl1, 6 exp.; PfΔp230p-1 clone 0022cl5, 5 
exp.; PfΔp230p-2 clone 0035cl4, 6 exp). In all experiments we observed a >98% reduction 
in oocyst development in mosquitoes that had been fed with PfΔp230p parasites; mean 
oocyst numbers ranging from 4 to 32 for WT-infected mosquitoes compared to 0.1 to 0.7 
in PfΔp230p-infected mosquitoes (100 mosquitoes analysed per experiment; Figure 2A, 
Table S3). In PfΔp230p-infected mosquitoes we observed a maximum of 5 oocysts per 
mosquito compared to 40 after WT feeding . No sporozoites were observed in salivary 
glands of PfΔp230p-infected mosquitoes. These results indicate t2he P. falciparum P230p 
plays an important role in mosquito transmission. 
The formation of ookinetes in PfΔp230p-1 and PfΔp230p-2 parasites is 
severely compromised
To better define the role of P230p in P. falciparum mosquito transmission we analysed 
gametocyte, gamete and ookinete formation of the two mutant lines. The in vitro 
production of male and female gametocytes of both PfΔp230p-1 and PfΔp230p-2 were 
in the same range as WT parasites (Table 1). However, the number of ‘retort-form’ and 
mature ookinetes was reduced by >97% in midguts of A. stephensi mosquitoes at 22 
h. after feeding (Figure 2A, Table 1). In PfΔp230p infected mosquitoes we observed 
no or very low numbers of retorts and mature ookinetes, with mean numbers ranging 
from only 0 to 1.5 (retorts) and 0 to 0.5 (mature ookinetes). In WT infected mosquitoes 
the numbers of retorts and mature ookinetes ranged between 6-21 and 7.5-27, 
respectively. This strong reduction in ookinetes numbers, indicate that either fertilisation 
or the development of fertilised female gametes is interrupted. We cannot discriminate 
between these two possibilities, since P. falciparum fertilised female gametes cannot easily 
be distinguished from unfertilized female gametes, thereby hampering quantification of 
fertilisation. However, since P230p is specifically expressed in male gametocytes the most 
likely explanation for the reduced ookinete formation is the inability of PfΔp230p male 
gametes to fertilize females. We therefore next analysed the formation of male gametes in 
more detail. 
sizes of restriction fragments (in red), location of primers (p) and the PCR amplicons and sizes of 
transcripts (in black) used to analyse correct disruption and transcription of the paralogous genes (B, 
C). HR1, HR2: p230p homology regions. The figure is not shown to scale. Primer sequences can be 
found in Table S1. B. Southern analysis of SphI/SpeI restricted DNA of WT and PfΔp230p-1 parasites 
confirms the specific and expected disruption of the p230p gene locus. DNA was hybridized with 
a probe targeting the homology region 2 (HR2; primers p3/p4) of p230p (left panel) and a specific 
probe of 745bp (primers p1/p2) of the 5’p230  open reading frame (right panel). The hybridization 
pattern observed with first probe  identified the expected different-sized DNA fragments in WT and 
PfΔp230p-1 parasites (4141 bp and 3755 bp); the second probe hybridized to a single expected 
fragment  (5747 bp) in both WT and PfΔp230p-1, indicating an unaltered p230 locus. Uncropped 
images of the Southerns are shown in Figure S3. C. Transcription analysis of the 6-Cys family 
members p230p, p230 and p48/45 in WT and PfΔ230p parasites by RT-PCR and Northern blot. Left 
panel: RT-PCR amplified transcripts of p230p (primers p5/p6; expected size: 259bp), p230 (primers 
p1/p2; expected size: 745bp),  p48/45 (primers p7/p8; expected size: 1219bp) and 18sRNA (primers 
p9/p10; expected size: 165bp). + and – denote the presence or absence of reverse transcriptase. 
Uncropped images of gels are shown in Figure S4. Right panel: Northern blot analysis of p230p 
and p230 transcripts confirming the absence of p230p and presence of p230 transcripts in PfΔ230p 
parasites. Upper panel: hybridization with an internal probe (259bp) from p230p (primers p5/p6, 
WT expected size: ~8kb); middle panel hybridization with a probe against the 5’p230 open reading 
frame (primers p1/p2, expected size: ~ 10kb); lower panel: ethidium bromide (EtBr) stained RNA as 
loading control. Uncropped images of the Northern blot analyses are shown in Figure S5. The size 
of expected RT-PCR products and transcripts are shown in black in a. Primer sequences are shown in 
Table S1. D. Immunofluorescence analyses of mature, stage V, WT and PfΔp230p gametocytes. Fixed 
cells were labelled with mouse anti-P230p polyclonal serum (anti-rMBP.PfB0400w) and with secondary 
conjugated  antibodies anti-IgG Alexa Fluor® 594 (red). Nuclei stained with the DNA-specific dye 
Hoechst-33342. All pictures were recorded with standardized exposure/gain times; anti-IgG Alexa 
Fluor® 594 (red). 0.6s; Hoechst (blue) 0.136 s; bright field 0.62 s (1x gain). Scale bar,  7µm.
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Figure 2. Mosquito development (ookinete and oocyst formation) and in vitro formation of exflagellation 
centres of PfΔp230p parasites. A. Mean oocyst numbers in A. stephensi mosquitoes at day 8 after 
feeding in different experiments (exp.) with 10-20 mosquitoes/exp.: WT (7 exp.); PfΔp230p-1 (6 exp.); 
PfΔp230p-2 (6 exp.). ***p=0.002 (unpaired T-test). B. Mean ookinete numbers (retort and mature 
forms) in A. stephensi mosquitoes 24 hours after feeding. Left panel: retort (immature) ookinetes 
with 10-20 mosquitoes/exp.: WT (7 exp.); PfΔp230p-1 (4 exp.); PfΔp230p-2 (6 exp.). **p=0.005 and 
***p=0.0006 (unpaired T-test). Right panel: mature ookinetes with 10-20 mosquitoes/exp.: WT (7 
exp.); PfΔp230p-1 (6 exp.); PfΔp230p-2 (6 exp.). ***p=0.0004 (unpaired T-test). C. Exflagellation 
centres (EC, circles) as observed by light microscopy analysis of live preparations of male gametocytes 
between 10 and 20 min after activation examined in a Bürker cell chamber. Only WT activated male 
gametocytes attach to red blood cells and form characteristic exflagellation centres (left panel; white 
circles). See also Supplementary videos S1-6 for the absence/presence of exflagellation centres. 
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PfΔp230p-1 and PfΔp230p-2 male gametes are unable to generate 
exflagellation centres
Both gametocyte production and sex ratio of mature gametocytes at day 14 were 
comparable between WT and PfΔp230p parasites (Table 1) and morphologically, at 
the light microscopy level, there is no difference between WT and PfΔp230p gametocytes 
(data not shown). After activation in FCS mature gametocytes from both WT and PfΔp230p 
cultures readily formed  high numbers of exflagellating male gametocytes as observed 
by light-microscopy. We estimate that >90% of stage V male PfΔp230p gametocytes 
showed exflagellation (from 3 experiments) (Table 1). These observations indicate that 
the formation of male gametes is not affected by the absence of P230p. However, 
a striking difference was the absence of PfΔp230p male gamete attachment to uninfected 
RBC and the formation of exflagellation centres observed 15-30 min post activation 
(Figure 2B and Supplementary videos  S1-S6).  Such exflagellation centres generally 
consist of one or more exflagellating male gametes attaching to a number of RBC [21]. 
While WT stage V gametocytes formed such centres by more than 90% of the activated 
male gametocytes, this was observed in less than 5% of activated PfΔp230p males 
(Table 1). These results indicate that in the absence of P230p, male gametes were 
incapable of effectively attaching to RBC. This phenotype is very similar to the phenotype 
described for P. falciparum mutants lacking P230 and indicates that both P230 and P230p 
play a role in interactions of male gametes with RBC. Whether the inability of male gametes 
to interact with RBC is solely responsible for the reduced ookinete formation, or whether 
P230p has an additional role in fertilisation, is unknown. It has been shown that the 6-cys 
family members, P230 and P48/45, form complexes with other proteins on the surface of 
gametes [22, 23]. We therefore examined if the expression of P230 and P48/45 was altered 
in activated PfΔp230p-1 and PfΔp230p-2 gametocytes by immunofluorescence analysis. 
Using anti-P230 and P48/45 antibodies we demonstrated that P230 and P48/45 were 
present in both activated PfΔp230p female and male gametocytes/gametes where staining 
patterns were comparable to what was observed in activated WT gametocytes (Figure 3A, 
B and Figure  S1D). The combined results indicate that the formation of exflagellation 
centres and subsequent reduced ookinete formation is directly P230p dependent and not 
a consequence of the loss of P230 or P48/45 on gametes in the PfΔp230p gametes.
The role of P230 and P230p in P. falciparum gamete binding to RBC is different to 
the role of these proteins in the rodent parasite P. berghei. Single gene-deletion mutants 
lacking expression of either P230 or P230p in P. berghei exhibit formation of exflagellation 
centres like WT, indicating that male gametes of these mutants bind normally to RBC [5]. 
To examine a possible compensatory role in RBC binding of the two P. berghei paralogs we 
generated a p230 and p230p double gene deletion mutant (Figure S2A and B). Activated 
male gametocytes of this mutant, PbΔp230Δp230p, formed WT-like levels of exflagellation 
centres  (Figure  S2C, Supplementary videos S7-12, Table S4) demonstrating an absence 
of a role of these proteins in RBC binding of P. berghei male gametes.
Figure 3. Expression of P230 an P48/45 in activated female and male gametes of PfΔp230p-1. A. 
Immunofluorescence analyses of female gametes 30 minutes after gametocyte activation in fetal calf 
serum. Unfixed parasites were labelled with mouse anti-P230 (MAb 63F2A2 ) or rat anti-P48/45 (MAb 
85RF45.1 ) antibodies followed by  secondary conjugated antibodies (i.e. anti-rat, anti-mouse IgG 
Alexa Fluor® 488 (green) or anti- mouse IgG Alexa Fluor ® 594 (red)). Nuclei stained with the DNA-
specific dye Hoechst-33342. All pictures were recorded with standardized exposure/gain times; Alexa 
Fluor® 488 (green)  0.7 s; anti-IgG Alexa Fluor ® 594 (red) 0.6s;  Hoechst (blue) 0.136 s; bright 
field 0.62 s (1x gain). Scale bar,  7µm. B. Immunofluorescence analyses of male gametes 15 minutes 
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Finally, we examined fertility of female gametes of the PfΔp230p lines, by crossing 
the GFP-expressing PfΔp230p  gametocytes with WT gametocytes and examining parasite 
development in mosquitoes. Mosquitoes with both GFP-positive and GFP-negative 
oocysts were obtained in multiple experiments (Figure 4; Table 2). GFP-positive oocysts 
can only result from cross-fertilisation of WT gametes and PfΔp230p gametes. In view of 
the male-specific expression of P230p and the male phenotype of PfΔp230p parasites, 
the presence of the GFP-positive oocysts most likely result from cross-fertilisation 
between WT male gametes and PfΔp230p female gametes. These observations are in 
support of normal fertility of PfΔp230p female gametes and reduced fertility of PfΔp230p 
male gametes.
Discuss ion
We demonstrate that P. falciparum P230p plays a vital role in parasite transmission through 
mosquitoes. Mutants lacking expression of P230p (PfΔp230p) have a strong reduction 
(>98%) in ookinete formation, which in turn results in a strong reduction in oocyst formation 
and absence of sporozoites in salivary glands. We show that the PfΔp230p male gametes 
have lost the capacity to bind to RBC and could not form the characteristic exflagellation 
centres. A function of P230p in male gamete fertility is in agreement with male specific 
expression of PfP230p and concomitant absence in female gametocytes/gametes [8-10, 
17-19]. Indeed the results of crossing experiments in mosquitoes, performed using 
a mixture of WT and PfΔp230p gametocytes, indicate that PfΔp230p females retain 
their fertility. The important role that P. falciparum P230p plays in mosquito transmission 
does not match the redundant function of P230p in the rodent parasites P. berghei and 
P. yoelii. Rodent parasites also express P230p specifically in male gametocytes [24], but 
mutants lacking P230p have no discernible defect and  exhibit normal gametocyte/
gamete formation, are fully able to form exflagellation centres and mosquito transmission 
is similar to WT parasites [5, 15]. We also demonstrate that the P. berghei P230 is not 
compensating for the loss of its paralogue P230p, since activated male gametocytes of 
P. berghei mutants lacking expression of both P230 and P230p can still bind to RBCs 
and form exflagellation centres. These observations demonstrate a critical difference in 
the function P230p performs in  rodent and human malaria parasites. For a few other 
6-Cys proteins there has been evidence for functional differences between the orthologs 
of rodent and human parasites. For example, the female-specific P47 protein is vital for 
the fertility of P. berghei female gametes, while this protein appears not to be crucial for P. 
falciparum female gamete fertility [5, 11]. Analysis of P. berghei mutants lacking P45/48 and 
mouse anti-P230 (MAb 63F2A2 ) or rat anti-P48/45 (MAb 85RF45.1) antibodies followed by secondary 
conjugated antibodies (i.e. anti-mouse IgG Alexa Fluor® 488 (green) or anti-rat IgG Alexa Fluor® 
594 (red)). Nuclei stained with the DNA-specific dye Hoechst-33342. All pictures were recorded with 
standardized exposure/gain times; Alexa Fluor ® 488 (green)  0.7 s; anti-IgG Alexa Fluor ® 594 (red). 
0.6s; Hoechst (blue) 0.136 s; bright field 0.62 s (1x gain). Scale bar,  7µm.
Figure 4. Crossing of GFP-expressing PfΔp230p gametocytes with WT gametocytes results in 
the formation of GFP-positive oocysts. a. GFP-positive oocyst in midguts of A. stephensi mosquitoes 
fed on a mixture of PfΔp230p-2  and WT gametocytes (day 10 after feeding). Arrows indicate GFP-
positive oocysts in the WT and PfΔp230p-2 cross and GFP-negative oocysts in WT fed mosquitoes.b. 
GFP-positive and GFP-negative oocysts in mosquitoes fed on a mixture of PfΔp230p-2  and WT 
gametocytes or only WT gametocytes (day 10 after feeding). See Table 25 for the ratio of GFP-positive 
and GFP-negative oocysts in mosquitoes fed on a mixture of PfΔp230p-2  and WT gametocytes. All 
pictures were recorded with standardized exposure/gain times to visualize differences in fluorescence 
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P230 demonstrates that these proteins are male-specific fertility factors [5, 6]. In contrast, 
P. falciparum P48/45 and P230 are expressed in both males and female gametes [8-10], 
which may suggest a role for these proteins in both male and female gamete fertility. 
Also other proteins expressed in gametocytes/gametes functional differences have been 
demonstrated between the equivalent proteins in rodent and human malaria parasites, for 
example members of the LCCL protein family. In rodent parasites most LCCL members are 
expressed after fertilisation, in the ookinete stage, and play a role in sporozoite formation 
[25, 26], whereas in P. falciparum these proteins are expressed in gametocytes and are part 
of protein complexes on the surface of gametocytes/gametes [27, 28]. 
The lack of RBC binding of PfΔp230p male gametes is similar to the phenotype of P. 
falciparum mutants lacking expression of its paralog, P230 [7]. These observations suggest 
that both proteins have a similar, but not interchangeable, function in RBC binding. We 
provide evidence that PfΔp230p male and female gametes retain expression of both 
P230 and P48/45, indicating that the lack of RBC binding is not due to the absence of 
expression of P230 and/or P48/45. These observations would suggest that RBC binding 
of male gametes is not due to direct interactions of P230 to RBC receptors as was also 
demonstrated in the studies using males lacking expression of P230 [7]. Moreover, P230 
unlike P230p is also expressed at the surface of female gametes [8-10, 23], which makes it 
less likely that P230 interacts directly with RBC. 
P230 and P48 form complexes with several other proteins at the surface of female 
gametes and zygotes [23, 29, 30]. Given that of P48/45, P230 and P230p are expressed in 
male gametes, it is conceivable that comparable complexes that may include additional 
proteins, are also formed at the surface of male gametes. The absence of either P230 or 
P230p may affect the correct formation of such protein complexes at the gamete surface, 
which may in turn lead to the same loss of RBC binding phenotype observed in mutants 
that lack either paralog. This would indicate that neither P230 nor P230p but rather other 
parasite proteins/factors are directly responsible for binding to RBC receptors. Future 
studies are needed to unravel in more detail the molecular interactions between male 
gametes and RBC and the Plasmodium ligand(s) that bind to the putative proteins, sialic 
acid and/or glycophorin receptors  on the RBC surface [21]. 
Whether the reduction in fertilisation and ookinete formation within the mosquito 
midgut of parasites lacking either P230 or P230p is directly due to the inability of male 
gametes to bind to RBC or whether these proteins have an additional role in fertilisation 
remains unknown. Studies on male gametes lacking P230 showed that the inability to 
form exflagellation centres did not affect the release of male gametes from activated 
gametocytes [7] and we also observed in vitro that PfΔp230p male gametes were released 
after gametocyte activation. It has been suggested that the RBC interactions may trigger 
changes in the gamete that are required for fertilisation such as the release of additional 
proteins, which through a process analogous to sperm capacitation, permit the male 
gamete to be able to bind to molecules in the zona pellucida of the oocyte and thereby 
initiating the process of male penetration of the female gamete [21]. Unfortunately, efficient 
in vitro assays for P. falciparum fertilisation are absent [31] and fertilised female gametes 
cannot easily be distinguished from unfertilized female gametes, thereby hampering more 
detailed analyses and quantification of fertilisation events. 
Our study expands the role of the 6-Cys proteins in fertilisation and specifically 
demonstrates that P230p, like P230 and P48/45, has a clear and vital role in P. falciparum 
male fertility, zygote formation and parasite transmission through mosquitoes.
MATERIALS AND METHODS
Parasites and culture
We analysed wild type (WT) P. falciparum NF54 parasites and two mutant lines PfΔp230p-
1 (GFP@cam clones 0022cl1 and 0022cl5) and PfΔp230p-2 (GFP@hsp70 clone 0035cl4) 
with a disrupted p230p gene locus (PF3D7_0208900). These mutants were generated in 
NF54 parasites by introducing a GFP-reporter cassette into the p230p gene locus using 
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a. Mean percentage of stage V male (m) and female (f) gametocytes (per 100 red blood cells) in day 14 cultures in 
1-2 experiments (exp.). SD: Standard deviation.
b. Mean number of exflagellating male gametocytes (per mL of culture) at 10-20 min after activation of day 14 
gametocyte cultures (SD: standard deviation)  
c. WT and PfΔp230p gametocytes were mixed in different ratios (1:1, 1:2, and 1:3) based on exflagellating male 
gametocytes counts per ml of gametocyte culture after activation with FCS.
d. Mean number of oocysts per mosquito at day 8 after feeding. Range corresponds to the mean number of oocyst 
in different experiments (1-2 exp. per crossing; 10-30 mosquitoes per exp.)
e. Percentage of GFP positive oocyst analysed in 5 individuals mosquitoes (1-2 exp.)
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CRISPR/Cas9 methodology [20]. In the two mutants, GFP is either under the control of 
the promoter from calmodulin (cam; PF3D7_1434200) or from heat shock protein 70 
(hsp70; PF3D7_0818900). The genotype and phenotype of (asexual) blood stages of 
these mutants have been reported previously [20]. WT NF54 parasites [32] had been 
obtained from the Radboud University Medical Center (Nijmegen, The Netherlands). NF54 
parasites were cultured following the standard conditions in RPMI-1640 culture medium 
supplemented with L-Glutamine 25mM HEPES (Gibco Life Technologies) and 50 mg/L 
hypoxanthine (Sigma). Culture medium was supplemented with 10% human serum and 
0.225% NaHCO3. Parasites were cultured at a 5% hematocrit under 4% O2, 3% CO2 and 
93% N2 gas-conditions at 75 rpm at 37°C in a semi-automated culture system [33]. Fresh 
human serum and human red blood cells (RBC) were obtained from the Dutch National 
Blood Bank (Sanquin Amsterdam, the Netherlands; permission granted from donors for 
the use of blood products for malaria research and microbiology safety-tests).
In addition, a P. falciparum (3D7) transgenic line that expresses a GFP-tagged version of 
Pfp230p (Pfp230p-GFP) was analysed for P230p expression and localisation. This line has 
been engineered to express endogenous PfP230p fused to GFP  to its carboxyl terminal 
and was generated using a single cross-over recombination strategy [9]. 
Two different P. berghei ANKA mutants were analysed that have been previously 
generated. One with a p230p gene disruption (line 676m1cl1; PbΔp230p; RMgm-29; 
www.pberghei.eu) [34] and the other with a p230 gene disruption (line 310cl1; 
PbΔp230; RMgm-350; www.pberghei.eu) [5]. In addition, we generated a double gene 
deletion P. berghei ANKA mutant with both the p230p (PBANKA_0306000) and p230 
(PBANKA_0306100) gene loci disrupted (see below).
Animal ethics statement
Female OF1 mice (6–8 weeks old; Charles River/Janvier) were used. All animal experiments 
of this study were in accordance with relevant guidelines and regulations approved by 
the Animal Experiments Committee of the Leiden University Medical Center (DEC 12042). 
The Dutch Experiments on Animal Act is established under European guidelines (EU 
directive no. 86/609/EEC regarding the Protection of Animals used for Experimental and 
Other Scientific Purposes).
Generation of the P. berghei double knock-out mutant PbΔp230Δp230p
To generate a P. berghei mutant lacking expression of both P230 and P230p we disrupted 
the p230 locus in the existing PbΔp230p mutant (676m1cl1; see above) which has 
a disrupted p230p locus. To disrupt p230 we used a DNA construct that had been used 
to create the mutant PbΔp230 (310cl1; see above). This construct (pL1139) integrates by 
double cross integration and replaces (part of) the p230 locus with the selectable marker 
cassette containing Toxoplasma gondii dihydrofolate reductase/thimidylate synthase 
(tgdhfr/ts) [5]. Parasites of line 676cl1 were transfected with this construct (exp. 2764) 
using standard transfection technologies and selection with pyrimethamine [35]. Selected 
parasites were cloned by limiting dilution and mutant 2764cl3 was used for genotype and 
phenotype analysis.
Genotyping and phenotyping P. berghei mutant PbΔp230Δp230p
Correct disruption of the p230p and p230 gene loci was performed by diagnostic PCR-
analysis and Southern analysis of pulsed field gel (PFG) separated chromosomes as 
described previously [35]. Briefly, for the PCR-analysis confirmation of disruption of p230 
was performed using the primers p13/p14 for 5’ integration and p17/p18 for 3’ integration 
of the construct and for p230p, 5’ and 3’ integration with primer pairs p21/p22 and p25/
p26, respectively (see Figure S2 and Table S1 for details of the primers and the PCR 
fragments). For Southern analysis, diagnostic probes against the 3’UTR of pbdhfr/ts and 
the tgdhfr/ts selectable marker were used.
In vitro activation of gametocytes to determine exflagellation, formation of 
exflagellation centres and formation of ookinetes were performed as described [5, 35]. In 
brief, 10-20 µl of tail blood from infected mice containing gametocytes was diluted in 1 ml 
of activation medium. Within 12-20 min after activation, exflagellating male gametocytes 
and exflagellation centres were quantified in a Bürker cell counter and 18-24 h later 
the number of zygotes/ookinetes formed was quantified.
Genotyping P. falciparum mutants PfΔp230p-1 and PfΔp230p-2 
Diagnostic PCR and Southern analysis of restricted genomic DNA to confirm disruption of 
p230p in mutants PfΔp230p-1 and PfΔp230p-2 have been reported [20]. We performed 
additional Southern analysis to confirm disruption of p230p and to confirm that 
the neighbouring p230 gene locus (PF3D7_0209000) remained unmodified. Total DNA 
was isolated from infected red blood cells (iRBC) obtained from 10ml cultures (parasitemia 
5-10%, 5% hematocrit), pelleted by centrifugation (400 g; 5 min). RBC were lysed with 5-10 
ml of cold (4°C) erythrocyte lysis buffer (10x stock solution 1.5 M NH4Cl, 0.1 M KHCO3, 
0.01 M Na2EDTA; pH 7.4; [35] and parasites pelleted by centrifugation (400g during 5 
min) and treated with RNAse and proteinase-K before DNA isolation by standard phenol-
chloroform methods. Genomic DNA was digested with SpeI and SphI restriction enzymes 
(4 h at 37°C) to confirm the specific disruption of Pfp230p locus. Restricted DNA was 
hybridized with 2 probes: one targeting the p230p homology region 2 (HR2) and one 
targeting the 5’ p230 open reading frame (5’-p230) amplified from WT NF54 genomic 
DNA by PCR using the primers P3/P4 for HR2 and P1/P2 for 5’-p230, respectively (see 
Table S1 for details of the primers).
Transcriptional analyses of 6-cys family proteins in the mutants PfΔp230p-1 
and PfΔp230p-2
To analyse transcription of 6-cys family proteins P. falciparum gametocytes were generated 
using standard culture conditions (see above) with some modifications [33]. Briefly, 
parasites from asexual stage cultures were diluted to a final parasitemia of 0.5% and 
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cultures were followed during 14 days without refreshing RBC. After 9 days these cultures 
were treated with 50mM of N-acetyl-D-glucosamine (Sigma) to kill asexual stages and to 
enrich for gametocytes. At day 14 the cultures were harvested and infected RBC (iRBC), 
enriched for gametocytes, pelleted by centrifugation (400g during 5min), washed three 
times with 1X PBS  and the iRBC lysed with saponin following standard procedures [36]. 
Total RNA was isolated from the pelleted parasites using the Kit RNA Pure Link TM RNA 
Mini kit (Invitrogen) according to the manufactures instructions. Northern blot analysis on 
the isolated RNA, was performed as previously described [36] using probes amplified from 
genomic DNA from WT NF54 parasites; one targeting  an internal fragment (259bp) of 
p230p  with primers P5/P6 and the other targeting a fragment (754bp) of the 5’ p230 open 
reading frame with primers P1/P2 (see Table S1 for details of the primers). RNA (1-5µg) 
isolated from the iRBC was further purified for RT-PCR analysis by adding 1X DNase I 
digestion buffer (Promega), 20 U of RNase inhibitor (RNasin, Promega) and 20 U of DNase 
I (Promega); this was incubated for 45 min at 37°C followed by chloroform/isoamyl alcohol 
purification and RNA precipitated in absolute ethanol[36] Subsequently, RT-PCR was 
performed using standard methods [36]. Briefly, 1-3µg of RNA was collected for first strand 
cDNA synthesis using the kit SuperScript III (Invitrogen) and PCR amplification (annealing 
temperatures ranging 50-57°C) was performed with KOD polymerase (Invitrogen). For 
amplification of the Pf48/45 gene (PF3D7_1346700)  the primers  P7/P8 were used, for 
Pfp230 primers P1/P2, for Pfp230p  primers P5/P6 and for 18S rRNA primers P9/P10 (see 
Table S1 for details of the primers). 
Expression analysis of 6-cys family proteins in P. falciparum gametocyes by 
immunofluorescence assay (IFA)
To analyse the expression of PfP48/45 and PfP230 in live  gametocytes by 
immunofluorescence microscopy, 500µl of the gametocyte culture was pelleted (400 g 30 
s) and gametocytes activated in 1 ml of fetal calf serum (FCS) for 1h at room temperature 
and samples collected for live fluorescence microscopy. To analyse PfP48/45 and PfP230 
expression in fixed (male) gametocytes, 20 µl of the activated cells were collected 15-20 
min after activation. This gamete enriched solution was  placed on a microscope slide, 
dried for 10 min, and fixed with ice-cold methanol for 5 min. After fixation the slides were 
blocked with 10% of FCS in 1X PBS for 1h.  Live and fixed cells were  washed with 1X PBS and 
incubated with monoclonal antibodies against PfP48/45 (rat MAb 85RF45.1; 1:200 dilution 
of 5µg/ml stock solution [37]), PfP230 (mouse MAb 63F2A2; 1:200 dilution of 5µg/ml stock 
solution [38]) for 30 min at 4°C for live imaging and 1h at room temperature for fixed slides. 
Subsequently, cells were rinsed 3 times with 1X PBS and incubated with the secondary 
antibodies Alexa FLuor®488/594-conjugated chicken anti-rat and anti-mouse (Invitrogen 
Detection technologies), respectively (both at 1:200). Finally, the cells were stained with 
the DNA-specific dye Hoechst-33342 at a final concentration of 10µM. Fixed cells were 
covered with 1-2 drops of an anti-fading agent (Vectashield), and a coverslip placed 
onto the cells and sealed with nail polish. Stained cells (live and fixed) were analysed for 
fluorescence using a Leica fluorescence MDR microscope (100x magnification). Pictures 
were recorded with a DC500 digital camera microscope using Leica LAS X software with 
the following exposure times: Alexa: 0.7 s; Hoechst 0.136 s; bright field 0.62 s (1x gain). 
To analyse PfP230p expression in stage V gametocytes by immunofluorescence slides for 
microscopy analysis were prepared as follows:  20 µl of the cell suspension containing 
activated gametocytes was placed per well of a  8-well black cell-line diagnostic microscope 
slide (Thermo Scientific), that was air dried, fixed with ice-cold absolute methanol (2 min) 
and subsequently washed 3 times with 1X PBS. Cells were permeabilized with 0.5% of 
Triton X-100 in 1X PBS for 1h and blocked with 10% FCS in 1X PBS. 20 µl of polyclonal 
serum raised in mice against recombinant PfP230p (1:200; anti-rMBP.PfB0400w 1:200 
dilution [17]) was incubated with the fixed gametocytes for 1 h at room temperature and 
slides were washed 3 times with 1XPBS. Subsequently each well was incubated with 20 
µl goat-anti-mouse secondary IgG monoclonal antibody conjugated to Alexa FLuor®594- 
(Supplier; 1:200 dilution) for 1h at room temperature. Slides were then washed 3 times 
with 1X PBS and stained with 20 µl of Hoechst-33342  in 1XPBS (10 µM) for 30 min at 37 
°C. The slides were washed 3 times in 1X PBS and the cells were analysed for fluorescence 
using a Leica fluorescence MDR microscope (see above for details).
Further analysis of PfP230p expression was performed by detecting the GFP pattern in 
the live or fixed gametocytes of Pfp230p-GFP line. Rabbit anti-GFP IgG (Invitrogen; 4 µg/
ml) and Goat anti-rabbit IgG conjugated to Alexa FLuor®488 (Invitrogen; 4 µg/ml) were 
used for detection of GFP in fixed activated mature gametocytes.
Phenotype analysis of gametocytes/gametes and mosquito stages of mutants 
PfΔp230p-1 and PfΔp230p-2
Gametocyte development was analysed in gametocyte cultures, established as described 
above. Exflagellation was determined after activation of P. falciparum stage V gametocytes 
with FCS.  To activate gametocytes 20 µl of the gametocyte cultures at day 14 were diluted 
1:1 with FCS at room temperature. Gametes and exflagellation centres were examined 
and quantified 10-20 min after activation using a Bürker cell counter. 
The number of male gametocytes per 105 red blood cells (RBC) was determined 
in stage V gametocyte cultures by analysing Giemsa stained slides. Quantification of 
exflagellating males of these cultures was performed in triplicate, using a Bürker chamber 
(at 40X magnification). The number of exflagellating males is given as the number of 
exflagellating males observed per 1x105 of total red blood cells (RBC). 
Exflagellation center formation was determined by counting the number  exflagellating 
males adhering to multiple red blood cells and forming characteristic dense clusters of 
RBC. Exflagellating males, which did not adhere to RBC and failed to form a characteristic 
dense cluster of RBC were scored as ‘non-adhering’ males. +++ denotes that more than 
90% of the exflagellating males formed the dense RBC clusters and – denotes that less 
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than 1% of exflagellating males formed the dense RBC clusters. For analysis of mosquito 
stages (ookinetes, oocysts and sporozoites) A. stephensi  were infected using the standard 
membrane feeding assay (SMFA) [39, 40]. Ookinetes were analysed and counted 22 h after 
feeding. Oocyst and salivary gland sporozoites were counted at day 6 and day 14 post 
feeding, respectively. For counting sporozoites, salivary glands from 10 mosquitoes were 
dissected and homogenized in a homemade glass grinder in 100 µl of RPMI-1640 (pH 7.2) 
and sporozoites were analysed in a Bürker cell counter using phase-contrast microscopy.
Cross-fertilisation of WT and PfΔp230p  gametocytes was performed by mixing 
gametocytes obtained from enriched gametocyte cultures (see above) from WT and 
PfΔp230p and feeding these mixtures to mosquitoes using SMFA. In different experiments 
WT and PfΔp230p gametocytes were mixed in different ratios (1:1, 1:2, and 1:3) based 
on exflagellating male gametocytes counts per ml of gametocyte culture after activation 
with FCS. At day 10 after feeding oocyst development was analysed with a fluorescence 
stereomicroscope Leica MZ16 FA and GFP-fluorescence was visualized using GFP 
filter settings (GFP exposure time: 4,2 s ). Pictures were recorded using a DM2500 
digital camera. 
Stat ist ics
All data were analyzed using the GraphPad Prism software package 5.04 (GraphPad 
Software, Inc). To calculate significant levels for ookinete and oocyst numbers the unpaired 
Student’s t-test was used. 
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Supplementary figure 1. Analysis of expression of P230p , P230 and P48/45 in mature and activated 
gametocytes of P230p-GFP parasites and PfΔp230p-2. A. GFP-fluorescence in  different stages 
of gametocyte development, stage II, III, IV  and mature, stage V, gametocytes of a transgenic P. 
falciparum (3D7) line that expresses a C-terminal GFP-tagged version of p230p (p230p -gfp). Scale 
bar,  7µm. B. GFP-fluorescence in live male gametocytes of the P230p-GFP line 15-20min after 
activation. Scale bar, 7µm. C. Immunofluorescence analysis of fixed activated male gametocytes of 
the P230p-GFP line 15-20min after activation. Cells were fixed with methanol and labelled with rabbit 
anti-GFP antibody followed by goat  anti-rabbit antibody secondary conjugated to Alexa Fluor® 
488. Scale bar, 7µm. D. Immunofluorescence analyses of mature, stage V, PfΔp230p-2  gametocytes 
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after activation with fetal calf serum. Upper panel, female gametes 30 minutes after gametocyte 
activation. Unfixed parasites were labelled with mouse anti-P230 (MAb 63F2A2 ) or rat anti-P48/45 
(MAb 85RF45.1 ) antibodies followed by  secondary conjugated antibodies (i.e. anti-mouse or anti-rat 
IgG Alexa Fluor® 488 (green)). Nuclei stained with the DNA-specific dye Hoechst-33342. All pictures 
were recorded with standardized exposure/gain times; Alexa Fluor® 488 (green)  0.7 s; Hoechst (blue) 
0.136 s; bright field 0.62 s (1x gain). Scale bar,  7µm. Lower panel, Immunofluorescence analyses 
of male gametes 15 minutes after gametocyte activation in fetal calf serum. Cells were fixed with 
methanol and labelled with mouse anti-P230 (MAb 63F2A2 ) or rat anti-P48/45 (MAb 85RF45.1) 
antibodies followed by secondary conjugated antibodies (i.e. anti-mouse IgG Alexa Fluor® 488 
(green) or anti-rat IgG Alexa Fluor® 594 (red)). Nuclei stained with the DNA-specific dye Hoechst-
33342. All pictures were recorded with standardized exposure/gain times; Alexa Fluor ® 488 (green) 
0.7 s; anti-IgG Alexa Fluor ® 594 (red). 0.6s; Hoechst (blue) 0.136 s; bright field 0.62 s (1x gain). Scale 
bar,  7µm.
Supplementary figure 2. Generation and analysis of a P. berghei mutant line (pbΔp230pΔp230) 
lacking expression of P230 and P230p. A. Schematic representation of the generation of the P. 
berghei double gene-deletion mutant pbΔp230pΔp230. To generate this mutant the p230 locus 
was disrupted in the existing PbΔp230p mutant (676m1cl1) which has a disrupted p230p locus 
containing a GFP-Luciferase expression cassette. To disrupt p230 a DNA construct (pL1139) was 
used, which integrates into the P. berghei genome by double cross-over integration and replaces 
(part of) the p230 locus with the selectable marker (SM) cassette containing Toxoplasma gondii 
dihydrofolate reductase/thimidylate synthase (tgdhfr/ts). Parasites of line 676cl1 were transfected with 
this construct (exp. 2764) using standard transfection technologies and selection with pyrimethamine. 
Selected parasites were cloned by limiting dilution and mutant 2764cl3 was used for genotype and 
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Primer sequences are shown Table S1. B. Diagnostic PCR (left, middle panel) and Southern analysis 
of PFG-separated chromosomes (right panel) confirms correct disruption of p230 and p230p in 
line 2764cl3. 5’and 3’integration PCR (int), shows the expected bands of 881 bp and 1117 bp for 
disruption of p230p (primers p13/p14 and p17/p18)  and 1224 bp and 1302 bp for p230 (primers 
p21/p22 and P25/26).  The GFP-Luciferase cassette in p230p was detected with primers p15/p16 
(529bp) and the tgdhfr/ts SM cassette in the p230 locus with primers p23/p24 (1039bp). Uncropped 
images of the gel images are shown in Figure S6. See A for primers, PCR amplicons and Table S1 
for primer sequences. Hybridization of PFG-separated chromosomes with the tgdhfr probe shows 
the integration of the tgdhfr/ts SM cassette in 230p on chromosome 3. Hybridization with the probe 
against 3’UTR of the P. berghei dhfr/ts gene recognizes the endogenous dhfr/ts gene on chromosome 
7 and the integrated casettes in p230 and p230p in chromosome 3. Uncropped images of PFG-
Southern analyses are shown in Figure S7. C. Exflagellation centres (EC, circles) as observed by 
light microscopy analysis of male gametocytes of pbΔp230p (line 676m1cl1), pbΔp230 (line 310cl1) 
and pbΔp230pΔp230 (line 2764cl3) between 10 and 20 min after activation in live preparations in 
a Bürker cell chamber. Scale bar, 7µm. See also Supplementary videos S7-S12 for the presence of 
exflagellation centres and Table S4 for quantification of exflagellation centres in the mutant and wild 
type parasites.
Supplementary figure 3. Unprocessed images of Southern blot analysis. The white boxes show 
the cropped image in Figure 1B. Molecular marker 1Kb plus ladder (M). DNA was electrophoresed 
in 0,8% agarose gel.
Supplementary figure 4. Unprocessed images of RT-PCR analysis. The white boxes show the cropped 
image in Figure 1C (left panel). Molecular marker 1Kb plus ladder (M). DNA was electrophoresed in 
1% agarose gel.
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Supplementary figure 5. Unprocessed images of Northern blot analyses. The white boxes show 
the cropped image in Figure 1C (right panel). P230 and P230p panels show autoradiograph images 
after probing with 230 or 230p probes. EtBr panel shows  electrophoresis gel  stained with ethidium 
bromide (EtBr) of WT and PfΔ230p parasites. 5ug of RNA was seeded per lane. RNA Molecular weight 
























































Supplementary figure 6. Unprocessed images of PCR analyses. The white boxes show the cropped 
image Figure 2  (Left and Middle panel). Molecular marker; 1Kb plus ladder (M). DNA was 
electrophoresed in 1% agarose gel.
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Supplementary figure 7. Unprocessed images of (PFG-separated) chromosomal Southern Blot 
analyses. The arrows indicated the lanes cropped out of this image and used in Figure S2B (Right 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 2. Published RNAseq and proteome data on expression of P230, P230p and 
P48/45 in male (m) and female (f) gametocytes
Protein
Lasonder, E.  
et.al.  2016
Miao, J.  
et.al. 2017














P230p 54 54 male only male only male only
P230 4,4 0,5 1,1 in male and female male only
P48/45 4,2 1,0 1,4 in male and female 4,1
1 The ratio of RNAseq RPKM values in separated male and female gametocytes (Lasonder, E. et.al, 2016, Nucleic 
Acids Res 44(13):p.6087-101).
2 The ratio of proteome spectra values in separated male and female gametocytes (Lasonder, E. et.al, 2016, Nucleic 
Acids Res 44(13):p.6087-101).
3 The ratio of proteome spectra values in separated male and female gametocytes (Miao, J. et.al, 2017,  Mol Cell 
Proteomics, 2017. 16(4): p. 537-551.).
4 The ratio of proteome spectra values in separated male and female gametocytes (Tao, D. et.al, 2014, Mol Cell 
Proteomics, 2014. 13(10): p. 2705-24.).
5 The ratio of proteome spectra values in separated male and female gametocytes (Khan, SM. et.al, 2005, Cell, 
2005. 121(5): p. 675-87).
Supplementary table 3. Oocyst and sporozoite production in A. stephensi mosquitoes of WT and 
pfΔp230p parasites 
Lines
No. of oocyst 
mean (range) 1





56 (11-90)NF54 (7 exp.)
Δp230p-1
0022cl1 (6 exp.) 0,39 (0,05-0,6) 0
0022cl5 (5 exp.) 0,38 (0,1-0,7) 0
Δp230p-2
0035cl4 (6 exp.) 0,12 (0-0,5) 0
1 Mean number of oocysts per mosquito at day 8 after feeding. Range corresponds to the mean number of oocyst 
in multiple experiments (5-7 exp. per line; 10-20 mosquitoes per exp.)
2 Mean number of salivary gland sporozoites per mosquito at day 14 after feeding. 





Supplementary table 4. Exflagellation and fertilization rates of WT, pbΔp230p, pbΔp230 and 
pbΔp230pΔp230 parasites in vitro
Lines















55-80(10)676m1cl1 50-92 (75) +++
pbΔp230
310cl1* 72-90 (80) +++ <0,1
323cl1* +++ <0,1
pbΔp230pΔp230
2764cl3 (n=2) 75-95 (85) +++ <0,1 (0,01)
1 Percentage of exflagellating male gametocytes between 10-20 minutes after activation. 
2 Presence of exflagellation centers between 10-20 minutes after activation. Exflagellation centers are counted in 
Bürker cel counter. +++: >90% of the exflagellating male  gametocytes form exflagellation centers
3 The fertilisation rate is the percentage of female gametes that develop within 24 hours into ookinetes in vitro.
* Data taken from van Dijk MR et.al, 2010, PLoS Pathog, 2010. 6(4): p. e1000853 
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Abstract
Transgenic malaria parasites expressing fluorescent and bioluminescent proteins are useful 
tools to interrogate malaria parasite biology and to quantify parasite-host interactions. 
Here we report the generation of a transgenic Plasmodium falciparum (Pf) NF54 line 
expressing a fusion gene of mCherry and luciferase under the control of the etramp10.3 
promoter. The Pf ETRAMP10.3 protein is related to the rodent Plasmodium UIS4 protein, 
which is also a member of the ETRAMP protein family. In rodent malaria Plasmodium 
species, the promoter of the uis4 gene has been used to drive high transgene expression 
in liver-stages parasites. CRISPR/Cas9 methodology was used to insert the mCherry-luc@
etramp10.3 expression cassette into the Pf p47 gene locus. We demonstrate mCherry 
expression in gametocytes, sporozoites and liver-stages. While we did not detect mCherry 
above background levels in asexual blood-stage parasites, luciferase expression was 
detected in asexual blood-stages as well as  gametocytes, sporozoites and liver-stages. 
Highest levels of reporter expression were detected in stage III-V gametocytes and in 
sporozoites. The expression of mCherry and luciferase in gametocytes and sporozoites 
makes this transgenic parasite line suitable to use in in vitro assays to examine the effect 
of inhibitors on gametocyte development and to analyse sporozoite biology.    
Introduct ion
Transgenic rodent and human malaria parasites expressing fluorescent and bioluminescent 
proteins are used extensively to interrogate parasite biology and host-parasite interactions 
associated with malaria pathology and are used as tools to evaluate anti-parasite 
inhibitors and vaccines [1]. In comparison to transgenic rodent malaria parasites (RMP) 
only a relatively limited number of transgenic Plasmodium falciparum (Pf) parasites 
expressing fluorescent or luminescent proteins are available. Transgenic Pf parasites have 
been used to quantify blood-stage growth in vitro in standard growth inhibition assays 
[2], to quantify parasite development in the mosquito in standard membrane feeding 
assays to measure transmission-blocking (TB) activity and in high-throughput screening 
of TB compounds against Pf gametocytes. For the TB assays transgenic Pf (NF54 strain) 
parasite lines have been used that express a GFP-luciferase fusion protein under control 
of the strong constitutive hsp70 [3] or the gametocyte-specific pfs16 promoter [4]. In 
addition, a transgenic Pf NF54 has been created that express the GFP-luciferase fusion 
protein under control of the constitutive eef1a promoter [5]. This reporter line has been 
used in multiple studies to analyse liver infection in immune compromised and humanized 
mice, engrafted with human liver tissue [6-8].
In multiple RMP transgenic lines the promoter of the uis4 gene has been used to drive 
expression of different transgenes, in sporozoites and liver-stages, such as genes encoding 
mCherry, ovalbumin or human malaria proteins [9-15]  The uis4 gene is highly transcribed 
in sporozoites and liver-stages and encodes a parasitophorous vacuole membrane (PVM) 
protein, that surrounds the parasite in the infected hepatocyte. Although uis4 transcripts 
are translationally repressed in sporozoites [16, 17], the transcripts containing transgenes 
under control of uis4 regulatory sequences are transcribed since translational repression 
in sporozoites is dependent on DNA sequences present within the uis4 open reading 
frame [9, 16]. In this study, we generated a transgenic Pf parasite that expresses a fusion 
of the proteins mCherry and luciferase (mCherry-Luc) under the control of the promoter 
region of etramp10.3 (PF3D7_1016900). We selected this promoter since etramp10.3 is 
related to uis4 which also belongs to the Plasmodium etramp gene family and both genes 
have the same syntenic genomic location. It has been previously reported that etramp10.3 
is expressed in Pf sporozoites as well as in blood- and liver-stages, where the protein is 
located at the PVM, similar to the PVM location of UIS4 in liver-stages of rodent malaria 
parasites [18]. 
We chose to generate an mCherry-expressing Pf line, as it could be used to visualise 
interactions of Plasmodium sporozoites with host-cells (e.g. immune cells or hepatocytes) 
which are often labelled with green fluorescent proteins. Moreover, we fused the mCherry 
gene to firefly luciferase as luciferase expression can be used to quantify parasite numbers 
(e.g. sporozoites and liver-stages) using simple and sensitive luminescence assays 
[19-21]. The mCherry-luciferase expression cassette was introduced, using a CRISPR/Cas9 
methodology into the p47 gene locus, a locus that has been previously used to introduce 
transgenes into the Pf genome [5, 22].
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Results  and discuss ion
Generation of a transgenic reporter line, mCherry-luc@etramp10.3, expressing 
a fusion protein of mCherry and Luciferase 
Using CRISPR/Cas9 gene editing we created a transgenic P. falciparum (Pf) parasite 
line that contains an mCherry-luciferase fusion gene under control of 1.7 kb of 5’UTR 
of the etramp10.3 gene (PF3D7_1016900). This expression cassette was introduced into 
the neutral p47 gene locus (PF3D7_1346800). We used a previously described Cas9 construct 
(pLf0019), containing the Cas9 expression cassette and a blasticidin (BSD) drug-selectable 
marker cassette [23] in combination with a sgRNA donor-DNA plasmid (pLf0049)(Figure 
S1). This plasmid contains the p47 targeting sequences, the mCherry-luc@ etramp10.3 
expression cassette and a hdhfr-yfcu drug-selectable marker cassette (See Figure 1 and 
Materials and Methods section for details of the generation of the constructs). Donor DNA 
plasmid pLf0049 aims to integrate the reporter mCherry-luc@etramp10.3 cassette into 
the p47 gene locus by double cross-over homologous recombination (Figure 1). 
Transfection of Pf NF54 parasites was performed using synchronized ring-stage 
parasites that were transfected with ~50 µg of each circular plasmid (Cas9 and sgRNA/
donor-DNA constructs; see Materials and Methods section) and selection of transformed 
parasites containing both plasmids (Cas9 and sgRNA/donor-DNA constructs) was 
performed by applying ‘double’ positive selection using the drugs WR99210 and BSD 
until parasites were detectable by thin blood-smear analysis (between day 14 to 26 post 
transfection). Subsequently, parasites were cultured for 2-4 days without drugs, followed by 
the application of negative (5-FC) selection to eliminate parasites that retain transfection 
constructs (i.e. donor-DNA) as episomal plasmids and to enrich for parasites in which 
the donor-DNA construct has integrated into the parasite genome. Subsequently, drug-
selected parasites were cloned by limiting dilution. Genotyping of two clones by Southern 
analysis and PCR revealed the correct integration of the mCherry-luc@etramp10.3 cassette 
into the Pf genome (Figure 1B). Blood-stages of both clones had growth rates comparable 
to blood-stages of the parent wild type (WT) NF54 strain (Figure 1C). For further phenotype 
analysis (as described below) we selected clone 3, which we confirmed as not retaining 
episomal plasmid by Southern blot analysis (Figure 1B).
mCherry and luciferase expression in mCherry-luc@etramp10.3 blood-stages
We analysed mCherry expression in cultured asexual blood-stages and gametocytes of 
the mCherry-luc@etramp10.3 line. In all asexual blood-stages (ring-forms, trophozoites and 
schizonts) we detected mCherry signals that were indistinguishable from the background 
fluorescence of uninfected red blood cells (Figure 1D). We next examined gametocytes 
cultures of the mCherry-luc@etramp10.3 line, which produced comparable numbers of 
mature stage V male and female gametocytes as WT NF54 parasites (Table S1). In mCherry-
luc@etramp10.3 stage III-V gametocytes a clear mCherry signal was detected (Figure 1E). 
Weak mCherry signals were detectable in at least 20% of stage II gametocytes, increasing 





Figure 1. A P. falciparum reporter line expressing mCherry-luciferase under control of the etramp10.3 
promoter: generation, genotyping and analysis of expression of mCherry and luciferase in asexual 
blood stages and gametocytes. A. Schematic representation of the Cas9 (pLf0019) and sgRNA/donor 
(pL0049) constructs generated to introduce the mCherry-luciferase expression cassette into the P. 
falciparum (Pf) p47 gene locus. The mCherry-luciferase fusion gene is under the control of the promoter 
of the etramp10.3 gene. p47 homology regions (HR1, HR2) used to introduce the donor DNA (i.e. 
gfp expression cassettes), location of primers (p) and sizes of restriction fragments (H: HpaI; in red) 
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We also examined expression of the mCherry-luciferase in blood-stage parasites by 
performing luminescence assays. Unlike mCherry, luminescence signals obtained from 
mixed asexual blood-stage parasites were significantly higher than uninfected cells (p < 
0.0005 in culture wells with more than 104 parasites) (Figure 1F). Gametocytes (stage IV/V) 
had on average 30-fold higher luminescence values (3 exp.; range 15-60 fold) compared to 
mixed asexual stages. The luminescence values obtained from mCherry-luc@etramp10.3 
gametocyte (IV/V) or mixed asexual stage dilution series demonstrate a linear relationship 
between the number of parasites and signal intensity in the range of 1x103 to 1x107 
parasites for gametocytes and  1x104 to 1x107 for asexual blood-stage parasites (Figure 
1F). The high activity of the etramp10.3 promoter in gametocytes is in agreement with 
the high levels of etramp10.3 transcripts and ETRAMP10.3 protein previously reported in 
gametocytes by genome-wide analyses of gene expression. Peak in etramp10.3 transcript 
abundance was observed in stage III gametocytes [24] and ETRAMP10.3 is detected in 
proteomic analyses of (male and female) gametocytes [25, 26]  and is more abundant 
in gametocytes compared to asexual blood-stages. The expression of ETRAMP10.3 in 
asexual blood-stages has been reported after proteomic analyses [27, 28] and has been 
and PCR amplicons (in black) are indicated. Primer sequences (shown in black and bold) are shown 
in Table S2. bsd – blasticydin selectable marker (SM); hdhfr::yfcu – SM in donor plasmid. mCh-luc@
etramp – the final reporter line mCherry-luc@etramp10.3. B. Southern analysis of HpaI restricted DNA 
(upper panel) and diagnostic PCR (lower panel) to confirm correct integration of construct pLf0049 
into the p47 locus. Digested DNA of wild type (WT), transfected, uncloned (uncl) parasites, selected 
parasite clones 3 and 4 and plasmid (PL) of mCh-luc@etramp was hybridized with a probe targeting 
the homology region 1 of p47 (HR1; primers p3/p4; see A), identified the expected different-sized 
DNA fragments in wild type (WT) and mcherry-luc@etramp10.3 (8.2 kb and 6.1 kp shown in red in 
A). The absence of hybridisation of digested DNA hybridized with a probe for ampicillin (amp) gene 
confirms absence of donor-DNA plasmid and single cross-over events in clone 3.. Diagnostic PCR of 
mCh-luc@etramp clone 3 confirms the presence of the mCherry-luciferase gene (lane 1; primers p11/
p12; expected size: 716bp), correct 3’ integration (lane 2; primers p13/p14; expected size: 2188bp) 
and absence of the p47 gene (lane 3; primers p15/p16); expected size: 216bp). Primer locations and 
product sizes are shown in A and primer sequences in Table S1). C. Growth of asexual blood-stages 
of the mcherry-luc@etramp10.3 lines (clone 3 and 4)  and WT parasites in semi-automated culture 
system for a period of 4 days. Cultures were initiated with a parasitemia of 0.5%. D. Fluorescence 
microscopy analysis of live mcherry-luc@etramp10.3 asexual blood-stages. No mCherry fluorescence 
signal above background were detected in the different stages. R: rings; T: trophozoites; ES: early 
schizonts; LS: late schizonts;. Nuclei were stained with Hoechst-33342. All pictures were recorded 
with standardized exposure/gain times to visualize differences in fluorescence intensity (mCherry 0.7 
s; Hoechst 0.136 s; bright field 0.62 s (1x gain)). Scale bar, 4µm. E. Fluorescence microscopy analysis 
of mCherry expression in live mcherry-luc@etramp10.3 gametocytes. Gametocyte stage II, III, IV and 
V are shown. Nuclei were stained with Hoechst-33342. All pictures were recorded with standardized 
exposure/gain times to visualize differences in fluorescence intensity (mCherry 0.7 s; Hoechst 0.136 s; 
bright field 0.62 s (1x gain)). Scale bar, 7µm. F. Correlation between luminescence levels and number 
of parasites in serial dilutions series of asexual blood stages (AS) and gametocytes stage III/IV (SS) of 
the mcherry-luc@etramp10.3 line. Wild type NF45 parasites (WT) were used as a control. Red dotted 
line: luminescence value of uninfected cells. The mean luminescence value of triplicate samples is 
shown; error bars represent the standard deviation. Correlation coefficient r (two-tailed Spearman’s 
test: 103-107 parasites): 1.00; p=0.016* for AS and 1.0;  p=0.016 * for SS.
confirmed by immunofluorescence analysis using anti-ETRAMP10.3 antibodies [18]. 
Moreover, unsuccessful attempts to delete the gene etramp10.3 indicates that it is essential 
during asexual blood-stage development [18]. This vital role of ETRAMP10.3 during 
blood-stage development is in contrast to rodent Plasmodium UIS4, which is dispensable 
for blood-stage development  [29, 30]. In previous studies using rodent parasites, where 
the usi4 gene has been replaced with the etramp10.3 gene, it was demonstrated that Pf 
ETRAMP10.3 is unable to complement the essential function of UIS4 in P. yoelii liver-stages 
[18]. These observations indicate that UIS4 and ETRAMP10.4 may have different or only 
partially overlapping roles in rodent and human malaria parasites.
mCherry and luciferase expression in mCherry-luc@etramp10.3 sporozoites
We examined mCherry expression in oocysts and sporozoites collected from Anopheles 
stephensi mosquitoes fed with mCherry-luc@etramp10.3 gametocytes (using the standard 
membrane feeding assay). mCherry-luc@etramp10.3 parasites produced oocysts 
and sporozoites in numbers that were in the same range as the parent wild type (WT) 
NF54 parasites (Table S1). No mCherry signals, distinguishable from background, were 
detected in maturing oocysts containing sporozoites (at day 8 and 11 after feeding) 
(Figure 2A). Salivary gland sporozoites, however, were clearly mCherry positive 
(Figure 2B, Figure S2). The activity of the etramp10.3 promoter in sporozoites is in 
agreement with detection of ETRAMP10.3 protein in proteomes of sporozoites [31, 32]. 
Expression of mCherry-luciferase in sporozoites was also confirmed by luminescence assays 
(Figures 2B,E and Figure 2B) and luminescence signals from a dilution series of purified 
sporozoites exhibit a linear relationship between sporozoite number and luminescence 
intensity in the range of 1.25x104 to 5x104  sporozoites. We also compared the luminescence 
signals of mCherry-luc@etramp10.3 sporozoites (5x104) with that of transgenic sporozoites 
expressing a GFP-luciferase fusion protein under control of the eef1α promoter [5]. 
The luminescence signal of mCherry-luc@etramp10.3 sporozoites was 14-fold higher than 
the luminescence signal obtained from the same number of GFP-luc@eef1α sporozoites 
(Figure 2E). 
mCherry and luciferase expression in mCherry-luc@etramp10.3 liver-stages
Cultured cryopreserved primary human hepatocytes were infected with 5x104 mCherry-
luc@etramp10.3 or GFP-luc@eef1α sporozoites per well of a 96-wells plate. Development 
of liver-stages of these two transgenic lines at day 2, 4 and 6 after infection was compared 
with WT liver-stages by immunofluorescence using  a rabbit polyclonal antibody against 
the cytoplasmic protein PfHSP70. The percentage of infected hepatocytes, the size of 
the liver-stages and the intensity of HSP70 staining were comparable between the transgenic 
and WT parasites at day 4 after infection and liver-stages of both transgenic lines were 
comparable at day 6.
Expression of mCherry in mCherry-luc@etramp10.3 liver-stages was analysed at day 
3, 4 and 5 after hepatocyte infection by immunofluorescence assay using anti-mCherry 
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Figure 2. A P. falciparum reporter line expressing mCherry-luciferase under control of the etramp10.3 
promoter: analysis of mCherry and luciferase expression in oocyst, sporozoites and liver stages. A. 
Fluorescence microscopy analysis of mCherry expression in live mcherry-luc@etramp10.3 oocyst in A. 
stephensi mosquitoes at day 10 after infection. No mCherry fluorescence signal above background 
was detected. Upper panel: complete midgut with 20to 30 oocysts.  Lower panel: a single oocyst. 
BF - bright field. Scale bar, 20µm. B. Left panel: Fluorescence microscopy analysis of mCherry 
antibodies and mCherry signals were detected at all days (Figure 2D). Expression 
of mCherry-luciferase in liver-stages was also confirmed by luminescence assays 
(Figure 2E). We compared the luminescence signals of mCherry-luc@etramp10.3 liver-
stages with those of GFP-luc@eef1α at the same point of development. The luminesce 
signals of mCherry-luc@etramp10.3 liver-stages, while significantly higher than background 
levels with a peak of expression at day 5, were 2.2 to7.6 fold lower at the same time point 
of development between day 3 and 7 after infection of the hepatocytes (Figure 2E).
To determine if mCherry-luc@etramp10.3 parasites could be used in a plate-based 
assay to test drug sensitivity of liver-stage parasites, we performed an drug assay 
using atovaquone, which has potent activity against developing liver stage parasites 
[33]. The inhibition of  in vitro  P. falciparum liver-stage development was determined 
by measurement of luminescence of  mCherry-luc@etramp10.3-infected hepatocytes 
maintained in 96-well plates and incubated with a serial dilution of atovaquone. 
Atovaquone was added to the 96-well cultures 3 hours after adding 5x104 sporozoites 
to cultures of  primary human hepatocytes and the cultures were allowed to proceed for 
expression in live mcherry-luc@etramp10.3 in salivary glands sporozoites collected at day 21 after 
infection of mosquitoes. Nuclei were stained with Hoechst33342. BF - bright field. Scale bar, 20µm. 
Right panel: Luminescence signals and correlation between luminescence levels and number of 
parasites in serial dilutions series of salivary gland sporozoites. Red dotted line: luminescence value 
of samples without sporozoites. The mean luminescence value of duplicate samples is shown; error 
bars represent the standard deviation. Correlation coefficient r (two-tailed Spearman’s  test) : 0.99; 
p=0.016*. C. Development of liver-stages of mCherry-luc@etramp10.3 and GFP-luc@eef1α parasites 
in cultured cryopreserved primary human hepatocytes which were infected with 5x104 sporozoites. 
Liver-stage development was analysed at day 2, 4 and 6 after infection and compared with WT 
liver-stages by immunofluorescence using antibodies against the cytoplasmic protein PfHSP70. 
The percentage of infected hepatocytes (left graph), the size of liver-stages (middle graph; mean 
surface area; arbitrary units - a.u.) and the fluorescence intensity of PfHSP70 staining (right graph; 
arbitrary units a.u. x106) were comparable between the transgenic and WT parasites at day 4 after 
infection and liver-stages of both transgenic lines were comparable at day 6. At least 20 parasites 
were assessed at each time point. nd: non determined. Significance values (unpaired two-tailed 
t test): n.s. – not significant D. Immunofluorescence analysis of mCherry expression in fixed liver-
stages in cryopreserved human liver hepatocytes. Hepatocytes were fixed at days 3, 4 and 5 after 
sporozoites infection and were stained with rabbit anti-PfHSP70 and goat anti mCherry antibodies. 
Secondary conjugated antibodies used: anti-IgG from rabbit Alexa Fluor® 488 (green) or anti-IgG 
from goat Alexa Fluor ® 594 (red). Nuclei stained with Hoechst-33342. All pictures were recorded with 
standardized exposure/gain times; Alexa Fluor® 488 (green)  0.7 s; anti-IgG Alexa Fluor ® 594 (red) 
0.6s; Hoechst (blue) 0.136 s; bright field 0.62 s (1x gain). Scale bar, 10µm. E. Luminescence levels in 
sporozoites (spz) and in liver-stages from mCherry-luc@etramp10.3 and gfp-luc@eef1a lines. Cultured 
cryopreserved primary human hepatocytes were infected with 5x104 sporozoites and luminescence 
was measured during a 7-day period. Uninfected hepatocytes were used as a control. Red dotted 
line: luminescence value of uninfected cells. The mean luminescence value of duplicate samples is 
shown; error bars represent the standard deviation. F. Sensitivity of mCherry-luc@etramp10.3 liver-
stages to atovaquone (ATQ). Inhibition of liver stage development was determined by measurement 
of luminescence at day 4 after infection of  cultured cryopreserved primary human hepatocytes with 
5x104 sporozoites of development. The IC50 value (7.9nM) was calculated by non-linear regression 
using GraphPad Prism software package 5.04. 
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4 days after which luminescence was determined. In this assay we determined an IC50 
value of atovaquone to be 7.9 nM (Figure 2F), which is close agreement to the previously 
established IC50 value of atovaquone against liver-stages [34]. 
The development and expansion of reporter lines in P. falciparum would increase 
the range of analyses that could be performed, both to interrogate P. falciparum gene 
function at different points of development and to permit the miniaturization and rapid 
screening of compounds or immune sera that target the parasite at different points of 
development. Indeed, mCherry-luciferase expressing sporozoites such as those described 
in this study could be used to better understand the interactions of sporozoites and host 
cells (i.e. in the skin) as well as to examine the action of drugs or vaccines that target 
gametocyte or liver stage parasites.
Materia ls  and methods
In vitro cultivation of P. falciparum blood stages
P. falciparum (Pf) parasites from the NF54 strain were used [23]. Parasites were cultured 
using standard culture conditions in a semi-automated culture system as described[23] 
Fresh human serum and human red blood cells (RBC) were obtained from the Dutch 
National Blood Bank (Sanquin Amsterdam, the Netherlands; permission granted from 
donors for the use of blood products for malaria research and microbiology tested for 
safety). RBC of different donors were pooled every two weeks, washed twice in serum 
free RPMI-1640 and suspended in complete culture medium to 50% haematocrit. Human 
serum of different donors were pooled every 4-6 months and stored at -20°C until 
required. Pf gametocytes cultures were generated using standard culture conditions with 
some modifications as described[23].  Briefly, parasites from asexual stage cultures were 
diluted to a final parasitemia of 0.5% and cultures were followed during 14 days without 
refreshing RBC. At day 14 the cultures were analysed for mature, stage V, gametocytes.
In addition, a transgenic P. falciparum (NF54) was used that contains a  reporter cassette 
with a fusion gene of GFP and luciferase (GFP-Luc) under control of eukaryotic elongation 
factor 1 alpha (eef1a) promoter [5]. 
Generation of the mcherry-luc@etramp10.3 parasite line
To create the reporter line we used a previously described Cas9 construct (pLf0019), 
containing the Cas9 expression cassette with a blasticidin (BSD) drug-selectable marker 
cassette [23] in combination with a sgRNA donor-DNA plasmid (pLf0049). The  sgRNA-
donor DNA construct (pLf0049) contains a hdhfr-yfcu drug-selectable marker (SM) cassette 
for selection with the drug WR99210. To generate pLf0049,  the intermediate plasmid 
pLf0039 (Figure S1) was modified by introducing two homology regions targeting of 
p47 (PF3D7_1346800). Homology region 1 (HR1) was amplified using primers P1/P2 
and homology region 2 (HR2) with P3/P4 from Pf NF54 genomic DNA (see Table S2 for 
primer details). HR1 was cloned in pLf0039 using restriction sites StuII/SacII and HR2 using 
ApaI/HindIII. Subsequently,  a guide RNA sgRNA targeting the p47 locus (gRNA019) was 
selected using the Protospacer software (alphaversion;https://sourceforge.net/projects/ 
protospacerwb/files/Release/), based on the best off targets hits score throughout 
the genome given by Protospacer and  the total number of mismatches of the sgRNA 
with respect to the PAM site. A 20 bp guide sgRNA sequence (using the primers P5/
P6), flanked on both sides by a 15 bp DNA sequence necessary for In Fusion cloning 
(HD Cloning Kit; Clontech), was annealed and used to replace the BtgZI adaptor 
in pLf0039 as previously described [35], resulting in pLf0047. The plasmid pLf0047 
was digested with BlnI and NruI to confirm successful cloning of the sgRNA and 
the correct sequence of the sgRNA (using primes P7/P8) confirmed by Sanger sequencing. 
An additional intermediate plasmid, pLf0130 (Figure S1) was modified by replacing 
the existing promotor region of the gapdh gene (PF3D7_1462800) by the promoter region 
of etramp10.3 promoter (PF3D7_1016900) of a reporter cassette containing mCherry fused 
to luciferase with the 3’UTR region of histidine-rich protein II (GeneID PF3D7_0831800; 
626 bp obtained by digestion of an intermediate plasmid pLf0053 ([23] with restriction 
sites ApaI/XbaI). The etramp10.3 promoter region (1.7kb) was amplified from Pf NF54 
genomic DNA using the primers P9/P10 and cloned into plf0130 using restriction sites 
SacIII/XhoI or KpnI. Next, to obtain the complete mcherry-luc @etramp10.3 expression 
cassette, pLf0130 was digested with ApaI/SacII and this cassette was cloned in pLf0047 
using the same enzymes, resulting in the final construct pLf0049.
Isolation of plasmids for transfection and transfection of synchronized ring stage 
parasites was performed as described [23] and parasites were transfected with a mixture of 
~50 µg of each circular plasmid (Cas9 and sgRNA/Donor DNA construct). After transfection, 
parasite cultures were maintained under standard culture conditions in the semi-automated 
culture system (see above).  Selection of transformed parasites was performed by applying 
‘double’ positive selection 24 h after transfection using the drugs WR99210 (2.6 nM) and 
BSD (5 µg/ml) as described [23]. Drug pressure in the cultures was maintained until thin 
blood-smears were parasite-positive (usually after 14 to 26 days). Positive selection will 
select for the parasites that were transfected successfully with both plasmids (Cas9 and 
sgRNA/Donor constructs). Subsequently, both drugs were removed from the cultures 
for 2-4 days, followed by applying negative selection by addition of 5-Fluorocytosine as 
described [23] in order to eliminate parasites that retained the crRNA/Donor construct as 
episomal plasmid and enriching for the transfected parasites containing the donor DNA 
integrated into the genome. Negative drug pressure in the cultures was maintained until 
thin blood-smears were parasite-positive (usually after 7 days). After negative selection 
infected RBC (iRBC) were harvested from cultures with  a parasitemia of 4 to 10% for 
genotyping by diagnostic PCR and Southern analysis (see next sections). Subsequently, 
selected parasites were cloned by limiting dilution as has been described previously [23]. 
Cloned parasites were transferred in 10 ml culture flasks at 5% haematocrit and cultured 
under standard culture conditions (see above) in the semi-automated culture system for 
collection of parasites for further genotype and phenotype analyses (see next section).
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Genotyping of mcherry-luc@etramp 10.3 parasites
For genotyping diagnostic PCR and Southern analysis of digested DNA were performed 
using DNA isolated from iRBC obtained from 10ml cultures (parasitemia 3 - 10%). DNA 
was isolated as described [23]. Correct integration of the donors constructs was analysed 
by PCR amplification of the mCherry-luciferase gene (primers P11/P12), the fragment for 
3’ integration (3’int; primers P13/P14) and the p47 gene (ORF; primers P15/P16). The PCR 
fragments were amplified using Go-taq® DNA polymerase (Promega) following standard 
conditions with an annealing temperature of 56°C for 20 sec and a elongation step of 72°C 
for 4 min. All other PCR settings were according to manufacturer’s instructions.
Southern blot analysis of digested DNA was performed with HpaI digested genomic 
DNA (4 hrs at 37°C). Digested DNA was hybridized with probes targeting the p47 
homology region 1 (HR1), amplified from NF54 genomic DNA by PCR using the primers 
P1/P2 and a second probe targeting ampicillin (Amp) gene, obtained by digestion of 
the intermediate plasmid pLf0040 with AatII/PvuI (550bp). 
Phenotype analysis of  of mcherry-luc@etramp 10.3 parasites 
Asexual blood stages: The growth rate of asexual blood stages (parasitemia) was monitored 
by FACS analysis of iRBC stained with the DNA-specific dye Hoechst-33258 in 1 ml of 
PBS by adding 4 µl of a 500 µM stock-solution (final concentration 2 µM), as has been 
described previously[23]. mCherry expression of asexual blood stages was analysed by 
standard fluorescence microscopy. In brief, 200 µl samples of iRBC were collected from 
10 ml cultures with a parasitemia between 4 and 10% and stained with the DNA-specific 
dye Hoechst-33342 by adding 4 µl of a 500 µM stock-solution (final concentration 10 µM) 
for 20 min at 37°C. Subsequently, a 5 µl was placed on a microscopic slide (mounted 
under a cover slip) and fluorescence in live iRBC analysed using a Leica fluorescence MDR 
microscope (100x magnification). Pictures were recorded with a DC500 digital camera 
microscope using Leica LAS X software and with the following exposure times: mCherry 
0.6 sec; Hoechst-33342 0.136 s; bright field 0.62 s (1x gain).
Luciferase expression was determined in asexual blood stages. A serial dilution of 
asexual blood stages was prepared from parasites samples that were collected (in triplicate) 
from asexual blood stage cultures with a final number of 5x106 parasites per sample. These 
were diluted with RPMI-1640 culture medium containing uninfected RBC (5% haematocrit) 
to prepare (triplicate) samples with 1x106, 1x105, 1x104, 1x103, 1x102, 1x101 parasites, 
respectively. Samples of 40 µl containing only uninfected RBC (5% haematocrit) were used 
as controls. The cells were pelleted by centrifugation (800g; 30s) and were lysed with 40 µl 
of cell culture Lysis 5X reagent from Promega (1 in 5 dilution in miliQ water). The complete 
lysates were collected in black 96-well plate (flat bottom) and luciferase activity was 
measured after adding 50 µl of the Luciferase substrate (Luciferase Assay System Promega 
). Luciferase activity (in relative light units; RLU) was measured using the Glomax multi 
detection system Luminometer (Promega) and the Instinct software (Promega). 
Gametocytes: Gametocyte production (stage V male/female gametocytes) and 
exflagellation of male gametocytes were analysed in gametocyte cultures established as 
described previously [36]. For analysis of mCherry expression,  stage II -V gametocytes 
were collected at  days 7, 9, 11 and 14. Samples (200 µl) were collected, pelleted by 
centrifugation (800 g; 30 s) and stained with Hoechst-33342 for mCherry expression 
analysis using fluorescence microscopy as described for asexual blood stages. Luciferase 
expression was determined in gametocytes (stage III-IV) collected at day 11. A similar 
serial dilution of gametocytes was prepared as was done as described for asexual blood 
stages and luciferase activity in gametocytes was determined as described for the asexual 
blood stages.
Oocysts and sporozoites: For analysis of mosquito stages (oocysts and sporozoites), 
Anopheles stephensi mosquitoes were infected with day 14 gametocytes cultures using 
the standard membrane feeding assay (SMFA) [37, 38]. Oocysts numbers and mCherry 
expression in oocysts was determined at day 8 and 10 after infection. mCherry expression 
was analysed using a Leica fluorescence MDR microscope (100x magnification). Pictures 
were recorded with a DC500 digital camera microscope using Leica LAS X software and with 
the following exposure times: mCherry 0.6 sec; Hoechst-33342 0.136 s; bright field 0.62 
s (1x gain). Collection of salivary gland sporozoite for counting numbers and expression 
of mCherry was performed at day 14 and 21 after feeding. For counting sporozoites, 
salivary glands from 30-60 mosquitoes were dissected, collected in 100 µl of RPMI-1640 
pH 7.2 and homogenized using a grinder. Sporozoites were counted using a Bürker cell 
counter using phase-contrast microscopy. For mCherry expression, the isolated sporozoite 
were pelleted by centrifugation (800 g; 5 min). The pellet was suspended in 40 µl 1X PBS 
and sporozoites stained with Hoechst-33342 (10 µM) for 30 min at 37°C. Of this solution, 
5 µl was placed on a microscopic slide (mounted under a cover slip) and fluorescence 
of sporozoites in live was analysed using a Leica fluorescence MDR microscope (100x 
magnification). Pictures were recorded with a DC500 digital camera microscope using 
Leica LAS X software and with the following exposure times: mCherry 0.6 sec; Hoechst-
33342  0.136 s; bright field 0.62 s (1x gain).
Luciferase activity in sporozoites was determined in duplicate samples (total volume of 
40 µl of RPMI) of a serial dilution of 0.31x104 – 5.0x104 salivary glands sporozoites.  50µl of 
D-Luciferin (0,4mg/ml; Perkin Elmer Life Sciences, Waltham, USA) was added to the 40µl 
of diluted sporozoites in a black 96-well plate (flat bottom). The in vivo imaging system 
Lumina (Caliper Life Sciences, USA) was used to measure luciferase activity. Imaging 
data were analysed using the Living Image® 4.5.5 software (Caliper Life Sciences, USA). 
Bioluminescence images were acquired with a 12,5 cm field of view (FOV), medium binning 
factor and an ‘auto-exposure’ time of maximum 2 minutes. 
Liver stages: Liver stages were cultured in vitro using  cryopreserved primary human 
hepatocytes obtained from Tebu-bio  (Tebu-bio.com – Life science Research) and thawed 
according to the instructions of Sekisui/Xenotech (Sekisui XenoTech, LLC; Kansas City). Cells 
were cultured in Williams’s E culture medium supplemented with 10% FCS, 1% penicillin-
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streptomycin, 1% fungizone, 0,1IU/ml insulin and 70µM hydrocortisone 21-hemisuccinate 
(Sigma). Hepatocytes were seeded  in Greiner clear bottom white 96-well plates at a density 
of 5x 104 cells per well, two days before infection with sporozoites as described previously 
[39]. Sporozoites were collected from infected mosquitoes at day 21 after as described 
above and hepatocyte cultures (at 37°C) were infected with 5x104 sporozoites per well. 
Three hours (hrs) after the addition of sporozoites, the cultures were washed  three times 
with 1X PBS to remove mosquito material as well as sporozoites and complete Williams’s 
E medium was added and cultures which were incubated overnight at 37°C. The day after, 
the culture medium was replaced and then was changed every 48 hrs until day 7.
Cultured cryopreserved primary human hepatocytes were infected with 5x104 
mCherry-luc@etramp10.3 and GFP-luc@eef1α sporozoites per well of a 96-wells plate. 
Development of liver-stages of these two transgenic lines at day 2, 4 and 6 after infection 
was compared with WT liver-stages by immunofluorescence using antibodies against 
the cytoplasmic protein PfHSP70 (rabbit, anti-PfHSP70; 1:75 dilution of 1mg/ml stock 
solution StressMarqBiosciences) and secondary antibody (goat anti-rabbit IgG AF594; 
1:200 dilution of 4mg/ml stock solution Invitrogen). Hepatocyte and parasite nuclei were 
stained with 300 nM DAPI (Invitrogen D1306). Fluorescence signals were visualized using 
a Cytation imager (Biotek, Winooski, VT). The percentage of infected hepatocytes, the size 
of the liver-stages and the intensity of PfHSP70 staining were analysed using the FIJI image 
analysis software package[40].
For analysis of mCherry expression in liver stages, infected hepatocytes were fixed 
(at day 3, 4 and 5) with 4% paraformaldehyde in 1X PBS during 1 h at room temperature. 
After fixation the wells were washed three times with 1X PBS and permeabilized with 20 µl 
of 0.5% triton in 1X PBS and then blocked with 10% of FCS in 1X PBS for 1 h. Fixed cells 
were washed with 1X PBS and incubated with monoclonal antibodies against PfHSP70 
(rabbit, anti-Pfhsp70; 1:200 dilution of 100µg/ml stock solution StressMarqBiosciences) 
and against mCherry (goat, anti-mCherry Mab Sicgen antibodies; 1:200 dilution of 3 
mg/ml stock solution ) for 1 h at room temperature. Subsequently, cells were rinsed 3 
times with 1X PBS and incubated with the secondary antibodies Alexa Fluor®488/594-
conjugated chicken anti-rabbit and anti-goat (Invitrogen Detection Technologies at 1:200). 
Finally, the cells were washed again three times with 1X PBS and stained with the DNA-
specific dye Hoechst-33342 at a final concentration of 10µM. Fixed cells were covered 
with 1-2 drops of an anti-fading agent (Vectashield), and  stained cells were analysed for 
fluorescence using a Leica fluorescence MDR microscope (100x magnification). Pictures 
were recorded with a DC500 digital camera microscope using Leica LAS X software with 
the following exposure times: Alexa 488: 0.7 sec; Alexa 594: 0.6 sec Hoechst 0.136 sec; 
bright field 0.62 sec (1x gain).
Luciferase expression in liver stages was monitored daily by adding 150µl of Bright-
Glo luciferase assay substrate (Promega, Madison, WI) to 150 µl of culture medium 
to each well and luminescence was quantified  using a Synergy 2 multi-purpose plate 
reader (Biotek, Winooski, VT). Background was determined by measuring wells with 
uninfected hepatocytes.
The sensitivity of liver stage development to atovaquone determined by measurement 
of luminescence of infected primary human hepatocytes maintained in 96-well plates and 
incubated with a serial dilution of atovaquone. Atovaquone was serially diluted in DMSO 
and then in Williams E culture medium to reach a final DMSO concentration of 0.1%. 
Atovaquone was added to the 96-well cultures 3 hrs after adding 5x104 sporozoites to 
cultures of  primary human hepatocytes. Medium containing drug was refreshed each 
day and the cultures were allowed to proceed for 4 days after which luminescence was 
determined as describe above.
Stat ist ics
Data were analysed using GraphPad Prism software package 5.04 (GraphPad Software, 
Inc). Significance difference analyses between WT and  the reporter line mcherry::luc@
etramp 10.3  was performed using the unpaired Student’s t-test. 
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Supplementary Data
Supplementary figure 1. Maps of DNA vectors to generate the transgenic P. falciparum line 
mCherry-luc@etramp10.3. A. Vector maps of the different plasmids used to generate the mCherry-
luc@etramp line. See Materials and Methods section for description and details of the generation 
of these plasmids.
Supplementary Figure 2. mCherry fluorescence of mCherry-luc@etramp10.3 salivary glands 
sporozoites. Upper panel: wild type P. falciparum NF54 (WT) salivary gland sporozoites. Lower panel: 
mCherry-luc@etramp10.3 salivary gland sporozoites. Nuclei stained with Hoechst-33342. All pictures 
were recorded with standardized exposure/gain times; mCherry (red) 0.6s; Hoechst (blue) 0.136 s; 
bright field 0.62 s (1x gain). Scale bar, 20µm.
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Supplementary table 1. Gametocyte, oocyst and sporozoite production in WT and mCherry-luc@
etramp10.3 parasites
Lines
No of stage V 
gametocytes1
No. of 




























1 Percentage  stage V male  and female  gametocytes (per 100 red blood cells) in day 14 cultures . For WT parasites 
the range is given for 5 experiments
2 Number of exflagellating male gametocytes per 10⁵ red blood cells at 10-20 min after activation of day 14 
gametocyte cultures). For WT parasites the range is given for 5experiments  
3 Number of oocyst per mosquito at day 9-10 after feeding ( 10-30 mosquitoes per exp.). For WT parasites 
the range is given for 5 experiments
4 Mean number of salivary gland sporozoites per mosquito at day 21 after feeding (20-30 mosquitoes per exp.) For 
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Rodent malaria parasites where the gene encoding circumsporozoite protein (CSP) has 
been replaced with csp genes from the human malaria parasites, Plasmodium falciparum 
or Plasmodium vivax, are used as pre-clinical tools to evaluate CSP vaccines in vivo. These 
chimeric rodent parasites produce sporozoites in Anopheles stephensi mosquitoes that 
are capable of infecting rodent and human hepatocytes. The availability of chimeric P. 
falciparum parasites where the pfcsp gene has been replaced by the pvcsp would open 
up possibilities to test P. vivax CSP vaccines in small scale clinical trials using controlled 
human malaria infection (CHMI) studies.
Methods
Using CRISPR/Cas9 gene editing two chimeric P. falciparum parasites, were generated, 
where the pfcsp gene has been replaced by either one of the two major pvcsp alleles, 
VK210 or VK247. In addition, a P. falciparum parasite line that lacks CSP expression was 
also generated. These parasite lines have been analysed for sporozoite production in An. 
stephensi mosquitoes.
Results
The two chimeric Pf-PvCSP  lines exhibit normal asexual and sexual blood stage 
development in vitro and produce sporozoite-containing oocysts in An. stephensi 
mosquitoes. Expression of the corresponding PvCSP was confirmed in oocyst-derived 
Pf-PvCSP sporozoites. However, most oocysts degenerate before sporozoite formation 
and sporozoites were not found in either the mosquito haemocoel or salivary glands. 
Unlike the chimeric Pf-PvCSP parasites, oocysts of P. falciparum parasites lacking CSP 
expression do not produce sporozoites. 
Conclusions
Chimeric P. falciparum parasites expressing P. vivax circumsporozoite protein fail to 
produce salivary gland sporozoites. Combined, these studies show that while PvCSP can 
partially complement the function of PfCSP, species-specific features of CSP govern full 
sporozoite maturation and development in the two human malaria parasites.
Keywords
Malaria, P. falciparum, P. vivax, circumsporozoite protein, CSP, gene complementation
Introduct ion
Plasmodium sporozoites enter the blood stream through the bite of an infectious mosquito, 
after which they quickly migrate to the liver and invade hepatocytes. After multiplication 
within hepatocytes, merozoites are formed and released into the blood stream where 
they invade erythrocytes. Proteins of the pre-erythrocytic life cycle stages, sporozoites and 
liver stages, are attractive vaccine targets and are the principal components of leading 
malaria vaccines against the human parasites Plasmodium falciparum and Plasmodium 
vivax [1-4]. The target antigen of the most advanced P. falciparum malaria vaccine (RTS,S) 
is the circumsporozoite protein (CSP), the major sporozoite surface protein [5, 6] and 
is also an important vaccine target for P. vivax [7, 8]. CSP plays a critical role both in 
sporozoite formation and in sporozoite invasion of mosquito salivary glands and liver cells 
of the host [9-12]. So far, pre-erythrocytic subunit malaria vaccines, including RTS,S, have 
shown low to modest protective efficacy, both in the clinic and in field studies [13-16]. 
Efforts to increase the protective efficacy of malaria vaccines is focussed on identifying 
novel antigens, combining multiple antigens in a vaccine and by improving the delivery 
and immunogenicity of these antigens by using a variety of novel immunization platforms. 
Testing the next generation of P. falciparum vaccines and vaccine formulations is 
greatly aided by the ability to vaccinate individuals and then examine vaccine efficacy 
by infecting them with malaria-parasites  in so called controlled human malaria infections 
(CHMI) [17-20]. CHMI studies have increased the speed of vaccine evaluation by using well-
controlled early-phase proof-of-concept clinical studies. Such studies facilitate the down-
selection of vaccine candidates and identifying those most suitable for further evaluation 
in more expensive and difficult phase 2 and 3 trials in areas where malaria is endemic. 
Although recently CHMI has also been developed for P. vivax [21] and has been applied 
to assess pre-erythrocytic vaccine candidates [22, 23], the use of P. vivax CHMI to rapidly 
screen different P. vivax vaccines is limited because of the lack of methods to continuously 
propagate P. vivax blood stages in culture and to produce gametocytes in vitro that can be 
used to infect mosquitoes to produce sporozoites for challenge infections [21]. Therefore, 
P. vivax CHMI is dependent on sporozoites that have been obtained from mosquitoes 
fed on infected patients [21]. Moreover, P. vivax sporozoites can produce hypnozoites, 
dormant forms that can persist in the liver for prolonged periods, which requires safe and 
effective means to clear these forms from the liver in CHMI studies [21, 24]. 
In preclinical evaluation of vaccines, chimeric rodent parasites expressing P. falciparum 
and P. vivax pre-erythrocytic antigens have been used to analyse protective immune 
responses induced by P. vivax or P. falciparum vaccines in vivo in mice. These chimeric 
parasites have been used to assess the protective immune responses induced by 
vaccination that influence sporozoite invasion of hepatocytes both in vitro and in vivo and 
the removal of infected hepatocytes in vivo [25]. For example, chimeric rodent malaria 
parasites have been generated where the endogenous csp gene has been replaced either 
with pfcsp or different pvcsp alleles. These chimeric parasites produce sporozoites that are 
infectious to rodent hepatocytes in vivo and human hepatocytes in culture [25]. 
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Based on the studies with chimeric rodent parasites we reasoned that the availability of 
chimeric P. falciparum parasites that express P. vivax antigens would open up possibilities 
to analyse protective immune responses induced by vaccination using P. vivax antigen-
based vaccines in CHMI bypassing the need for P. vivax parasite production and measures 
to ensure that P. vivax hypnozoites are removed. As a proof of concept two chimeric P. 
falciparum  parasites were generated using CRISPR/Cas9 gene editing methodologies, 
where the pfcsp gene was replaced by one of the two major pvcsp alleles, VK210 and 
VK247 [26]. These chimeric lines, pf-pvcsp(vk210) and pf-pvcsp(vk247), had wild type-like 
blood stage development and produced normal numbers of oocysts. Unlike the absence 
of sporozoite formation in pfcsp deletion parasites, sporozoite formation did occur inside 
oocysts of both chimeric lines; however between 50 and 90%  of the oocysts degenerated 
before sporozoite formation and no sporozoites were detected sporozoites in salivary 
glands. The lack of complete functional complementation was unexpected, since chimeric 
rodent Plasmodium berghei parasites expressing PvCSP-VK210 and PvCSP-VK247 are 
able to produce salivary gland sporozoites in An. stephensi mosquitoes that are infective 
to mice [27, 28]. The findings in this study and the species-specific features of CSP that 
may govern full maturation and development of sporozoites of the two human malaria-
parasite species are discussed.
Results
Generation of two chimeric P. falciparum parasites lines expressing PvCSP-210 
or PvCSP-247
Using CRISPR/Cas9 gene editing, two chimeric P. falciparum parasites lines were created, 
pf-pvcsp(vk210) and pf-pvcsp(vk247), where the P. falciparum csp gene has been replaced 
by either one of the two major P. vivax csp alleles, VK210 and VK247.  A previously 
described Cas9 construct (pLf0019), containing the Cas9 expression cassette with 
a blasticidin (BSD) drug-selectable marker cassette [29], was used in combination with 
two sgRNA donor-DNA containing plasmids, pLf0042 and pLf0043. These constructs are 
used to target the pfcsp gene locus and as ‘DNA-donor’ sequences they replace pfcsp 
with either pvcsp-vk210 or the pvcsp-vk247 full-length gene coding sequences (Figure 1). 
The coding sequences of pvcsp-vk210 (GenBank accession number P08677; Belem strain) 
and pvcsp-vk247 (GenBank accession number M69059.1; Papua New Guinea strain) were 
amplified from existing plasmids P. bergheiG01-PvCSP-vk247 (pL1943) and P. bergheiG01-
PvCSP-vk210 (pL1942) [27]. The two homology regions targeting Pfcsp (PF3D7_0304600) 
were amplified from genomic P. falciparum DNA (NF54 strain). Both constructs contain 
a hdhfr-yfcu drug-selectable marker cassette.
Transfections of P. falciparum NF54 parasites were performed using synchronized ring 
stage parasites that were transfected with ~50 µg of each circular plasmid (Cas9 and 
sgRNA/donor-DNA constructs; see Figure S1) and selection of transformed parasites 
containing both plasmids (Cas9 and sgRNA/donor-DNA constructs) was performed by 
Figure 1. Generation and genotyping of two chimeric P. falciparum parasites (Pf-pvcsp). A Two 
Pf-pvcsp parasite lines were generated using CRISPR/Cas9 methodology. The coding sequence (CDS) 
of Pfcsp gene was replaced by insertion of the Pvcsp(vk210) and Pvcsp(vk247) CDS using donor-DNA 
plasmids pLf0042 and pLf0043. A schematic representation of the Pfcsp locus before and after 
insertion of the construct showing the location of the restriction sites (A: AvaII, E: EcoRV), sizes (in 
bp) of restriction fragments (red for Southern blot analysis), location of primers (p), PCR amplicons 
and sizes (in bp) of the fragments (in black (B, C). HR1, HR2: Pfcsp homology (targeting) regions. 
The figure is not shown to scale. Primer sequences can be found in Additional file 7. B. Diagnostic 
PCR and long-range PCR (LR-PCR) confirming the correct integration of the Pvcsp CDS into the PfCSP 
locus. Diagnostic PCR: Pfcsp open reading frame (lane 2; primers p17/p18); Pvcsp open reading 
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applying ‘double’ positive selection with the drugs WR99210 and BSD, until parasites 
were detectable by thin blood-smear analysis (between day 14 to 26 post transfection). 
Subsequently, parasites were cultured for 2-4 days without drugs, followed by applying 
negative selection to eliminate parasites that retained the transfection constructs 
(i.e. donor-DNA) as episomal plasmids and to enrich for transfected parasites in which 
the donor-DNA construct has integrated into the parasite genome. Genotyping of selected 
parasite populations by long-range PCR revealed that both pvcsp(vk210) and pvcsp(vk247) 
cassettes had integrated into the P. falciparum genomes (Figure 1B) and Southern blot 
analysis of cloned lines confirmed correct integration of the constructs (Figure 1C). 
Phenotype analyses, as described below, were performed using pf-pvcsp(vk210) clone 7 
and pf-pvcsp(vk247) clone 5.  Sequence analysis of the long-range PCR products confirmed 
the correct sequence of pvcsp genes and replacement of the pfcsp gene in both pf-pvcsp 
lines (See Figure S2). 
Pf-PvCSP210 and Pf-PvCSP210 parasites form oocysts but salivary gland 
sporozoites are absent in An. stephensi mosquitoes
The growth of asexual blood stages in cultures and gametocyte production of both 
pf-pvcsp lines was comparable to that of the parental P. falciparum NF54 wild type 
(WT) parasite strain (see Figure S3, Table 1). Gametocyte cultures of the Pf-PvCSP lines 
produced WT-like numbers of mature, stage V, gametocytes of both sexes. Mature male 
gametocytes of both lines underwent exflagellation upon activation and were able to form 
male gametes (Table 1).
Anopheles stephensi mosquitoes were fed with either WT gametocytes or gametocytes 
of the pf-pvcsp lines using the standard membrane feeding assay and the number of 
oocysts in mosquito midguts was determined at day 10 post infection and the presence 
of sporozoites in the haemocoel and salivary glands was analysed at day 14 and day 
21. Dissection of WT and  pf-pvcsp infected mosquitoes revealed that all lines produced 
comparable numbers of oocysts; however, no sporozoites were detected in salivary glands 
in mosquitoes infected with either of the pf-pvcsp lines (Table 1). Moreover, no sporozoites 
from the pf-pvcsp lines were found in haemocoel fluid after mosquito dissection; in 
p23). LR-PCR:   products  were run undigested or digested with EcoRV (LR-PCR+E)  in order to 
confirm double cross-over recombination. LR-PCR (lane 4) of cloned parasites of Pf-pvcsp(vk210)(cl7; 
primers p15/p16), Pf-pvcsp(vk247)(cl5; primers p15/p16) and WT. LR-PCR fragments digested with 
EcoRV (lane 5) for confirmation of double cross-over integration. C. Southern blot analysis of AvaII 
restricted DNA of WT and chimeric Pf-Pvcsp parasites confirms the specific integration of the Pvcsp 
genes into the pfcsp gene locus. DNA was hybridized with a probe targeting the homology region 
2 of pfcsp (upper panels; HR2; primers p3/p4; see A). In addition, to show absence of donor-DNA 
plasmid and single cross-over events, DNA was hybridized with a probe for the ampicillin gene (lower 
panels; intermediate donor-DNA plasmid pLf0040 digested with AatII and PvuI). The hybridization 
pattern observed with the HR2 probe identified the expected different-sized DNA fragments in WT 
and pf-pvcsp parasites (2057 bp and 5294 bp). 
contrast, when WT infected mosquitoes were dissected many sporozoites were observed 
in haemocoel fluid.
These observations indicate that the chimeric parasites expressing PvCSP are unable 
to produce sporozoites that are competent in invading salivary glands.
pf-pvcsp lines produce sporozoites in oocysts but most oocysts degenerate 
before sporozoite formation and release of sporozoites
For two Plasmodium species it has been shown that csp deletion mutants can form 
oocysts; however by light-microscopy, these oocysts are highly vacuolated and do not 
show signs of sporozoite formation  [30, 31]. Therefore, oocyst development of  pf-pvcsp 
was analysed in greater detail by light microscopy and PvCSP expression was examined 
by immunofluorescence microscopy. After feeding with both pf-pvcsp lines, oocysts 
were readily detected at day 10, in which sporozoite formation occurred (Figure 2A). 
However, analysis of oocysts between day 10 and 14 showed that most oocysts started to 
degenerate before full maturation as shown by the absence of clear sporozoite formation 
and the presence of large vacuoles in the cytoplasm of maturing oocysts (see Figure S4). 
In WT-infected mosquitoes, 30% of the oocysts were characterized as degenerate at day 
Table 1. Gametocyte, oocyst and sporozoite production in WT, pf-pvcsp(vk210), pf-pvcsp(vk247) 
and PfΔcsp
Lines
No of gametocytes  
Stage V male/female 
mean (SD) 1
No. of exflagellation 
mean (SD) 2






m: 0.6 (0.2) f: 1.3(0.3)
(3 exp.)
1436 (191)











0050cl2 (n=1) ND ND 9.1 (1 exp.) Negative
pf-pvcs(vk247)






0113cl1 (n=1) ND 875 (1exp.) 4.6 Negative
0113cl3 (n=2) m: 0.6 f: 1.1 (1 exp.) 1010 (388) 
 (3 exp.)
2.2 and 3.2 
 (2 exp.)
Negative
1 Mean percentage  of stage V male (m) and female (f) gametocytes (per 100 red blood cells) in day 14 cultures in 
2-7 experiments (exp.)
2 Mean number of exflagellating male gametocytes (per 10⁵ red blood cells) at 10-20 min after activation of day 14 
gametocyte cultures (s.d.: standard deviation)  
3 Mean number of oocyst per mosquito at day 9-10 after feeding. Range corresponds to the mean number of 
retorts in multiple experiments (1-5 exp. per line; 10-30 mosquitoes per exp.)
4 Mean number of salivary gland sporozoites per mosquito at day 21 after feeding. Range corresponds to the mean 
number of sporozoites in multiple experiments (1-5 exp. per line; 20-30 mosquitoes per exp.) 
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Figure 2. Oocyst and sporozoite formation of two chimeric P. falciparum parasite lines (pf-pvcsp) 
and a  PfCSP knockout line (PfΔcsp). A. Light microscope pictures of oocysts at day 10 after feeding 
gametocytes to Anopheles stephensi mosquitoes. Upper panel pf-pvcsp and wild type P. falciparum 
(WT) oocyst in which sporozoite formation occurs (see Additional file 3 for pictures of pf-pvcsp oocyst 
that degenerate before sporozoite formation). No sporozoite formation was observed in PfΔcsp 
oocysts. Scale bar, 20µm. Lower panel: free pf-pvcsp sporozoites that are released from oocysts by 
application of force to oocysts in dissected midguts.  Scale bar, 20µm. B. Percentage of degenerated 




10, whereas in Pf-PvCSP(vk210) and Pf-PvCSP(vk247) infected mosquitoes 52% and 87% 
degenerate oocysts were countedy (Figure 2B). No spontaneous release of sporozoites 
from mature pf-pvcsp oocysts was detected and no sporozoites could be found free 
in the haemocoel or in salivary glands, even up to day 21 after feeding. Only through 
the application of force to oocysts in dissected midguts could mechanically liberated 
oocyst-derived pf-pvcsp sporozoites be recovered (Figure 2A).
Chimeric sporozoites of both pf-pvcsp(vk210) and pf-pvcsp(vk247) express PvCSP
To analyse expression of PvCSP in pf-pvcsp sporozoites, oocyst-derived sporozoites 
were collected by differential centrifugation of extracted, mechanically crushed, infected 
midguts. These sporozoites were stained with antibodies specific for PvCSP-VK210, 
PvCSP-VK247 and PfCSP. Sporozoites of pf-pvcsp(vk247) and pf-pvcsp(vk210) only 
reacted with their cognate anti-PvCSP-VK247 or anti-PvCSP-VK210 antibodies and WT 
sporozoites only with anti-PfCSP antibodies (Figure 3; Figure S4). These results indicate 
that the corresponding PvCSP is expressed in developing oocysts and oocyst-derived 
sporozoites of the pf-pvcsp lines and that the failure of formation of fully competent 
sporozoites is not due to the absence of PvCSP expression. 
A P. falciparum NF54 mutant that lacks expression of PfCSP forms oocysts but 
sporozoite formation is absent
To investigate whether the formation of sporozoites in chimeric pf-pvcsp oocysts was 
due to partial complementation of PfCSP by PvCSP, a P. falciparum mutant lacking CSP 
expression was generated. This mutant (PfΔcsp) was generated by disrupting the pfcsp 
gene by CRISPR/Cas9 gene editing using a construct (pL0083) that contained an mCherry 
reporter cassette (under control of the constitutive gapdh promoter; see Figure S5A) 
flanked by pfcsp targeting sequences. This construct is designed to replace the pfcsp gene 
with the mCherry-expression cassette and contains a hdhfr-yfcu drug-selectable marker 
cassette. Transfection of P. falciparum NF54 parasites was performed by spontaneous 
plasmid uptake from plasmid-loaded red blood cells cultured under static conditions. 
Uninfected RBC were mixed with 50 µg of two sgRNA/Cas9 constructs  (pLf0071 and 
pLf0072) and 50 µg of the donor-DNA construct (pLf0083). After electroporation, these 
uninfected cells were mixed with iRBC containing P. falciparum NF54 parasites and 
selection of transformed parasites was performed with the drug WR99210 during a period 
of 6 days. Subsequently the drug was removed and parasites were harvested at 0.6-0.8% 
parasitaemia for mCherry fluorescence microscopy analysis to determine the ratio of WT 
and mutant parasites expressing mCherry. Parasites were collected from cultures that 
contained >80% mCherry-positive parasites (at a 4-10% parasitaemia). Genotyping of 
selected and cloned mCherry-positive parasites by diagnostic PCR and Southern blot 
analysis showed integration of the mCherry-expression cassette into the pfcsp gene (see 
Figure S5B and C). 
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Figure 3. PvCSP(VK210) and PvCSP(VK247) expression in oocyst-derived sporozoites of two chimeric 
P. falciparum parasite lines (pf-pvcsp). Immunofluorescence analyses of wild type P. falciparum (WT) 
sporozoites and oocyst-derived pf-pvcsp sporozoites. Fixed sporozoites were labelled with mouse 
anti-PvCSP-VK210 mAb, anti-PvCSP-VK247mAb and mouse anti-PfCSP antibodies. As a control an 
antibody against PfHSP70 was used. Secondary conjugated antibodies used: anti-IgG Alexa Fluor® 
488 (green) or anti-IgG Alexa Fluor ® 594 (red). Nuclei stained with the DNA-specific dye Hoechst-
33342. All pictures were recorded with standardized exposure/gain times; Alexa Fluor® 488 (green) 
0.7 s; anti-IgG Alexa Fluor ® 594 (red) 0.6s; Hoechst (blue) 0.136 s; bright field 0.62 s (1x gain). Scale 
bar, 7µm.
The growth of asexual blood stages in cultures and gametocyte production of 
the PfΔcsp line was comparable to that of WT P. falciparum NF54 parasites (see Figure S3; 
Table 1). Gametocyte cultures of the PfΔcsp lines produced WT-like numbers of mature, 
stage V, gametocytes of both sexes. Mature male gametocytes of both lines underwent 
exflagellation upon activation and were able to form male gametes (Table 1). Anopheles 
stephensi mosquitoes were fed with WT gametocytes and PfΔcsp gametocytes using 
standard membrane feeding. The number of oocysts was determined at day 10 post 
feeding and the presence of sporozoites in salivary glands analysed at day 14 and 21 
after feeding. PfΔcsp parasites were able to produce oocysts in the mosquitoes but no 
sporozoites were detected in salivary glands after feeding (Table 1). Moreover, sporozoite 
formation was not detected in oocysts (3 exp.; 30 mosquitoes per experiment). All oocysts 
degenerated before full maturation as shown both by the absence of sporozoite formation 
and the presence of large vacuoles in the cytoplasm of the oocysts (see Figure 2; 
Figure S6). This oocyst phenotype is comparable to the phenotype observed in P. berghei 
and Plasmodium knowlesi mutants lacking CSP expression [30, 31]. The absence of 
sporozoite formation in PfΔcsp oocysts is in support of partial complementation of PfCSP 
by PvCSP in the pf-pvcsp lines where sporozoites are formed in a fraction of the oocysts.  
Heterologous CSP replacement and expression in different Plasmodium species
Several rodent malaria parasite mutants have been generated in which their endogenous 
csp gene has been replaced by a csp gene from another Plasmodium species. In most of 
these mutants the heterologous CSP protein can complement the function of endogenous 
CSP (Table 2). In both Plasmodium yoelii and P. berghei, P. falciparum CSP can replace 
and functionally complement rodent parasite CSP. In addition, multiple chimeric P. berghei 
lines have been generated that express P. vivax CSP alleles (Table 2) and these lines 
produce salivary gland sporozoites that are capable of infecting mice. In P. berghei only 
replacement of PbCSP with CSP of the avian malaria parasite Plasmodium gallinaceum 
did not lead to full complementation and pb-pgcsp parasites produced strongly reduced 
numbers of salivary gland sporozoites, which are not infective to mice [32]. Recently, 
the generation of two chimeric pb-pvcsp lines, expressing the pvcsp (vk210/vk247) genes 
was reported [27].  The pvcsp-210 and pvcsp247 genes used to generate the chimeric 
pf-pvcsp lines described in this study were amplified from the constructs used to generate 
the rodent pb-pvcsp lines. The pb-pvcsp lines produced salivary gland sporozoites in 
An. stephensi mosquitoes that were fully infectious to mice and these lines have been 
used to analyse protective immunity induced in mice by vaccines that target PvCSP [27]. 
Oocyst formation and sporozoite production of pb-pvcsp(vk210) was comparable to that 
of WT parasites but sporozoite production of pb-pvcsp(vk247) was reduced (Table 2). 
Oocyst formation and sporozoite production of these lines was analysed in more detail 
and confirmed the WT-like formation of oocysts and sporozoites in pb-pvcsp(vk210) (see 
Figure S7). The number of salivary gland sporozoites of pb-pvcsp(vk247) was however 
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Table 2. Parasite lines of different Plasmodium species expressing heterologous or mutated CSP and 











Chimeric CSP parasite  lines
P. berghei Py CSP WT WT [32]; 75
P. berghei Pf CSP WT Reduced (90%) [52]; 69
P. berghei Pf CSP WT Reduced (90%) 342
P. berghei Pf CSP WT WT [53]; 4110
P. berghei Pf CSP WT WT [54]; 4135
P. yoelii Pf CSP WT WT [55]; 1442
P. berghei Pv CSP-210 WT WT [27]; 4136
P. berghei Pv CSP-247 WT WT [28]; 1443
P. berghei Pv CSP-247 WT Reduced (30%) [27]; 4137
P. berghei Pg CSP WT Absent [32]; 74 WT oocyst sporozoite 
formation
P. falciparum Pv CSP-210 WT Absent This study Sporozoite formation in 
fraction of oocysts
P. falciparum Pv CSP-247 WT Absent This study Sporozoite formation in 
fraction of oocysts
Knock-out CSP parasite lines
P. berghei - WT Absent [30]; 9 No sporozoite formation
P. knowlesi - WT Absent [31] No sporozoite formation
P. falciparum - WT Absent This study No sporozoite formation
Mutated CSP parasite lines  (with a sporozoite production phenotype)
P. berghei Mut. Pb CSP WT Absent [33]; 72 PbCSP with truncated 
3’UTR; reduced sporozoite 
formation in oocysts
P. berghei Mut. Pb CSP WT Absent [38]; 73 Mutations of the C-terminal 
GPI-anchor. No sporozoite 
formation in oocysts
P. berghei Mut. Pb CSP WT Absent [34]; 1148 PbCSP lacking repeat 
region; reduced sporozoite 
formation in oocysts;  
no midgut/salivary  
gland sporozoites
P. berghei Mut. Pb CSP WT Absent [34]; 1149 PbCSP lacking repeat 
region and NH2 terminus; 
no sporozoite formation  
in oocysts;
P. berghei Pb/Pg CSP WT Absent [56]; 770 pbcsp replaced by pgcsp 
with  repeat region  
of pbcsp
1 Expression of heterologous CSP or mutated CSP
2 Oocyst numbers and salivary gland sporozoite numbers in infected An. stehensi mosquitoes compared to wild 
type (WT) infected mosquitoes. WT = numbers in the same range as WT-infected mosquitoes
3  Mutant ID in the RMgmDB database: www.pberghei.eu
significantly reduced (p<0.0001***) compared to WT or pb-pvcsp(vk210) parasites (see 
Figure S7). By analysis of oocysts of both lines at day 14 post feeding, we observed 
increased numbers of degenerated oocysts in the pb-pvcsp(vk247), a phenotype that was 
similar to oocysts of the pf-pvcsp  lines, i.e. absence of sporozoite formation and vacuolated 
oocyst morphology (see Additional file 6). These observations indicate that the differences 
in numbers of salivary gland sporozoites between the P. berghei lines results from a better 
ability of P. vivax CSP(VK210) to complement PbCSP function than PvCSP(VK247).
Discuss ion
Chimeric P. falciparum parasites where the csp gene has been replaced with coding 
sequences of P. vivax csp, either Pvcsp(vk210) or Pvcsp(vk247), do not form salivary gland 
sporozoites. These observations indicate that PvCSP cannot functionally complement 
PfCSP. Although PvCSP-expressing sporozoites are formed within oocysts of both chimeric 
lines, most oocysts degenerate before sporozoite formation and no sporozoites are 
released from oocysts resulting in the lack of sporozoites in the haemocoel or in salivary 
glands. The inability of P. vivax CSP to functionally complement P. falciparum CSP is 
unexpected as studies in the rodent parasite P. berghei have shown that the P. berghei 
CSP can be functionally replaced by CSP from different Plasmodium species, including 
the human Plasmodium species, P. vivax and P. falciparum (Table 2). Chimeric pb-pvcsp 
sporozoites expressing the same two PvCSP alleles VK210 and VK247, which were used 
in this study, are able to invade An. stephensi salivary glands and are infectious to mice. 
CSP is a multifunctional protein that has an essential role in the formation of sporozoites 
inside oocysts as well as in sporozoite release, motility and host-cell invasion [9-12]. Mutants 
of P. berghei and the primate parasite P. knowlesi lacking CSP expression do form oocysts 
but sporozoite formation inside oocysts is absent [30, 31]. Maturing oocysts of these csp-
deletion mutants are highly vacuolated and have no signs of sporozoite formation that 
could be detected by light microscopy. In addition, highly vacuolated oocysts and absence 
of sporozoite formation were observed in mosquitoes fed with the P. falciparum mutant 
lacking CSP, PfΔcsp generated in this study. These observations confirm the essential role 
of CSP early in the formation of Plasmodium sporozoites and in oocyst maturation. 
In contrast to the PfΔcsp parasites, where no sporozoite formation was detected in 
maturing oocysts, we observed Pf-Pvcsp oocysts with sporozoite formation and we were 
able to obtain oocyst-derived sporozoites of both chimeric lines. These sporozoites 
expressed PvCSP as shown by immunofluorescence analysis with antibodies specific for 
either PvCSP VK210 or VK247. These observations indicate that the PvCSP proteins can 
be used to initiate sporozoite formation in P. falciparum oocysts but are unable to fully 
complement the function of PfCSP in oocyst maturation and sporozoite development. 
Despite the formation of typical elongated sporozoites in some oocysts of Pf-Pvcsp fed 
mosquitoes, most oocysts exhibit a vacuolated morphology and degenerate before 
sporozoite formation. Oocyst degeneration was clearly visible from day 10 onwards and 
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between day 10 and 21 no increase in oocysts with sporozoite formation was observed, 
indicating that the absence of sporozoite formation at day 10 is not the result of a delayed 
maturation of the oocysts. In addition, no evidence was found for spontaneous release of 
sporozoites of the oocysts that contained sporozoites and we did not observe haemocoel 
or salivary gland sporozoites in Pf-Pvcsp infected mosquitoes up to day 21 post feeding. 
Free sporozoites were only observed when oocysts were ruptured by applying mechanical 
forces on these oocysts.
It seems unlikely that the failure of PvCSP to functionally complement PfCSP is due to 
incorrect expression of the PvCSP proteins in the pf-pvcsp lines. The same pvcsp genes 
as used for successful complementation of CSP in  P. berghei [27] were used to replace 
P. falciparum csp and  the pvcsp genes were amplified from the same plasmids that were 
used for generation of the pb-pvcsp lines. In addition, the pvcsp gene coding sequence 
in the genome of the pf-pvcsp lines was placed under control of the endogenous pfcsp 
promoter and transcriptional terminator sequences to ensure correct timing and level of 
CSP expression. It has been shown that the 3’ untranslated region (3’-UTR) of P. berghei 
csp plays an important role in accurate CSP expression as truncation of pbcsp 3’-UTR 
results in reduced CSP expression, reduced oocyst sporozoite formation and degeneration 
of oocysts [33]. 
The inability of PvCSP to replace the PfCSP function in the chimeric pf-pvcsp lines is 
therefore most likely due to sequence differences between these csp genes that lead to 
structural differences of the CSP proteins, which may affect interactions with other parasite 
proteins that are essential for proper sporozoite formation. These can be protein interactions 
that influence correct transport of CSP from within the oocyst-cytoplasm to the membrane 
of developing sporozoites or interactions that affect its localization or maintenance on 
sporozoites [9-12, 34]. Mutational analyses of P. berghei CSP have shown that different 
regions/sequence motifs of CSP are involved in correct formation of sporozoites in oocysts 
(Table 2).  The overall structure of CSP of different Plasmodium species is conserved. CSP 
is a GPI anchored protein that has a central amino acid repeat region, the sequence and 
number of repeats varies across Plasmodium species. These repeats are flanked by two 
conserved domains; region I at the N terminus of the repeats, and the thrombospondin 
repeat (TSR) domain C-terminal to the repeats [9]. The repeat regions of PfCSPs consist 
of predominantly NANP repeats, which differs in length between individual P. falciparum 
strains  [35, 36]. The repeat region of CSP of two major strains of P. vivax,VK210 and 
VK247 are different from PfCSPs and these consists of 10-11 copies of GDRA(A/D)GQPA 
or ANGA (G/D)(N/D)QPG in CSP-VK210 and CSP-VK247, respectively[37]. The GPI-anchor 
and the repeat region have been shown to play an essential role in correct sporozoite 
formation in P. berghei  oocysts (Table 2). Mutant parasites expressing CSP without GPI-
anchor, or with a mutated GPI-anchor, fail to produce sporozoites and the phenotype is 
similar to mutants that lack CSP expression, i.e. complete absence of sporozoite formation 
[38]. The repeat region of CSP appears to play a critical role in the formation of P. berghei 
sporozoites. P. berghei parasites expressing mutated CSP lacking only the repeat region 
are affected in the later stages of sporozoite formation [34], a phenotype that more 
closely resembles the phenotype of the pf-pvcsp lines. It has been proposed that the CSP 
repeats play a structural role and their absence may result in misfolding of CSP and this 
could affect the interaction of CSP with other sporozoite proteins, which are required 
for final oocyst and sporozoite maturation [34]. However, P. berghei parasites that lack 
the N-terminal portion of CSP, but retain the signal sequence, the repeat region and 
the C’-terminal region of the protein, can still produce  salivary gland sporozoites[39] 
The phenotype of chimeric P. falciparum expressing PvCSP might therefore be explained 
by a disturbed interaction of PvCSP with other P. falciparum proteins, interactions that are 
mediated by the repeat sequences and which are necessary for complete maturation and 
release of oocyst sporozoites. In contrast, it would appear that both PvCSP and PfCSP are 
able to interact with these CSP interacting proteins in P. berghei. Plasmodium berghei 
parasites where PbCSP has been replaced with either PvCSP(VK210) or PvCSP(VK247) 
produced infectious salivary gland sporozoites, although parasites expressing 
PvCSP(VK247) produced significantly less salivary gland sporozoites than either WT or 
PvCSP(VK210)-expressing parasites. Mosquitoes infected with pb-pvcsp(vk247) contained 
degenerate oocysts with a vacuolated morphology that resembled pf-pvcsp parasites. 
These observations indicate that PvCSP(VK247) is less effective in complementing P. 
berghei CSP function in sporozoite maturation and release from oocysts. However, the pb-
pvcsp(vk247) sporozoites that had invaded the salivary glands were not affected in their 
ability to infect mice. 
Further studies using parasites expressing chimeric CSP molecules, comprised of 
different domains of PfCSP and PvCSP, are required to reveal which CSP domains are 
essential for sporozoite maturation and release and can explain the failure of PfCSP 
complementation by PvCSP. The inability of pf-pvcsp lines to produce salivary gland 
sporozoites means that these lines cannot be used for CHMI studies. 
Conclus ions
Chimeric P. falciparum parasites expressing P. vivax circumsporozoite protein fail to 
produce salivary gland sporozoites. While PvCSP-expressing sporozoites are formed 
within oocysts, most oocysts degenerate before sporozoite formation, no sporozoites are 
released from oocysts and results in the absence of sporozoites in either the mosquito 
haemocoel or salivary glands. Combined,  these observations show that while PvCSP can 
partially complement the function of PfCSP, species-specific features of CSP govern full 
sporozoite maturation and development in the two human malaria parasites.
The inability of P. vivax CSP to functionally complement P. falciparum CSP is unexpected 
as studies in the rodent parasite P. berghei have shown that the P. berghei CSP can be 
functionally replaced by CSP from different Plasmodium species, including the human 
Plasmodium species, P. vivax and P. falciparum. It seems unlikely that the failure of PvCSP 
to functionally complement PfCSP is due to incorrect expression of the PvCSP proteins, as 
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the same pvcsp genes were used that were able to successfully complement the function 
of CSP in P. berghei. Further studies on the role of different CSP elements from different 
Plasmodium species and their potential interactions with other Plasmodium proteins may 
not only reveal the species-specific mechanisms that govern sporozoite formation and 
function but may also provide essential information that can be used to create human 
infectious chimeric pf-pvcsp sporozoites. 
Materia ls  and methods
Plasmodium falciparum and Plasmodium berghei parasites and in vitro 
cultivation of P. falciparum blood stages
Plasmodium falciparum parasites from the NF54 strain[40] were obtained from the Radboud 
University Medical Center (Nijmegen, The Netherlands). Parasites were cultured following 
the standard conditions in RPMI-1640 culture medium supplemented with L-glutamine 
and 25mM HEPES (Gibco Life Technologies), 50 mg/L hypoxanthine (Sigma). Culture 
medium was supplemented with 10% human serum and 0.225% NaHCO3. Parasites were 
cultured at a 5% haematocrit under 4% O2, 3% CO2 and 93% N2 gas-conditions at 75 rpm 
at 37°C in a semi-automated culture system in 10ml flasks (Infers HT Multitron and Watson 
Marlow 520U). Fresh human serum and human red blood cells (RBC) were obtained from 
the Dutch National Blood Bank (Sanquin Amsterdam, the Netherlands; permission granted 
from donors for the use of blood products for malaria research and microbiology test for 
safety). RBC of different donors were pooled every two weeks, washed twice in serum free 
RPMI-1640 and suspended in complete culture medium to 50% haematocrit. Human serum 
of different donors were pooled every 4-6 months and stored at -20°C until required.
In addition, P. falciparum gametocytes cultures were generated using standard culture 
conditions (see above) with some modifications [41]. Briefly, parasites from asexual stage 
cultures were diluted to a final parasitaemia of 0.5% and cultures were followed during 
14 days without refreshing RBC. After 9 days these cultures were treated with 50mM of 
N-acetyl-D-glucosamine (Sigma) to kill asexual stages and to enrich for gametocytes. At 
day 14 the cultures were analysed for mature, stage V, gametocytes.
Four different mutant lines of the rodent parasite P. berghei were used that have 
been previously reported. i) A transgenic reference line of P. berghei ANKA, expressing 
the fusion protein GFP-Luciferase (line 676m1cl1; PbΔp230p; RMgm-29; www.pberghei.
eu)[42]; ii) A mutant that expresses P. vivax CSP (VK210 allele). In this mutant the pbcsp 
gene has been replaced with the pvcsp-vk210 gene (line 2196cl1; RMgm-4136; www.
pberghei.eu); [27]; iii) A mutant that expresses PvCSP (VK247 allele). In this mutant 
the pbcsp gene has been replaced with the pvcsp-vk247 gene (line 2199cl1; RMgm-4137; 
www.pberghei.eu; [27]; 
Generation and selection of the chimeric lines pf-pvcsp(vk210) and   
pf-pvcsp(vk247) 
In order to create pf-pvcsp(vk210) and pf-pvcsp(vk247), the previously described pLf0019 
construct, containing the cas9 gene was used [29] and 2 different sgRNA-donor DNA 
containing plasmids, pLf0042 (targeting PfCSP and containing the pvcsp-vk210 gene) and 
pLf0043 (containing the pvcsp-vk247). The pLf0019 construct contains a blasticidin (BSD) 
drug-selectable marker cassette and both sgRNA-donor DNA constructs (pLf0042 and 
pLf0043) contain a hdhfr drug-selectable marker cassette for selection with WR99210. 
To generate pLf0042 and pLf0043, plasmid pLf0033 (see Figure S1) was modified by 
introducing two homology regions targeting Pfcsp (PF3D7_0304600). Homology region 
1 (HR1) was amplified using primers P1/P2 and homology region 2 (HR2) with P3/P4 from 
P. falciparum NF54 genomic DNA (see Table S1 for primer details). HR1 was cloned in 
pLf0033 using restriction sites kpnI/EcoRI and HR2 using EcoRI/AatII. The pvcsp alleles 
pvcsp-vk210 (GenBank accession number P08677; Belem strain) and pvcsp-vk247 
(GenBank accession number M69059.1; Papua New Guinea strain) were amplified from 
existing plasmids PbG01-PvCSP-vk247 and PbG01-PvCSP-vk210 [27] using the primers 
P5/P6 and cloned into pL0033 containing the HR using restriction sites EcoRV/EcoRI, 
resulting in intermediate plasmids pLf0040 and pLf0041 (pvcsp-vk210  and pvcsp-
vk247; see Figure S1). An additional plasmid, AS301 (see Additional file 1) was used to 
clone the guide sgRNA (AS301-sgRNA2) specific for pfcsp. The sgRNA sequence was 
identified using the Protospacer software (alphaversion; https://sourceforge.net/projects/ 
protospacerwb/files/Release/) and was amplified using the primers P7/P8. This sgRNA 
was selected based on the best-off targets hits score throughout the genome given by 
Protospacer and the total number of mismatches of the sgRNA with respect to the PAM 
site. A 20 bp guide sgRNA sequence, flanked on both sides by a 15 bp DNA sequence 
necessary for In Fusion cloning (HD Cloning Kit; Clontech), was annealed and used to 
replace the BtgZI adaptor as previously described [43]. The construct was then digested 
with BlnI and NruI to evaluate the successful cloning of the sgRNA and later confirmed by 
Sanger sequencing using primers P9/P10. Finally, the AS301-sgRNA2 was digested with 
EcoRV/ApaI and cloned into the vectors pLf0040 and Plf0041 using the restriction sites 
StuI/ApaI resulting in the final constructs pLf0042 and pLf0043 (see Figure S1). 
Plasmids for transfection were isolated from 250 ml cultures of Escherichia coli 
XL10-Gold Ultracompetent Cells (Stratagene) by maxi-pep (using HiSpeed® Plasmid 
Maxi Kit (Qiagen®)) to generate 25-50 µg of DNA used per transfection. Transfections 
of P. falciparum NF54 parasites were performed using ring stage parasites obtained from 
cultures with a parasitaemia of 6-15% that were synchronized by 5% D-sorbitol treatment 2 
days before transfection [44].  Infected RBC were pelleted by centrifugation (1150 g, 5 min) 
and 300 µl of the pelleted cells were transferred to a 0.2 cm cuvette and mixed with ~50 µg 
of each circular plasmid (Cas9 and sgRNA/Donor DNA constructs) in 100 µl cytomix [45]. 
Electroporation was performed with a single pulse (310 V and 950µF) in the Biorad Gene 
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Pulser Xcell electroporator (including CE- and PC module) and cells were immediately 
transferred in a 10 ml culture flask and cultures were maintained under standard conditions 
in the semi-automated culture system (see above).  Selection of transformed parasites was 
performed by applying ‘double’ positive selection 24 h after transfection using the drugs 
WR99210 (2.6 nM) and BSD (5 µg/ml). For WR99210 100 µl of a stock solution (2.6 µM) 
was added to 100 ml complete culture medium resulting in a final concentration of 2.6 nM. 
To prepare the WR99210 stock-solution WR99210 was dissolved in DMSO (100mM). For 
BSD 50 µl of a stock solution (10mg/ml) was added to 100 ml complete culture medium 
resulting in a 5 µg/ml final concentration. Drug pressure in the cultures was maintained until 
thin blood-smears were parasite-positive (usually after 14 to 26 days). Positive selection 
will select for the parasites that were transfected successfully with both plasmids (Cas9 and 
sgRNA/Donor constructs). Subsequently, both drugs were removed from the cultures for 
2-4 days, followed by applying negative selection by addition of 5-Fluorocytosine (5-FC; 
130 µl of a stock solution (0.77 mM) in 100 ml complete medium with a final concentration 
of 1 µM; [46]) in order to eliminate parasites that retained the crRNA/Donor construct 
as episomal plasmid and enrich for the transfected parasites containing the donor DNA 
integrated into the genome. Negative drug pressure in the cultures was maintained until 
thin blood-smears were parasite-positive (usually after 7 days). After negative selection 
infected RBC (iRBC) were harvested from cultures with a parasitaemia of 4 to 10% for 
genotyping by diagnostic PCR and Southern blot analysis (see next sections). Subsequently, 
selected parasites were cloned by limiting dilution (see next sections).
Generation and selection of the PfΔcsp line
In order to create the PfΔcsp line, a new plasmid (pLf0070: that contain both the crRNA 
and the Cas9-expression cassette, was modified in order to introduce sgRNAs against 
Pfcsp. This plasmid, kindly obtained from Dr. Marcus Lee (Wellcome Trust Sanger Institute, 
Wellcome Genome Campus, Hinxton, Cambridgeshire, UK) is based on plasmid pDC2-
cam-Cas9-U6.2-hdhfr [47] with a smaller U6 cassete (693bp) and with the Cas9 gene 
harmonized to P. falciparum. Two plasmids with two different sgRNAs (026 and 012) were 
generated. Briefly, pLf0070 was digested with BbsI and sgRNA026 was cloned using 
the primers P11/P12 and sgRNA012 using the primers P13/P14. The primers (100 µM each 
primer) were phosphorylated with T4 polynucleotide kinase (10 Units per reaction) during 
30 min at 37°C, followed by an annealing program of  5 min incubation at 94°C and a ramp 
down to 25°C at 5°C per min, and subsequently ligated into the vector using T4 ligase (5 
units) resulting in plasmid pLf0071 and plasmid pLf0072 (see Figure S1). A second DNA 
donor plasmid was generated by replacing the Pvcsp-vk210 gene of the pLf0040 construct 
(see above) by an mCherry expression cassette obtained from an intermediate plasmid 
pLf0055 (see Figure S1). In this cassette mCherry is under control of the promoter region 
of gapdh (GeneID PF3D7_1462800) and the 3’UTR of histidine-rich protein II(GeneID 
PF3D7_0831800). The complete mCherry expression cassette was removed from pLf0055 
by digestion with the EcoRI/NruI and cloned into pLf0040 digested with EcoRI/EcoRV 
resulting in the DNA donor vector pLf0083 (see Figure S1). This donor DNA construct 
has a drug selectable marker cassette containing a fusion of the positive selectable 
marker hdhfr and the negative selectable marker yfcu (yeast cytosine deaminase/uridyl 
phosphoribosyl transferase).
Transfections of Pf NF54 parasites was performed by spontaneous plasmid uptake from 
plasmid-loaded red blood cells cultured under static conditions [48]. Briefly, 300 µl of 
pelleted, uninfected RBC were transferred to a 0.2 cm cuvette and mixed with 50 µg of 
both sgRNA constructs (25 µg of pLf0071 and 25µg of pLf0072) and 50µg of the donor 
construct (pLf0083) suspended in 200 µl of cytomix. Electroparation was performed as 
described in the previous section. After electroporation of the uninfected RBC, iRBC 
containing P. falciparum NF54 parasites were added to a concentration of 0.1%. Selection 
of transformed parasites was performed when cultures reached a parasitaemia of 3% (after 
approx. 3 days) with 100 µl of WR992010 (2.6nM) during a period of 6 days. Subsequently 
the drug was removed and parasites were harvested at 0.8% of parasitaemia for mCherry 
fluorescence microscopy analysis to determine the ratio of wild type and mutant parasites 
present in the population. Parasites were collected from cultures that contained >80 
mCherry-positive parasites (at a 4% to 10% parasitaemia) for genotyping by diagnostic 
PCR and Southern blot analysis and for cloning (see next section).
Cloning of transfected P. falciparum parasites
Based on the PCR confirmation of the integration, the transfected parasites were cloned 
by the method of limiting dilution as previously described [49] with minor modifications. 
Briefly, infected RBC from cultures with a 4% to 10% parasitaemia were diluted with 
uninfected RBC to 105 iRBC/100 µl in 2 ml culture medium (1% haematocrit and 20% 
serum). Serial dilutions were then performed with uninfected RBC in complete medium 
(1% haematocrit and 20% serum) and cultured in a total volume of 100 µl incubated in 96 
well plates, resulting in 8 rows with the following numbers of iRBC per well: 100, 10, 5, 2.5, 
1.25, 0.6, 0.3, 0.15. Plates were incubated in a Candle Jar at 37°C and culture medium 
was changed every other day. Every 5 days RBC were added resulting in an increase of 
the haematocrit from 1% to 5%. Between days 10-14 samples were collected for thick 
smear analysis from the rows with the highest numbers of iRBC/well; 50 µl medium was 
removed and from the remaining culture 5 µl was used directly for preparing thick smears. 
At day 21 thick smears were made from all rows. Clones were selected from dilutions/row 
with less than 30% of the wells parasite positive. These clones were transferred in 10 ml 
culture flasks at 5% haematocrit under standard culture conditions (see previous sections) 
in the semi-automated culture system for collection of parasites for further genotype and 
phenotype analyses (see next section).
Genotyping of the pf-pvcsp(vk210), pf-pvcsp(vk247) and pfΔcsp lines
For genotyping of the chimeric pf-pvcsp lines and the pfΔcsp line diagnostic PCR and 
Southern blot analysis of digested DNA were performed from material isolated from iRBC 
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obtained from 10ml cultures (parasitaemia 3 - 10%), pelleted by centrifugation (1150 g; 
5 min.). RBC were then lysed with 5-10 ml of cold (4°C) erythrocyte lysis buffer (10x stock 
solution 1.5 M NH4Cl, 0.1 M KHCO3, 0.01 M Na2EDTA; pH 7.4; [44]) and parasites were 
treated with RNAse and proteinase-K before DNA isolation by standard phenol-chloroform 
methods. Correct integration of the donor constructs was analysed by standard and long-
range PCR (LR-PCR). In brief, for the chimeric pf-pvcsp lines integration of the pvcsp 
cassettes was confirmed by LR-PCR using the primers P15/P16 (and analysed by EcoRV 
digestion). The PCR-amplified product was cloned in a TopoTA vector for sequencing 
(see Table S1 for details of the primers and Figure S2 for sequence data). The LR-PCR 
fragments were amplified using KOD Hot start polymerase following standard conditions 
with an annealing temperature of 53.5°C for 15 sec and an elongation step of 68°C for 9 
min. For the PfΔcsp line, 5’-integration PCR was performed using the primers P15/P19 and 
to confirm the presence of the mCherry gene PCR was performed with the primers P20/P21. 
The PCR fragments were amplified using Go-taq®  DNA polymerase (Promega) following 
standard conditions with an annealing temperature of 56°C for 20 sec and a elongation 
step of 72°C for 4 min. All other PCR settings were according to manufacturer’s instructions.
Southern blot analysis for the chimeric pf-pvcsp lines was performed with genomic 
DNA digested with AvaII (4 hrs at 37°C) in order to confirm integration of the replacement 
of pfcsp by the pvcsp genes Fig. 1C). Digested DNA was hybridized with probes targeting 
the Pfcsp homology region 2 (HR2), amplified from NF54 genomic DNA by PCR using 
the primers P3/P4 and a second probe targeting ampicillin (Amp) gene, obtained by 
digestion of the intermediate plasmid pLf0040 with AatII/PvuI (550 bp). For Southern blot 
analysis of PfΔcsp, genomic DNA was digested with AvaII and XhoI (4 hrs at 37°C) and 
digested DNA was hybridized with the same probes used with the Pf-Pvcsp lines (HR2 and 
Amp probes see Additional file 5 C).
Phenotype analysis of P. falciparum parasites: blood stages, gametocytes, 
oocysts and sporozoites 
The growth rate of asexual blood stages of the pf-pvcsp and pfΔcsp lines was monitored 
in 10 ml cultures maintained in the semi-automated culture system under standard culture 
conditions (see above). Briefly, a 0.5% parasitaemia culture was established in complete 
culture medium at a haematocrit of 5%. Medium was changed twice daily and the culture 
maintained for a period of 5 days without refreshing RBC. For determination of the course 
of parasitaemia, triplicate samples of 100 µl were collected daily from all cultures and cells 
pelleted by centrifugation (9485 g ; 30 s) and stained with Giemsa. mCherry expression 
of in PfΔcsp blood stages was analysed by standard fluorescence microscopy. In brief, 
200 µl samples were collected from 10 ml cultures with a parasitaemia between 4 and 
10% and stained with the DNA-specific dye Hoechst-33342 by adding 4 µl of a 500 µM 
stock-solution (final concentration 10 µM) for 20 min at 37°C. Subsequently, a 5 µl drop 
was placed on a microscopic slide (mounted under a cover slip) and fluorescence in live 
iRBC analysed using a Leica fluorescence MDR microscope (100x magnification). Pictures 
were recorded with a DC500 digital camera microscope using Leica LAS X software and 
with the following exposure times: mCherry 0.6 sec; Hoechst-33342  0.136 s; bright field 
0.62 s (1x gain). 
Gametocyte production by the pf-pvcsp and pfΔcsp lines was analysed in gametocyte 
cultures, established as described in the previous sections.  To activate gametocytes for 
exflagellation 20 µl samples of the P. falciparum stage V gametocyte cultures at day 14 
were diluted 1:1 with FCS at room temperature. Gametes and exflagellation centres were 
examined and quantified 10-20 min after activation using a Bürker cell counter. For analysis 
of mosquito stages (oocysts and sporozoites) of the chimeric pf-pvcsp lines, An. stephensi 
were infected using the standard membrane feeding assay (SMFA) [50, 51]. Oocysts 
were analysed between day 8 and 14 for sporozoite production and the percentage 
of degenerated oocyst determined. Oocysts were qualified as degenerated based on 
the following criteria: no sporozoite formation visible and oocyst cytoplasm vacuolated. 
Salivary gland sporozoites were counted at day 14 and 21 post feeding. For counting 
sporozoites, salivary glands from 30-60 mosquitoes were dissected and homogenized 
using a grinder in 100 µl of RPMI pH 7.2 and sporozoites were analysed in a Bürker cell 
counter using phase-contrast microscopy.
Analysis of PvCSP expression in oocyst-derived sporozoites of the pf-
pvcsp(vk210) and  pf-pvcsp(vk247) lines 
To analyse CSP expression in oocyst-derived sporozoites of the pf-pvcsp lines by 
immunofluorescence microscopy, midguts from 30-60 An. stephensi mosquitoes were 
collected in an eppendorf tube at day 10 after feeding in RPMI-1640 medium containing 
3% BSA. Midguts were mechanically crushed using a grinder and centrifuged with low 
speed (62 g) for 3 min at 4°C. Subsequently, the supernatant containing oocyst-derived 
sporozoites was collected for fluorescence microscopy and samples (20 µl) were placed on 
a 8-well black cell-line diagnostic microscope slide (Thermo Scientific), dried for 10 min, and 
fixed with 4% paraformaldehyde for 30 min at room temperature. After fixation the slides 
were washed three times with 1X PBS and permeabilized with 20 µl of 0.5% triton in 1X 
PBS and then blocked with 10% of FCS in 1X PBS for 1h . Fixed cells were washed with 1X 
PBS and incubated with monoclonal antibodies against PvCSP(vk210) (mouse, anti-PvCSP-
VK210 MAb (MR4); 1:200 dilution of 109µg/ml stock solution [27]) PvCSP-(vk247) (mouse, 
anti-PvCSP-VK247 MAb (MR4); 1:200 dilution of 125µg/ml [27]), PfCSP (mouse, anti-PfCSP 
(210 A) MAb(MR4); 1:200 dilution of 8µg/ml stock solution REF) and PfHSP70  (rabbit, 
anti-PfHSP70; 1:200 dilution of 100µg/ml stock solution StressMarqBiosciences) for 1h at 
room temperature. Subsequently, cells were rinsed 3 times with 1X PBS and incubated 
with the secondary antibodies Alexa FLuor®488/594-conjugated chicken anti-mouse and 
anti-rabbit (Invitrogen Detection technologies at 1:200). Finally, the cells were washed 
again three times with 1X PBS and stained with the DNA-specific dye Hoechst-33342 at 
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a final concentration of 10µM. Fixed cells were covered with 1-2 drops of an anti-fading 
agent (Vectashield), and a coverslip placed on the cells and sealed with nail polish. Stained 
cells were analysed for fluorescence using a Leica fluorescence MDR microscope (100x 
magnification). Pictures were recorded with a DC500 digital camera microscope using 
Leica LAS X software with the following exposure times: Alexa 488: 0.7 sec; Alexa 594: 0.6 
sec Hoechst 0.136 sec; bright field 0.62 sec (1x gain).
Phenotype analysis of Plasmodium berghei parasites: oocysts, sporozoites and 
sporozoite infectivity
Feeding of An. stephensi mosquitoes with P. berghei parasites, determination of oocyst 
production and sporozoite collection were performed as described [27]. Determination 
of parasite liver load by in vivo imaging and determination of the prepatent period in 
mice after intravenously injection of 1000 salivary gland sporozoites was performed as 
described [27]. 
Statistics
Data were analysed using GraphPad Prism software package 5.04 (GraphPad Software, 
Inc). Significance difference analyses between WT, pf-pvcsp and the pfΔcsp lines was 
performed using the unpaired Student’s t-test,
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Supplementary Data
Supplementary figure 1. Vector maps of the P. vivax csp genes introduced into P. falciparum. A. 
Vector maps of the different plasmids used to generate two chimeric P. falciparum parasite lines (pf-
pvcsp) expressing P. vivax CSP(VK210) of CSP(VK247) and a P. falciparum line lacking expression of 
CSP (PfΔcsp). See Methods section for description and details of the generation of these plasmids.
Supplementary figure 2. Sequence analysis of the P. vivax csp genes introduced into P. falciparum. 
Long-range PCR fragments (see Fig. 1) were cloned into pET TOPO TA (Invitrogen) and sequenced. 
See Additional file 7 for primer sequences used for sequencing the complete fragment. A. LR-PCR 
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Supplementary figure 3. Growth of asexual blood stages and mCherry expression in blood stages. 
A. Growth of asexual blood stages of two chimeric P. falciparum parasite lines (pf-pvcsp(vk210) and 
pf-pvcsp(vk247), a P. falciparum line lacking expression of CSP (PfΔcsp) and P. falciparum wild type 
(WT) parasites. Parasites of the different cloned lines were cultured in semi-automated culture system 
for a period of 7 days. Cultures were initiated with a parasitaemia of 0.5%. Arrows indicate the dilution 
of the cultures with fresh red blood cells to have a final parasitaemia of 1%. B. mCherry-expressing 
blood stages of PfΔcsp parasites where the csp gene has been disrupted by insertion of an mCherry 
expression cassette (see Additional file 4 for details of the generation of PfΔcsp). Scale bar, 7µm.
A
B
Supplementary figure 4. PvCSP(VK210) and PvCSP(VK247) expression in oocyst-derived sporozoites 
of two chimeric P. falciparum parasite lines (pf-pvcsp). Immunofluorescence analyses of wild type 
P. falciparum (WT) sporozoites and oocyst-derived pf-pvcsp sporozoites. Fixed sporozoites were 
labelled with mouse anti-PvCSP-VK210 mAb, anti-PvCSP-VK247mAb and mouse anti-PfCSP 
antibodies. Secondary conjugated antibodies used: anti-IgG Alexa Fluor® 488 (green. Nuclei stained 
with the DNA-specific dye Hoechst-33342. All pictures were recorded with standardized exposure/
gain times; Alexa Fluor® 488 (green) 0.7 s; Hoechst (blue) 0.136 s; bright field 0.62 s (1x gain). 
Scale bar, 7µm.
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Supplementary figure 5. Generation and genotyping a P. falciparum mutant line lacking expression 
of CSP (PfΔcsp). A. The PfΔcsp line was generated using CRISPR/Cas9 methodology. The pfcsp 
gene was replaced by insertion of a mCherry expression cassette (mCherry under control of the of 
the constitutive gapdh promoter) using donor-DNA plasmids pLf0086.  A schematic representation 
of the pfcsp locus before and after insertion of the construct showing the location of the restriction 
sites (A: AvaII ), sizes (in bp) of restriction fragments (red for Southern blot analysis), location of 
primers (p), PCR amplicons and sizes of the fragments (in black) used to analyse correct disruption of 
the pfcsp and insertion of the mCherry cassette (B, C). HR1, HR2: pfcsp homology (targeting) regions. 




PCR confirming correct integration of the mCherry cassette into the PfCSP locus. 5’ integration 
PCR (lane 2; primers p15/p19); pfcsp open reading frame (lane 3; primers p17/p18);  P. falciparum 
sequestrin  as a control gene (lane 1; primers p22/p23); mCherry gene (lane 4; primers P20/P21) of 
cloned parasites of PfΔcsp (cl3) and WT. C. Southern blot analysis of AvaII/XhoI restricted DNA of 
WT and PfΔcsp parasites confirms the specific integration of the mCherry cassette into the pfcsp 
gene locus. DNA was hybridized with a probe targeting the homology region 2 (upper panels; HR2; 
primers p3/p4; see A) of pfcsp. The hybridization pattern observed with the HR2 probe identified 
the expected different-sized DNA fragments in WT and pf-pvcsp parasites (2057 bp and 4105 bp). 
In addition to show absence of donor-DNA plasmid and presence of single cross-over events DNA 
was hybridized with a probe for the ampicillin gene (lower panels; intermediate donor-DNA plasmid 
pLf0040 digested with AatII and PvuI). 
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Supplementary figure 6. Degenerated oocysts of two chimeric P. falciparum parasite lines (pf-pvcsp) 
and a PfCSP knockout line (PfΔcsp). Light microscope pictures of degenerated oocysts at day 10 after 
feeding gametocytes to Anopheles stephensi mosquitoes. These oocysts are classified as degenerate 
based on the absence of sporozoite formation and vacuolated cytoplasm. See Figure 2 for pf-pvcsp 
and wild type P. falciparum (WT) oocyst in which sporozoite formation occurred. No sporozoite 
formation was observed in PfΔcsp oocysts. Scale bar, 20µm.
A
B
Supplementary figure 7. Chimeric rodent parasite lines pb-pvcsp(vk210) and pb-pvcsp(vk247) are 
able to produce salivary gland sporozoites that are infectious to mice. A. Upper panel, left: Light 
microscope pictures of wild type P. berghei (WT) and pb-pvcsp oocyst at days 7, 10 and 14 after 
feeding of An. stephensi mosquitoes. Black arrows indicate oocyst with sporozoite formation and 
white arrows  indicate degenerated, vacuolated oocyst without sporozoite formation (scale bar, 10 
µm). Upper panel, right, Percentage of degenerated oocyst in An. stephensi mosquitoes (n=5) at day 
14 after feeding (***p=<0,0001; unpaired T-test). Lower panel: Oocyst and sporozoite production 
of wild type P. berghei (WT) and pb-pvcsp parasites. B. In vivo imaging of parasite liver loads at 44 
h after injection of mice with salivary gland sporozoites of wild type P. berghei (WT) and pb-pvcsp 
parasites. Left panel: luminescence signals in the different groups of mice. Right panel: quantification 
of the bioluminescence signals in the different groups of mice measured as Relative Luminescence 
Units (RLU).
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Supplementary Table 1. List of primers used in this study
Primer ID Gene ID Sequence Enzymes Product (bp) Description
P1 PF3D7_0304600 ATAGGTACCAGCACGTGATAAAGTAATTG KpnI
1007
Forward HR 1 pfcs





Forward HR 2 pfcs
PF3D7_0304600 AATCGACGTCTTAGCTTTTAGTATAGGATAG AatII Forward HR 2 pfcs
P5 GGGGATATCGCGGCCGCACAAAATCTATATATACACGCATATATTTAAAATG EcoRV/NotI 1188 Forward ORF pvcsp-vk210/247
P6 AGAATGAATTCTCATGCGTAATGTTTATTTAATTAAATAATGC EcoRI Reverse ORF pvcsp-vk210/247
P7 PF3D7_0304600 TAAGTATATAATATTTAAGGCCTCAACAAATAAAAGTTTTAGAGCTAGAA Forward gRNA012
P8 PF3D7_0304600 TTCTAGCTCTAAAACTTTTATTTGTTGAGGCCTTAAATATTATATACTTA Reverse gRNA012




















Forward gRNA012 Pf csp ko

















Forward long range PCR
Reverse long range PCR
Forward Pf csp orf


















































Conclus ions and discuss ion
In this thesis we describe a set of studies that employed novel CRISPR/Cas9 methodologies 
to improve Plasmodium falciparum genetic modification. This was done in order to create 
novel transgenic parasites, which can be used to better interrogate host-pathogen 
interactions or used in anti-malarial drug and vaccine research. We first focused on 
improving P. falciparum CRISPR/Cas9 gene editing technology and on identifying a suitable 
‘neutral’ locus to introduce transgenes into the parasite genome. Using this improved 
CRISPR/Cas9 methodology, transgenic P. falciparum parasites were created that express 
either fluorescent-luminescent reporter proteins or express a major vaccine candidate 
from the other major human malaria parasite, P. vivax.
Improved CRISPR/Cas9 genetic  modif icat ion 
of  P. fa lc iparum  (Chapter 3)
The RNA-guided CRISPR/Cas9 (clustered regularly interspaced short palindromic 
repeats/CRISPR-associated protein 9) system has transformed genome editing in 
a wide variety of organisms [1]. This powerful genome editing technique has also been 
applied to P. falciparum and provides an efficient method for manipulating the parasite 
genome, including site-directed mutagenesis, gene disruption and the introduction of 
transgenes [2, 3].
In Chapter 3 we describe further improvements of the CRISPR/Cas9 transfection 
constructs and selection protocol in order to more rapidly modify the P. falciparum 
genome and to introduce transgenes into the parasite genome without the inclusion of 
drug-selectable marker genes. This method was used to stably integrate three different 
GFP-expression cassettes into the P. falciparum genome, where GFP is under the control 
of promoters of three different Plasmodium genes. The selection procedure to obtain 
genetically modified P. falciparum parasites before the use of CRISPR/Cas9 methods 
required 1-3 months of continuous culture to select for parasites where episomal plasmids 
became integrated into the parasite’s genome, either by single or by double cross-over 
recombination [4]. Moreover, the process of removing introduced drug-selectable markers 
from genetically modified parasites, which involved multiple steps of cloning, can typically 
take 5 months or more to complete [5]. With the methods described in Chapter 3 we 
describe a protocol where cloned, drug-selectable marker-free parasite lines that stably 
express reporter proteins can be obtained within a period of 10-12 weeks. The CRISPR/
Cas9 Plasmodium transfection method requires the introduction of two plasmids into 
the parasite by electroporation. In one of the plasmids, the sgRNA/donor plasmid, we 
have placed the selectable-marker cassette outside the donor-DNA cassette, which results 
in the introduction of a transgene into the parasite genome without  the introduction 
of a drug-selectable marker. Hence the locus can be modified without the inclusion of 
a drug-selectable marker cassette. These constructs can easily be modified to also perform 
other genetic manipulations, notably gene-disruptions and gene-mutations, which can 
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be used to interrogate gene function and importance. A consequence of the absence 
of a drug-selectable marker in the genome is that these ‘marker-free’ parasites can be 
further modified more rapidly and easily to create parasites that have multiple genetic 
modifications, for example, ‘double’ modified parasites that contain both a reporter gene 
as well as a disrupted or mutated gene. Indeed, such rodent malaria mutants have been 
used extensively to analyse the phenotypic consequences of a gene disruption/mutation, 
in vitro and in vivo,  using a variety of imaging technologies.
The GFP-expression cassettes were introduced into the p230p gene locus of the P. 
falciparum genome. The p230p locus was selected as we predicted it to be a ‘neutral’ locus 
based on rodent Plasmodium studies, i.e. the loss of this P. falciparum gene would not affect 
parasite development. However, disruption of the p230p gene unexpectedly resulted in 
P. falciparum parasites that could not infect and develop in mosquitoes. We describe 
in Chapter 4 the phenotype of the ‘p230p gene-deletion’ mutants in mosquitoes and 
the potential role of the P230p protein in mosquito development. In P. falciparum the p47 
gene locus has been most frequently used to introduce transgenes into the P. falciparum 
genome [6, 7]. We initially had selected the p230p gene locus to introduce transgenes 
as an alternative to the p47 gene, since the P47 protein has been shown to be important 
for limiting defence responses against the parasite in mosquitoes [8, 9]. Consequently, P. 
falciparum parasites lacking P47 expression have a reduced capacity to transmit through 
some species of Anopheles mosquitoes, as they are less capable of escaping the mosquito 
immune response. In two rodent Plasmodium species the male-specific P230p protein 
appears to be dispensable throughout the parasite’s complete life cycle [10-12]. P. berghei 
and P. yoelii mutants lacking expression of P230p can develop in the vertebrate host and 
in the mosquito vector without a discernible phenotype and p230p knock-out parasites 
manifest a wild type parasite phenotype. As rodent Plasmodium P230p is not essential, 
the p230p gene is a frequently used locus to introduce additional transgenes into rodent 
malaria parasite genomes [11]. In contrast, we found that P. falciparum p230p cannot be 
used as a ‘neutral locus’, in particular for the generation of genetically modified parasites 
that need to be examined in mosquitoes or in liver stages (see also Chapter 4).
Future studies
We generated a set of CRISPR/Cas9 constructs that can be modified and used in future 
studies to remove or introduce transgenes into the P. falciparum genome. For example, 
these can be used to i) generate reporter lines that express additional (fluorescent/
bioluminescent) reporter proteins; ii) to analyse the genetic regulatory elements that 
control Plasmodium gene expression; iii) change the homology regions of the sgRNA/
donor DNA construct to permit introduction of transgenes into different P. falciparum 
genetic loci; or iv) to introduce other transgene (e.g. reporter) expression cassettes 
under the control of different regulatory promoter and transcription terminator 
(5’- and 3’-UTR) regions.
In this study we generated three different reporter parasite lines, principally to identify 
strong constitutive promoters that can be used to drive reporter gene expression. We 
found that the cam promoter resulted in relatively weak GFP-expression compared to 
gapdh and hsp70 in blood stage parasites, which is in agreement with Plasmodium RNAseq 
gene-expression data. The Plasmodium hsp70 promoter has been used frequently to drive 
transgene expression in rodent reporter parasites. The gapdh promoter has not been 
extensively examined in either rodent or human parasites. GAPDH is an enzyme involved 
in glycolysis, the main pathway for ATP production in Plasmodium [13], and therefore this 
protein is likely to be expressed throughout the complete life cycle. Indeed, proteome 
analyses of oocysts and sporozoites provide evidence for high abundance of GAPDH in 
these stages (PlasmoDB; www.plasmodb.org). Therefore, we believe that both hsp70 and 
gapdh promoters may be used to drive transgene expression throughout the complete 
parasite life cycle. 
Further improvements could be made to the CRISPR/Cas9 methodology. In particular 
the replacement of the ‘two plasmid’ based transfection system, which results in reduced 
transfection efficacy and requires double drug selection, with a more efficient and rapid 
‘single plasmid’ transfection method [14]. 
This study revealed that 230p gene locus, unexpectedly, was not suitable for creation of 
transgenic parasite lines that could transmit through mosquitoes. Therefore, identification 
of additional ‘neutral’ genetic loci in P. falciparum is required to expand the possibilities for 
creating transgenic reporter lines that can be used at multiple points of the parasite life-
cycle. This is even more pressing, since the most frequently used locus for introduction of 
transgenes is the p47 gene, whose removal has been shown to compromise P. falciparum 
development in different strains of Anopheles mosquitoes.
The phenotype of  P. fa lc iparum  mutants 
lacking P230p express ion (Chapter 4)
The GFP-expression cassettes in the reporter P. falciparum lines described in Chapter 3 
were introduced into the genome in the p230p gene locus. As we mentioned above, 
disruption of the p230p gene resulted in parasites that could not infect and develop 
in mosquitoes. In Chapter 4 we describe studies to analyse the phenotype of 
the p230p ‘gene-deletion’ mutants in mosquito stages and to identify its potential role in 
parasite fertilization. 
The P230p protein belongs to the s48/45 domain 6-cysteine (6-cys) family of Plasmodium 
proteins, a small family with 14 members that show stage-specific expression throughout 
the parasite life cycle, with most members localizing to the surface of parasites [15]. Most 
members have critical roles in parasite development, either in the vertebrate host or in 
the mosquito vector, and several members are leading targets for malaria vaccines. These 
include vaccine antigens that target parasites in the mosquito, the so-called transmission 
blocking vaccine antigens, i.e. P48/45 and P230 [16-18]. In P. falciparum these proteins 
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are expressed in both male and female gametocytes/gametes [19-21]. In two rodent 
Plasmodium species the paralog of P230, the male-specific P230p protein, appears to be 
dispensable throughout the parasite’s complete life cycle [10-12].  
We found that P. falciparum mutants lacking P230p expression (PfΔp230p) produced 
wild type numbers of male and female gametocytes that retained expression of P48/45 and 
P230. Upon activation, male PfΔp230p gametocytes undergo exflagellation and form male 
gametes. However, these male gametes are unable to attach to red blood cells, resulting 
in the absence of characteristic exflagellation centres in vitro. In the absence of P230p, 
zygote formation as well as oocyst and sporozoite development were strongly reduced 
in mosquitoes. These observations demonstrate that P230p, like P230 and P48/45, has 
a vital role in P. falciparum male fertility and zygote formation and identifies P230p as one 
of a limited number of gamete-specific proteins critical for P. falciparum transmission.
The function of P230p in male gamete fertility is in agreement with male-specific 
expression of PfP230p and concomitant absence in female gametocytes/gametes [19-24]. 
The important role that P. falciparum P230p plays in mosquito transmission does not match 
the redundant function of P230p in the rodent parasites P. berghei and P. yoelii. Rodent 
parasites also express P230p specifically in male gametocytes [25], but mutants lacking 
P230p have no discernible defect and  exhibit normal gametocyte/gamete formation. 
Activated male gametocytes are fully able to form exflagellation centres and mosquito 
transmission is similar to WT parasites [10, 11]. 
In Chapter 4 we also provide evidence that P. berghei P230 is not compensating for 
the loss of its paralogue P230p, since activated male gametocytes of P. berghei mutants 
lacking expression of both P230 and P230p can still bind to RBCs and form exflagellation 
centres. These observations demonstrate a critical difference in the function P230p performs 
in rodent and human malaria parasites. For a few other 6-Cys proteins evidence has been 
found for functional differences between the orthologs of rodent and human parasites. 
For example, the female-specific P47 protein is vital for the fertility of P. berghei female 
gametes, while this protein does not appear to be crucial for P. falciparum female gamete 
fertility [10, 26]. Analysis of P. berghei mutants lacking P45/48 and P230 demonstrates that 
these proteins are male-specific fertility factors [10, 27]. In contrast, P. falciparum P48/45 
and P230 are expressed in both males and female gametes [19-21], which may suggest 
a role for these proteins in both male and female gamete fertility. 
The lack of RBC binding of PfΔp230p male gametes is similar to the phenotype of P. 
falciparum mutants lacking expression of its paralog P230 [28]. These observations suggest 
that both proteins have a similar, but not interchangeable, function in RBC binding. We 
provide evidence that PfΔp230p male and female gametes retain expression of both 
P230 and P48/45, indicating that the lack of RBC binding is not due to the absence of 
expression of P230 and/or P48/45. These observations would suggest that RBC binding 
of male gametes is not due to direct interactions of P230 to RBC receptors as was also 
demonstrated in studies using male gametes lacking expression of P230 [28]. 
Future studies
P230 and P48 form complexes with several other proteins at the surface of female gametes 
and zygotes [29-31]. Given that P48/45, P230 and P230p are expressed in male gametes, 
it is conceivable that comparable complexes, including additional proteins, are also 
formed at the surface of male gametes. The absence of either P230 or P230p may affect 
the correct formation of such protein complexes at the gamete surface, which may in turn 
lead to the same loss of the RBC-binding phenotype observed in mutants that lack either 
paralog. Future studies are needed to unravel in more detail the molecular interactions 
between male gametes and RBC and the Plasmodium ligand(s) that bind to the putative 
protein receptors, sialic acid and/or glycophorin on the RBC surface [32]. 
Since both P230 and Pf48/45 are present on the surface of P. falciparum gametes 
and have a critical role in fertilization they are actively being pursued as malaria vaccine 
candidates. Immunization with these antigens provoke antibody-based responses in 
the host that could limit parasite transmission in mosquitoes, so called transmission 
blocking vaccination [33]. Therefore, our observations of the vital role of P230p in P. 
falciparum fertilization and zygote formation, like P230 and P48/45, would indicate that 
studies should be performed to investigate its potential as a transmission blocking vaccine 
candidate antigen; for example, to examine whether immunization with P230p could also 
generate antibody responses that could limit parasite development in mosquitoes. 
A P. fa lc iparum  NF54 reporter l ine express ing 
mCherry- luc i ferase in gametocytes, 
sporozoites and l iver stages (Chapter 5)
In Chapter 3 we described studies to generate and analyse different P. falciparum 
transgenic lines expressing GFP from different promoters. This was performed in order to 
create highly fluorescent reporter parasites that express GFP throughout the complete life 
cycle. However, given that the insertion of a transgene into the P. falciparum p230p locus 
resulted in parasites that could not infect mosquitoes (Chapter 3 and 4), we reverted to 
using the standard ‘neutral’ p47 gene locus for introduction of a novel reporter expression 
cassette. In Chapter 5 we describe the creation and evaluation of a reporter line that 
expresses a fusion of mCherry and luciferase, driven by the etramp10.3 gene promoter. 
We selected the etramp10.3 promoter as this gene has structural similarity to the rodent 
Plasmodium uis4 gene and etramp10.3 and uis4 have the same syntenic genomic location. 
In multiple rodent malaria transgenic lines the uis4 promoter has been used to drive 
expression of different transgenes, specifically in sporozoites and liver stages, such as genes 
encoding mCherry, ovalbumin or human malaria proteins [34-40]. We chose to generate 
an mCherry-expressing P. falciparum line in order to visualise interactions of Plasmodium 
sporozoites with host-cells (e.g. immune cells or hepatocytes) that are often labelled with 
green fluorescent proteins. Moreover, we fused the mCherry gene to the gene encoding 
firefly luciferase as luciferase expression can be used to quantify parasite numbers (e.g. 
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sporozoites and liver-stages) using simple and sensitive luminescence assays [41-43]. 
Using the CRISPR/Cas9 methodology, described in Chapter 3, we inserted the mCherry-
luc@etramp10.3 expression cassette into the p47 gene locus. We demonstrated that this 
transgenic parasite line (mCherry-luc@etramp10.3) expresses mCherry in gametocytes, 
sporozoites and liver-stage parasites. While we did not detect mCherry above background 
levels in asexual blood-stage parasites, we were able to measure luciferase expression  in 
asexual blood-stages as well as in gametocytes, sporozoites and liver-stages. The highest 
levels of reporter expression were detected in stage III-V gametocytes and in sporozoites. 
The high activity of the etramp10.3 promoter in gametocytes is in agreement with 
the high levels of etramp10.3 transcripts and ETRAMP10.3 protein levels previously reported 
in gametocytes by genome-wide analyses of gene expression. The peak etramp10.3 
transcript abundance was observed in stage III gametocytes [44], and ETRAMP10.3 is 
detected in proteomic analyses of (male and female) gametocytes [20, 21]  and is 
more abundant in gametocytes compared to asexual blood-stages. The expression of 
ETRAMP10.3 in asexual blood-stages has been reported in proteomic analyses [45, 46] and 
has been confirmed by immunofluorescence analysis using anti-ETRAMP10.3 antibodies 
[47]. Moreover, unsuccessful attempts to delete the gene etramp10.3 indicates that it 
is essential during asexual blood-stage development [47]. A vital role for ETRAMP10.3 
during blood-stage development is in contrast to the rodent Plasmodium UIS4 protein, 
which is dispensable for blood-stage development  [48, 49]. In previous studies using 
rodent parasites, where the usi4 gene has been replaced with the etramp10.3 gene, 
ETRAMP10.3 is unable to complement the essential function of UIS4 in P. yoelii liver-
stages [47]. These observations indicate that UIS4 and ETRAMP10.4 may have different 
or only partially overlapping roles in rodent and human malaria parasites. The expression 
of mCherry and luciferase in gametocytes and sporozoites makes this transgenic parasite 
line suitable to use in in vitro assays to examine the effect of drugs/inhibitors and vaccine-
induced immune responses on gametocyte and sporozoite development, as well as to 
analyse sporozoite biology in mosquitoes, skin and hepatocytes.
Future studies
The development and expansion of reporter lines in P. falciparum will increase the range of 
analyses that could be performed, as has been the case with reporter lines of the rodent 
parasites P. berghei and P. yoelii. Studies with P. falciparum transgenic reporter parasites, 
possibly using protocols established with rodent malaria reporter lines, may help to 
better interrogate P. falciparum gene function at different points of development, and 
will enhance screening of compounds or immune sera in miniaturized, high throughput 
and rapid assays that inhibit the parasite at different points of development. For example, 
mCherry-luciferase expressing parasites, such as described in this study, could be used to 
better understand the interactions of sporozoites and host cells (i.e. in the skin) as well as 
to examine the action of drugs or vaccines that target gametocyte or liver stage parasites.
Additional reporter lines are required for P. falciparum, in particular those that show 
high reporter expression throughout liver stage development (i.e. stronger than either 
GFP-luc@ef1α or mCherry-luc@etramp10.3), both for sensitive drug tests as well as for 
the possibility of flow sorting of infected hepatocytes. We are currently creating and 
testing next-generation P. falciparum reporter lines, using data from multi-stage RNAseq 
transcription analyses to identify suitable strong and constitutive promoters.
Chimeric  Plasmodium falc iparum 
paras ites express ing Plasmodium vivax 
c i rcumsporozoite protein fa i l  to produce 
sal ivary gland sporozoites (Chapter 6)
Rodent malaria parasites where the gene encoding circumsporozoite protein (CSP) has 
been replaced with csp genes from the human malaria parasites, P. falciparum (Pf) or P. vivax 
(Pv), are being used as pre-clinical tools to evaluate vaccines targeting CSP in vivo. These 
chimeric rodent parasites produce sporozoites in A. stephensi mosquitoes that are capable 
of infecting rodent and human hepatocytes. The availability of chimeric P. falciparum 
parasites where the Pfcsp gene has been replaced by pvcsp would open up possibilities 
for testing P. vivax CSP vaccines in small scale clinical trials using controlled human malaria 
infection (CHMI) studies. Testing the next generation of P. falciparum vaccines and vaccine 
formulations is greatly aided by the ability to vaccinate individuals and then examine 
vaccine efficacy by infecting immunized individuals with WT malaria parasites in controlled 
human malaria infections (CHMI)[50-53]  Although recently CHMI has also been developed 
for P. vivax [54] and has been applied to assess pre-erythrocytic vaccine candidates [22, 
23], P. vivax CHMI to screen different P. vivax vaccines is extremely limited, due in large 
part to the lack of methods to continuously propagate P. vivax blood stages in culture 
and to produce gametocytes in vitro that can be used to infect mosquitoes and produce 
sporozoites for challenge infections [54]. P. vivax CHMI is largely dependent on sporozoites 
which have been obtained from mosquitoes fed on infected patients [54]. We reasoned 
that the availability of chimeric P. falciparum parasites that express P. vivax antigens would 
open up possibilities to analyse protective immune responses induced by P. vivax antigen-
based vaccines followed by CHMI with chimeric Pf-Pv parasites, bypassing the need for P. 
vivax sporozoite production and, equally importantly, eliminating the measures required 
to ensure that P. vivax dormant liver stages, hypnozoites, have been removed. In Chapter 
6, we describe proof-of-concept studies where we generated two chimeric P. falciparum 
parasites using CRISPR/Cas9 gene editing methodologies, in which the pfcsp gene was 
replaced by one of the two major pvcsp alleles, either VK210 or VK247 [55]. 
We found that the two chimeric Pf-PvCSP lines exhibit normal asexual and sexual blood 
stage development in vitro and produce sporozoite-containing oocysts in A. stephensi 
mosquitoes. Expression of the corresponding PvCSP was confirmed in oocyst-derived 
Pf-PvCSP sporozoites. However, most oocysts degenerate before sporozoite formation and 
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sporozoites were not found in either the mosquito haemocoel or in salivary glands. Unlike 
the chimeric Pf-PvCSP parasites, oocysts of P. falciparum parasites lacking CSP-expression 
do not produce sporozoites. These observations indicate that the PvCSP proteins can 
be used to initiate sporozoite formation in P. falciparum oocysts but are unable to fully 
complement the function of PfCSP in oocyst maturation and sporozoite development. 
It seems unlikely that the failure of PvCSP to functionally complement PfCSP is due to 
incorrect expression of the PvCSP proteins in the Pf-PvCSP lines. We used the same Pvcsp 
genes, as used for successful complementation of CSP in P. berghei (Pb) [56], to replace 
P. falciparum csp. These Pvcsp genes were amplified from the same plasmids that were 
used for generation of the Pb-Pvcsp lines. In addition, the Pvcsp gene coding sequence 
in the genome of the Pf-PvCSP lines was placed under control of the endogenous Pfcsp 
promoter and transcriptional terminator sequences to ensure correct timing and level of 
CSP expression. It has been shown that the 3’ untranslated region (3’-UTR) of P. berghei 
csp plays an important role in accurate CSP expression, and truncation of Pbcsp 3’-UTR 
results in reduced CSP expression, reduced oocyst sporozoite formation and degeneration 
of oocysts [57]. The inability of PvCSP to replace the PfCSP function in the chimeric 
Pf-PvCSP lines is therefore most likely due to sequence differences between these csp 
genes resulting in structural differences of the CSP proteins, which may affect interactions 
with other parasite proteins that are essential for proper sporozoite formation. These can 
be protein-interactions that influence correct transport of CSP from within the oocyst-
cytoplasm to the membrane of developing sporozoites or protein-interactions that affect 
CSP localization or maintenance on sporozoites [58-61].  As mentioned above, it is possible 
to create infectious chimeric P. berghei parasites expressing PvCSP. It therefore appears 
that both PvCSP and PfCSP are able to interact with these CSP interacting proteins 
in P. berghei. 
Future studies
Currently, the inability of the two Pf-PvCSP lines to produce salivary gland sporozoites 
means that these parasites cannot be used for CHMI studies. Further studies are required 
to investigate if it is possible to create P. falciparum parasites that express P. vivax CSP 
molecules; this may consist of creating P. falciparum parasites expressing hybrid CSP 
proteins that contain different domains of PfCSP and PvCSP. Studies using parasites 
expressing hybrid CSP molecules may also reveal which CSP domains are essential for 
sporozoite maturation and release and may provide insight into the failure of PfCSP 
complementation by PvCSP.  
While it was not possible to directly create P. falciparum parasites where CSP had been 
replaced with PvCSP, it may be possible to replace in P. falciparum other vaccine candidate 
antigens with the P. vivax equivalent, and as such make these parasites suitable for CHMI 
studies. Finally, it may be possible to create transgenic sporozoites that express the target 
antigen of both P. falciparum and P. vivax in the same parasite, and such parasites could 
be used as an enhanced irradiated or genetically attenuated sporozoite vaccine that could 
induce protective immune responses against infection with both human malaria parasites. 
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De beschikbaarheid van een verscheidenheid aan transgene knaagdier malariaparasieten 
die verschillende reportereiwitten tot expressie brengen onder controle van stadium 
specifieke- of constitutieve promotors, is van grote waarde gebleken in studies naar de 
functie van genen van de parasiet en in onderzoek gericht op de evaluatie van nieuwe 
medicijnen en vaccins. De beschikbaarheid van vergelijkbare transgene Plasmodium 
falciparum reporterlijnen zou het onderzoek naar gen-functies en de ontwikkeling van 
nieuwe behandeltherapieën voor humane parasieten kunnen versnellen. In Hoofdstuk 2 
geven we een overzicht van het gebruik van transgene knaagdier en humane 
malariaparasieten voor vaccinonderzoek.
In deze thesis beschrijven we een reeks van studies uitgevoerd met P. falciparum naar 
de ontwikkeling van nieuwe CRISPR/Cas9 methodieken ter optimalisatie van de genetische 
modificatie en het genereren van nieuwe transgene P. falciparum reporterparasieten 
waarmee parasiet-gastheer interacties kunnen worden geanalyseerd en welke toegepast 
kunnen worden in het onderzoek naar nieuwe medicijnen en vaccins. We hebben ons 
eerst gericht op het verbeteren van de CRISPR/Cas9 genoommodificatietechniek  en het 
introduceren van transgenen in een nieuw, potentieel neutraal, locus van het P. falciparum 
genoom. Gebruik makend van deze verbeterde CRISPR/Cas9 methodieken werden 
transgene P. falciparum parasieten ontwikkeld die of fluorescente-luminescente reporter 
eiwitten tot expressie brengen of een potentieel vaccin kandidaat eiwit van P. vivax, een 
andere belangrijke humane malariaparasiet.
In Hoofdstuk 3 beschrijven we studies gericht op het optimaliseren van genetische 
modificatie middels CRISPR/Cas9 voor het introduceren van transgenen in het genoom 
van P. falciparum. We rapporteren over het nog verder verbeteren van zowel de CRISPR/
Cas9 DNA constructen als de selectieprocedure om zo het genoom van P. falciparum 
sneller en efficiënter te kunnen modificeren en om het mogelijk te maken om transgenen 
in het genoom in te brengen zonder selectiemarkers. Deze methode is gebruikt voor 
de stabiele integratie van het gen coderend voor GFP in het P. falciparum genoom. 
Het GFP gen werd geïntroduceerd onder controle van promotors van 3 verschillende 
Plasmodium genen (calmodulin, gapdh en hsp70) om te selecteren voor constitutieve 
en sterke promotors, die ingezet kunnen worden voor het aansturen van expressie van 
reporter genen in verschillende levensstadia van de parasiet. Bovenstaande genen 
werden geselecteerd op basis van hun hoge transcriptie in bloedstadia. We tonen aan 
dat de in vitro groei-kinetiek en medicijn-gevoeligheidsprofielen van de bloedstadia van 
de in deze studie gegenereerde reporter parasietlijnen (GFP@cam, GFP@gapdh en GFP@
hsp70) vergelijkbaar zijn met die van de P. falciparum wildtype (NF54) moederlijn. Zowel 
de seksuele als aseksuele bloedstadia van de drie reporterlijnen lieten GFP fluorescentie 
zien en flowcytometrische analyse van de fluorescentie intensiteit heeft aangetoond  dat 





De verbeterde CRISPR/Cas9 constructen en protocollen zullen er toe bijdragen dat 
sneller genetisch gemodificeerde P. falciparum parasietlijnen ontwikkeld kunnen worden, 
waaronder lijnen die verschillende reportereiwitten onder verschillende (stadium-
specifieke) promotors tot expressie brengen. Bovendien zal deze methode het uitvoeren 
van opeenvolgende gen-deleties en gen-mutaties vergemakkelijken, wat van waarde kan 
zijn bij gen functieanalyses en voor het genereren van meervoudig genetische verzwakte 
parasieten, geschikt voor vaccins. 
In bovengenoemde studies voor de introductie in het genoom van de gfp expressie-
cassettes werd gebruik gemaakt van het p230p gen-locus. Omdat dit locus in knaagdier 
malariaparasieten niet essentieel is, ongeacht het ontwikkelingsstadium van de parasiet, 
werd verondersteld dat dit gen-locus in de humane malariaparasiet neutraal is (een locus 
dat gemodificeerd kan worden zonder verandering van het fenotype van de verschillende 
ontwikkelingsstadia van de levenscyclus). Echter, parasieten waarvan het p230p gen-locus 
was uitgeschakeld waren geheel onverwacht niet langer in staat muggen te infecteren en 
zich in de mug te ontwikkelen.
In Hoofstuk 4 beschrijven we het fenotype van de p230p gen-deletie mutanten 
(PfΔp230p) in muggen en de mogelijke rol van het P230p eiwit in de ontwikkeling van 
de parasiet in het muggenstadium. P230p behoort tot de kleine familie van zogenaamde 
s48/45-domain 6-cysteine (6-cys) eiwitten. Twee andere eiwitten die tot deze familie 
behoren, P48/45 en P230, zijn mede bepalend voor de vruchtbaarheid van gameten 
en zodanig belangrijke antigeenkandidaten voor transmissie-blokkade vaccins. In 
tegenstelling tot P48/45 en P230, die in zowel mannelijke als vrouwelijk parasieten 
tot expressie worden gebracht, komt P230p uitsluitend tot expressie in mannelijke 
gametocyten en gameten van zowel knaagdier als humane malariaparasieten. De PfΔp230p 
mutanten produceerden normale aantallen mannelijke en vrouwelijke gametocyten 
waarvan expressie van P48/45 en P230 onveranderd was. Met de activatie van mannelijke 
gametocyten vindt ‘exflagellatie’ plaats waarbij de mannelijke gameten worden gevormd. 
Echter, in tegenstelling tot wild type gameten waren de PfΔp230p gameten niet in 
staat zich aan rode bloedcellen te hechten waardoor de vorming van karakteristieke 
‘exflagellatie-centra’ in vitro achterwege bleef. Daarnaast bleek de vorming van zygoten en 
ontwikkeling van zowel oocysten en sporozoieten in muggen is in afwezigheid van P230p 
sterk gereduceerd (>98%). Mannelijke gameten van knaagdier malariaparasieten waarvan 
P230p is uitgeschakeld daarentegen laten een normale binding aan rode bloedcellen zien 
en de vruchtbaarheid en vorming van oocysten van deze parasieten zijn vergelijkbaar met 
wildtype parasieten. Deze observaties tonen aan dat P. falciparum P230p, net als P230 
en P48/45, een sleutelrol speelt in de vorming van zygoten en dat verder onderzoek naar 
P230p als aangrijppunt voor transmissie-blokkade vaccins zinvol is. 
In Hoofstuk 5 beschrijven we het vervaardigen en evalueren van een P. falciparum 
reporterlijn, die een fusie-eiwit bestaande uit luciferase en mCherry, onder controle van 
de etramp10.3 promotor, tot expressie brengt. Deze transgene parasieten werden in 
kweken van bloed- en leverstadia geanalyseerd, alsmede in muggen. Het P. falciparum 
ETRAMP10.3 eiwit is gerelateerd aan het UIS4 eiwit van knaagdier malariaparasieten 
welke ook tot de familie van ETRAMP eiwitten behoort. De promotor van uis4 
wordt toegepast voor de expressie van transgenen in de leverstadia van knaagdier 
malariaparasieten. Gebruik makend van de in Hoofstuk 3 beschreven CRISPR/Cas9 
methodieken werd de mCherry-luc@etramp10.3 expressie-cassette geïntegreerd in het 
reeds eerder gekarakteriseerde, neutrale gen-locus P. falciparum p47 .  Deze reporterlijn 
laat expressie van mCherry zien in gametocyten, sporozoieten en leverstadia, terwijl 
mCherry niet aangetoond kon worden boven de achtergrond van aseksuele bloedstadia 
en zich ontwikkelende oocysten. Expressie van luciferase werd aangetoond in aseksuele 
bloedstadia, gametocyten, sporozoieten en leverstadia met de hoogste expressie gemeten 
in stadium III-V gametocyten en sporozoieten. Expressie van mCherry en luciferase in 
gametocyten en sporozoieten maakt deze transgene parasietlijn uitermate geschikt 
voor het analyseren van de effecten van remmers van de gametocyt-ontwikkeling en het 
analyseren van de biologie van sporozoieten en leverstadia.
In Hoofdstuk 6 beschrijven we de ontwikkeling van twee chimere P. falciparum 
parasieten (Pf-PvCSP) waarvan het csp gen, met behulp van CRISPR/Cas9 methodieken, 
werd vervangen door twee csp gen varianten (VK210 & VK247) van de humane parasiet 
P. vivax. Als zijnde de belangrijkste oppervlakte-eiwit van sporozoieten, speelt CSP een 
belangrijke rol in sporozoiet formatie en bij de invasie van de speekselklieren van de mug en 
levercellen van de gastheer door sporozoieten. Het CSP antigeen is het aangrijpingspunt 
van het tot nu toe meest geavanceerde malariavaccin (RTS,S) en is ook een zeer belangrijke 
antigeen voor de ontwikkeling van een vaccin tegen P. vivax. Knaagdier malariaparasieten 
waarvan het csp gen werd vervangen door csp genen van de humane parasiet P. falciparum 
of P. vivax worden gebruikt in preklinische evaluaties van CSP vaccins in vivo. Deze chimere 
knaagdier malariaparasieten produceren sporozoieten in A. stephensi muggen welke in 
staat zijn levercellen van knaagdieren en mensen te infecteren. De beschikbaarheid van 
chimere P. falciparum parasieten waarin het csp gen is vervangen door het csp gen van P. 
vivax zou mogelijkheden bieden voor het testen van P. vivax CSP vaccins in kleinschalige 
klinische trials gebaseerd op ‘controlled human malaria infection’ (CHMI) studies. De twee 
ontwikkelde chimere Pf-PvCSP parasietlijnen vertoonden een normale ontwikkeling van 
aseksuele en seksuele bloedstadia in vitro en waren in staat sporozoiet-bevattende oocysten 
te produceren in A. stephensi muggen. We hebben bevestigd dat sporozoieten, afkomstig 
uit de Pf-PvCSP oocysten, de overeenkomstige PvCSP variant tot expressie brengen, maar 
een groot deel van de oocysten degenereert reeds voordat de sporozoieten volledig tot 
ontwikkeling zijn gekomen en sporozoieten werden niet aangetoond in de hemocoel noch 
in de speekselklieren van de mug. In de oocysten van P. falciparum waarvan CSP werd 
uitgeschakeld daarentegen werden geen sporozoieten geproduceerd. Deze observaties 
tonen aan dat PvCSP de functie van PfCSP deels kan complementeren, maar dat soort-
specifieke eigenschappen van CSP noodzakelijk zijn voor het doorlopen van de volledige 





For rodent malaria parasites the availability of a variety transgenic parasite lines expressing 
different reporter proteins under the control of stage-specific or constitutive promoters 
have been of great benefit to studies to reveal parasite gene function and to studies 
focussed on the evaluation of novel drugs and vaccines. The availability of similar transgenic 
P. falciparum reporter lines would also help to advance gene-function studies and studies 
aiming at development of new therapies for P. falciparum parasites. We review the use of 
transgenic rodent and human parasites for malaria vaccine research in Chapter 2. 
In this thesis, we describe a set of studies performed in P. falciparum to develop novel 
CRISPR/Cas9 methodologies to improve P. falciparum transgenesis and to create novel 
transgenic reporter parasites that can be used to analyse host-pathogen interactions and 
for anti-malarial drug and vaccine research. We first focused on improving CRISPR/Cas9 
gene editing technologies and the introduction of transgenes into the P. falciparum genome 
using a new potential ‘neutral’ locus. Using this improved CRISPR/Cas9 methodology, 
transgenic P. falciparum parasites were created that either express fluorescent-luminescent 
reporters or express a major vaccine candidate from the other major human malaria 
parasite, Plasmodium vivax.
In Chapter 3 we describe studies aiming at improving CRISPR/Cas9 genetic modification 
for introduction of transgenes into the genome of P. falciparum. We report on further 
improvements to both the CRISPR/Cas9 transfection constructs and selection protocol 
to more rapidly modify the P. falciparum genome in order to introduce transgenes into 
the parasite genome without the inclusion of drug-selectable marker genes. This method 
was used to stably integrate the gene encoding GFP into the P. falciparum genome under 
the control of promoters of three different Plasmodium genes (calmodulin, gapdh and 
hsp70) to select for constitutive and strong promoters that can be used to drive reporter 
gene expression. These genes were selected as they are highly transcribed in blood stages. 
We show that the three reporter parasite lines generated in this study (GFP@cam, GFP@
gapdh and GFP@hsp70) have in vitro blood stage growth kinetics and drug-sensitivity 
profiles comparable to the parental P. falciparum (NF54) wild-type line. Both asexual and 
sexual blood stages of the three reporter lines expressed GFP with GFP@hsp70 having 
the highest fluorescent intensity in schizont stages as shown by flow cytometry analysis of 
GFP-fluorescence. The improved CRISPR/Cas9 constructs and protocol will aid in the rapid 
generation of transgenic and modified P. falciparum parasites, including those expressing 
different reporters proteins under different (stage specific) promoters. In addition, this 
method will make it easier to perform successive gene-deletions and gene-mutations, 
which will be of value to interrogate parasite gene function and for the development 
of multiple-attenuated malaria parasites suitable for vaccination. In these studies gfp-
expression cassettes were introduced into the genome in the p230p gene locus.  This 
gene locus was predicted to be a ‘neutral’ locus (a locus that can be modified without 
altering the phenotype of the different life cycle stages), since in rodent malaria parasites 
the gene encoding P230p is dispensable throughout the complete life-cycle. Unexpectedly, 
disruption of the P230p locus in P. falciparum created parasites that could not infect and 
develop in mosquitoes. 
In Chapter 4 we describe the phenotype in mosquitoes of the p230p gene-deletion 
mutants (PfΔp230p) and the potential role of the P230p protein in mosquito development. 
P230p belongs to the small family of so called s48/45 domain 6-cysteine (6-cys) proteins. 
Two other members of this family, P48/45 and P230, are important for gamete fertility 
in rodent and human malaria parasites and are leading transmission blocking vaccine 
antigens. While P48/45 and P230 are expressed in male and female parasites, P230p is 
expressed only in male gametocytes and gametes in both rodent and human malaria 
parasites. The PfΔp230p mutants produced normal numbers of male and female 
gametocytes, which retained expression of both P48/45 and P230. Upon activation male 
PfΔp230p gametocytes undergo exflagellation and form male gametes. However, male 
gametes were unable to attach to red blood cells resulting in the absence of characteristic 
exflagellation centres in vitro. In the absence of P230p, zygote formation as well as oocyst 
and sporozoite development were strongly reduced (>98%) in mosquitoes. In contrast, 
male gametes of rodent malaria parasites lacking P230p show normal attachment to red 
blood cells and have fertilisation rates and oocyst production that is comparable to wild 
type parasites. These observations demonstrate that P. falciparum P230p, like P230 and 
P48/45, has a vital role in P. falciparum male fertility and zygote formation and warrants 
further investigation as a potential transmission blocking vaccine candidate.
In Chapter 5, we describe the creation and evaluation of a P. falciparum reporter 
line that expresses a fusion of mCherry and luciferase driven by the promoter of 
the etramp10.3 gene and we examine these transgenic parasites in blood- and liver-
stage cultures as well in mosquitoes. The P. falciparum ETRAMP10.3  protein is related 
to the rodent Plasmodium UIS4 protein, which is also a member of the ETRAMP protein 
family. The promoter of the uis4 gene has been used to drive high transgene expression 
in liver-stages of rodent malaria parasites.  The CRISPR/Cas9 methodology described 
in Chapter 3 was used to insert the mCherry-luc@etramp10.3 expression cassette into 
the previously characterised ‘neutral’ P. falciparum p47 gene locus. This reporter line 
demonstrates mCherry expression in gametocytes, sporozoites and liver-stages, whereas 
asexual blood stages and developing oocyst did not show mCherry signals different from 
background levels. Luciferase expression was demonstrated in asexual blood-stages, 
gametocytes, sporozoites and liver-stages, with high level reporter expression in stage III-V 
gametocytes and in sporozoites. The expression of mCherry and luciferase in gametocytes 
and sporozoites makes this transgenic parasite line a suitable tool to analyse the effect of 
inhibitors on gametocyte development and to analyse sporozoite and liver-stage biology.
In Chapter 6 we describe the creation of two chimeric P. falciparum parasites (Pf-
PvCSP), using CRISPR/Cas9 gene editing methodologies, where the gene encoding 
circumsporozoite protein (CSP), was replaced by two csp gene variants (VK210 and VK247) 








role both in sporozoite formation and in sporozoite invasion of mosquito salivary glands 
and liver cells of the host. CSP is the target antigen of the most advanced P. falciparum 
malaria vaccine (RTS,S) and is also an important vaccine target for P. vivax. Rodent malaria 
parasites where the gene encoding circumsporozoite protein (CSP) has been replaced with 
csp genes from the human malaria parasites, P.  falciparum  or P. vivax, are used as pre-
clinical tools to evaluate CSP vaccines in vivo. These chimeric rodent parasites produce 
sporozoites in Anopheles stephensi mosquitoes that are capable of infecting rodent 
and human hepatocytes. The availability of chimeric P. falciparum parasites where the P. 
falciparum csp gene has been replaced by the P. vivax csp would open up possibilities 
to test P. vivax CSP vaccines in small scale clinical trials using controlled human malaria 
infection (CHMI) studies. The two chimeric Pf-PvCSP  lines exhibited normal asexual and 
sexual blood stage development in vitro and produced sporozoite-containing oocysts 
in A. stephensi mosquitoes. We confirmed that the oocyst-derived Pf-PvCSP sporozoites 
express the corresponding PvCSP. However, most oocysts degenerate before sporozoite 
formation and sporozoites were not found in either the mosquito hemocoel or salivary 
glands. Unlike the chimeric Pf-PvCSP parasites, oocysts of Pf parasites lacking CSP 
expression do not produce sporozoites. Combined our observations show that while 
PvCSP can partially complement the function of PfCSP, species-specific features of CSP 
govern full sporozoite maturation and development in the two human malaria parasites.
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